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YATHAM et al.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates
were published in collaboration with the International Society for Bipolar Disorders

Funding information
Canadian Network for Mood and Anxiety
Treatments, Grant/Award Number: N/A

(ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the
significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacologi-

[copyright line and Funder information
updated after the first online publication
on 21st April 2018].

cal and psychological treatments. These advances have been translated into clear and
easy to use recommendations for first, second, and third- line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience,
and consensus ratings of safety, tolerability, and treatment-emergent switch risk. New
to these guidelines, hierarchical rankings were created for firstand second-line treatments recommended for acute mania, acute depression, and maintenance treatment in
bipolar I disorder. Created by considering the impact of each treatment across all
phases of illness, this hierarchy will further assist clinicians in making evidence-based
treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first-
line treatments for acute mania. First-line options for bipolar I depression include
quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or
adjunctive lamotrigine. While medications that have been shown to be effective for
the acute phase should generally be continued for the maintenance phase in bipolar I
disorder, there are some exceptions (such as with antidepressants); and available data
suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole
monotherapy or combination treatments should be considered first-line for those initiating or switching treatment during the maintenance phase. In addition to addressing
issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific
populations, such as women at various stages of the reproductive cycle, children and
adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The
CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

1 | INTRODUCTION

of the range of interventions available for this complex and varied illness, with the goal of providing clear, easy to use recommendations

In the 20 years since the Canadian Network for Mood and Anxiety

for clinicians to improve outcomes in their patients.

Treatments (CANMAT) first published guidelines on the management

Given that 13 years have elapsed since the publication of the last

of BD (BD),1 there has been an explosion of research on treatment of

full edition in 2005, the objective of these 2018 CANMAT and ISBD

this illness. During this time period, CANMAT has strived to translate

Bipolar Disorder Management Guidelines is to provide a compre-

advances in research into international consensus on evidence-based

hensive, up-to-date review of research evidence on the treatment

clinical management; first by publishing 2005 guidelines accompanied

of various phases of BD, translated into clinical recommendations

by expert commentaries, then by providing updates in 2007,2 20093

for evidence-based management. Updated principles related to di-

and 20134 in collaboration with the International Society for Bipolar

agnosis and management are also included, in response to signif-

Disorders (ISBD). The main objective of these publications was to syn-

icant changes made in the 5th edition of the American Psychiatric

thesize the wealth of evidence on the efficacy, safety, and tolerability

Association Diagnostic and Statistical Manual for Mental Disorders
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(DSM-5).5 With increased research into various treatments for BD,

TABLE 2

the evidence ratings have also been modified to increase rigor; for
instance, minimum sample sizes are now specified for randomized
controlled trials (RCTs) at each level of evidence (Table 1).

Definitions for line of treatment ratings

Line

Evidence level

First

Level 1 or level 2 evidence for efficacy plus
clinical support for safety/tolerability and no
risk of treatment-emergent switcha

Second

Level 3 or higher evidence for efficacy plus
clinical support for safety/tolerability and low
risk of treatment-emergent switcha

Third

Level 4 evidence or higher for efficacy plus
clinical support for safety/tolerability

Not recommended

Level 1 evidence for lack of efficacy, or level 2
evidence for lack of efficacy plus expert
opinion

As with previous editions of CANMAT guidelines, clinical support
for efficacy was an important consideration in arriving at the final
treatment recommendations (Table 2). Major conflicting data are addressed in blue text boxes (figures) to clarify the rationale for arriving
at a specific level of evidence for efficacy.
In the current edition, an additional distinction is made between
safety and tolerability, and a consensus rating is assigned to each
medication on these two measures when used in both the acute
and maintenance phase. Further, a rating is also assigned to each
medication for its propensity to switch patients into mania or depression (treatment-emergent switch). More information on these
ratings can be found in the respective treatment sections, as well

99

a

The text will specifically note when lack of clinical support for safety/
tolerability or risk of treatment-emergent switch has impacted
recommendations.

as in Section 8.
The final grading of recommendations into first, second, or third-

previous ongoing treatment was partially effective, and the addition of

line considers levels of evidence for efficacy, clinical support based

the new agent will provide benefits in either an additive or synergistic

on experience, and consensus ratings of safety, tolerability, and risk

manner. In contrast, agents specifically listed as adjunctive therapy may

of treatment-emergent switch. In addition, hierarchical rankings were

have no evidence for efficacy as monotherapy, and/or may have safety

created and are listed in the tables for firstand second line recom-

concerns if prescribed as monotherapy (eg. antidepressants), and are

mendations for acute mania, depression and maintenance treatment

only recommended for use in combination with other evidence-based

in bipolar I disorder (BDI). This hierarchy was created by considering

agents.

the impact of each treatment across all phases of illness (Figure 1).

As with previous editions, these guidelines also have a “not rec-

The rationale for the hierarchical approach is that BD is a chronic

ommended” category which includes treatments that have clearly

lifetime condition with recurrent mood episodes and subsyndromal

been shown to be ineffective in double-blind RCTs. Further, we have

mood symptoms, and most if not all patients will require maintenance

included another category called “no specific recommendation/agents

treatment. Since treatments that are prescribed for an acute mood ep-

that require further study” to list treatments with insufficient evidence

isode are usually continued into maintenance treatment, maintenance

or clinical experience to make a recommendation, or where there is a

efficacy should be considered when choosing acute-phase treatments.

reason to believe that negative trials failed because of methodologi-

Treatments that have demonstrated efficacy across the spectrum

cal problems-especially when the results are inconsistent with what is

of the illness should thus be tried first before treatments that have

expected based on the pharmacological properties of treatment and

demonstrated efficacy for only selective phases of the disorder. As an

clinical experience. Inclusion in this category means the efficacy of

example, if two treatments are shown to be similarly effective in acute

these agents is unknown at this time.

mania, and if only one of these treatments has demonstrated efficacy

As in previous editions, these guidelines are organized into eight

for maintenance treatment, the treatment with evidence for mainte-

sections (Table 3), including the Introduction. Foundations of man-

nance would be placed higher in the hierarchical ranking.

agement (Section 2) discusses the epidemiology of BD, screening

Of note, when a treatment is listed as a monotherapy, that implies

and diagnostic considerations, the importance of monitoring risk for

that it may be used on its own or in combination with other ongoing

suicide, the chronic disease management model and patient-centred

treatments, even if there are no specific studies demonstrating the ef-

care (including shared decision making), as well the importance of

ficacy of that combination. In this situation, the assumption is that the

incorporating psychoeducation and other psychosocial treatment

TABLE 1

Definitions for level of evidence ratings

Level

Evidence

1

Meta-analysis with narrow confidence interval or replicated double-blind (DB), randomized controlled trial (RCT) that
includes a placebo or active control comparison (n ≥ 30 in each active treatment arm)

2

Meta-analysis with wide confidence interval or one DB RCT with placebo or active control comparison condition
(n ≥ 30 in each active treatment arm)

3

At least one DB RCT with placebo or active control comparison condition (n = 10-29 in each active treatment arm) or
health system administrative data

4

Uncontrolled trial, anecdotal reports, or expert opinion

100
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What are hierarchical rankings?
Hierarchical rankings of treatment op ons are new to the 2018 Guidelines. They were created for first and second line treatment
recommenda ons for acute mania, depression, and maintenance treatment of bipolar I disorder; and will further assist clinicians in making
evidence based treatment decisions.
These orders were created by considering the efficacy of each treatment across all phases, as well as acute and maintenance safety and
tolerability and the risk for treatment emergent switch. Thus, for example if two treatments were shown to be similarly effec ve in acute
mania, and if only one of these treatments has demonstrated efficacy for maintenance treatment, or had beer safety or tolerability, that
treatment would be placed higher in the hierarchical recommenda on.
When making treatment decisions, we recommend that agents listed higher in the hierarchy be tried first, unless there are pa ent-specific
reasons for choosing an agent lower in the order (such as pa ent preference, prior treatment non/response, or clinical features which favor
treatments lower in the ranking).
F I G U R E 1 Hierarchical rankings of treatment recommendations: How were they arrived at? [Colour figure can be viewed at
wileyonlinelibrary.com]
TABLE 3

Sections

Section 1: Introduction
Section 2: Foundations of management
Section 3: Acute management of bipolar mania
Section 4: Acute management of bipolar I depression
Section 5: Maintenance therapy for bipolar I disorder

applicable for practitioners from across the globe. As with previous
publications, CANMAT will strive to publish regular updates to these
guidelines, incorporating new knowledge useful for practising clinicians.
As not all medications included in these guidelines will be available
in all countries, including Canada, clinicians are advised to follow the
recommendations of local regulatory bodies.

Section 6: Bipolar II disorder
Section 7: Specific populations
Section 8: Safety and monitoring

strategies into treatment. Additional information on presentation
and hierarchical rankings of treatment options for acute mania
(Section 3) and depression (Section 4) are reviewed, and include
descriptions of clinical features that may help direct treatment
choices. The importance of long-term maintenance treatment and
promotion of treatment adherence for mood stability, as well as hierarchical rankings of treatment options are discussed in Section 5.
An expert review of the available evidence for treatments of bipolar
II disorder (BDII) and recommendations based on those findings are
presented in Section 6. The management issues related to specific
populations, including women at various stages of the reproductive
cycle, children and adolescents, older adults, and those with psychiatric or medical comorbidity are each discussed in Section 7. Finally,

2 | FOUNDATIONS OF MANAGEMENT
2.1 | Epidemiology
2.1.1 | Prevalence
Bipolar disorder is a common and disabling mental illness with significant morbidity and mortality. The estimates of prevalence of BD vary.
The World Mental Health Survey Initiative reported total lifetime (and
12-month) prevalence estimates of 2.4% (1.5%) across BDI, BDII and
subthreshold BD subtypes. While the prevalence rates for each subtype varied across the nine countries studied, subthreshold BD was
the most common at 1.4% (0.8%), followed by BDI at 0.6% (0.4%) and
BDII at 0.4% (0.3%).6 While Canada was not included in this study,
similar results were reported from the Canadian Community Health
Survey-Mental Health, which found the lifetime prevalence of BDI
was 0.87% and that of BDII was 0.67%.7

the principles of medical monitoring and an overview of safety and
tolerability concerns for recommended treatments are provided in
Section 8.

2.1.2 | Age of onset

For convenience and to avoid confusion, these guidelines also

Bipolar disorder frequently manifests in late adolescence and

include a table of commonly used terms (with an explanation of the

young adulthood, with an overall average age of onset of 25 years.

intended meaning) that may have overlapping definitions or criteria in

Statistical models suggest the presence of three age of onset sub-

the literature (Table 4).

groups within BDI and these can be categorized into a large early-

These guidelines are intended for use by psychiatrists and primary

onset group (mean ± standard deviation (SD) 17.24 ± 3.20 years),

care providers who care for patients with BD throughout the lifespan,

and smaller middle-
o nset (23.93 ± 5.12 years) and late-
o nset

supporting them to provide evidence-based assessment, treatment of

(32.20 ± 11.96 years) groups, with the proportion of individu-

acute symptoms, prevention of episode recurrence, and management of

als falling into each category being 41.7%, 24.7% and 33.6%

comorbidities. These guidelines are not meant to replace clinical judge-

of the total sample, respectively. 8 However, the ages of onset

ment or define standards of care. While designed with Canadian physi-

tend to differ somewhat depending upon the origins of sam-

cians in mind, input from experts from the ISBD makes these guidelines

ples analysed. For instance, a recent study showed that the

|
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TABLE 4
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Clarifying overlapping terminology

Term

Use

Mood stabilizer

Use in the literature is inconsistent, and so this term will not be used in these guidelines

Divalproex

Encompasses valproate, valpromide, valproic acid and divalproex sodium

Conventional
antipsychotics

Include first-generation antipsychotics with high affinity for dopamine D2 receptors. Note these are referred to as dopamine
receptor antagonists (D2) in the new neuroscience-based nomenclature

Atypical
antipsychotics

Comprise second-generation antipsychotics with affinity for dopamine D2 and serotonin 5-HT2 receptors as well as those that
have partial agonist effects at D2/D3 receptors. Note these are referred to as dopamine and serotonin receptor antagonists (D2
and 5-HT2A), dopamine 2 partial agonists and serotonin receptor antagonists, and dopamine 2/3 partial agonists in the new
neuroscience-based nomenclature

Recurrence

Re-emerging episode(s) of mania or depression whether it be within the previous episode or a new episode. Note that, while the
literature may use “relapse” and “recurrence”, respectively, inconsistencies in how they are applied and their irrelevance to
treatment decisions mean we will use “recurrence” to refer to both

Maintenance

Prophylactic therapy after stabilization of acute manic or depressive episodes

mean age of onset for a USA sample was 20 years, with ages

a systematic review addressing cost of illness studies, with findings

of onset of 14.5 ± 4.9 years (63%), 26.5 ± 7.6 years (28.5%),

demonstrating that the worldwide annual costs per person with BD

and 39.5 ± 12.5 years (8.5%) for early-, middle- and late-o nset

range from US $1904 to $33 090; higher per person costs associated

groups, respectively; while a European sample showed a later

with BDI, delayed or misdiagnosis, frequent psychiatric interventions,

mean age of onset of 29 years and a later onset in each of the

use of atypical antipsychotics, treatment non-adherence, poor prog-

three categories, with 19 ± 2.7 years (24.8%), 27.2 ± 6.3 years

nosis, relapse, and comorbidity.26

(50.7%), and 41.8 ± 10.7 years (24.5%) as the ages of onset for
early, middle and late-o nset groups, respectively. 9 Those with an
earlier age of onset tend to have a longer delay to treatment,
greater depressive symptom severity, and higher levels of comorbid anxiety and substance use. 10 While manic episodes can

2.2 | Diagnostic assessment
2.2.1 | DSM-5 diagnostic criteria

occur for the first time after the age of 50 years as a part of BDI,

Bipolar disorder encompasses a spectrum of diagnostic subgroups

the possibility of organic mania should be considered and inves-

primarily divided according to the severity of mood elevation expe-

tigated in these cases.

11

rienced during acute episodes5 On this spectrum, BDI is placed at
one pole due to the presence of threshold manic episodes in which
features include inflated self-esteem, decreased need for sleep, pres-

2.1.3 | Burden of illness

sured speech, racing thoughts, distractibility, psychomotor agitation,

People living with BD experience substantial impairment, being symp-

and risky behaviour that leads to significant functional impairment, and

tomatic with syndromal or subsyndromal symptoms, particularly those

may include psychotic features, and/or necessitate hospitalization. At

of depression, for approximately half of their lives.12,13 Patients are

the other end of the spectrum, cyclothymia is characterized by sub-

unable to maintain proper work role function approximately 30% or

threshold presentation of hypomanic and depressive symptoms that,

more of the time.

14

Quality of life is reduced in both symptomatic and

while chronic, do not meet diagnostic criteria for a major depressive

non-symptomatic patients when compared to healthy controls,15-17

episode or manic/hypomanic episode. BDII sits between the two con-

and several domains of functioning have been identified by patients

ditions with hypomanic episodes qualitatively like manic periods but,

as being of particular importance- including physical, sleep, mood,

although distinct and observable, are not of a sufficient duration or

cognition, leisure, social, spirituality, finances, household, self-esteem,

severity to cause significant functional impairment, hospitalization, or

independence, identity, work, and education.18 For both psychosocial

psychosis. Individuals with BDII also experience threshold depressive

functioning and quality of life, impairments are more pronounced in

episodes.

patients with depressive symptoms,19-21 in those with more previous episodes/longer duration of illness,

20,22

and in those with lower

cognition.23

DSM-5 has replaced the BD not otherwise specified (NOS) category in DSM-IV with two new categories; other specified bipolar and
related disorder and unspecified bipolar and related disorder. Also,

Consistent with these observations, the Global Burden of Disease

DSM-5 includes substance/medication-induced bipolar and related

Study attributed 9.9 million years lost to disability (YLD) to BD, mak-

disorder and bipolar and related disorder due to another medical

th

ing it the 16 leading cause of YLD worldwide.

24

The impact that BD

condition. For more detailed discussion of diagnostic categories, the

has on young people is even greater, with being the sixth leading

reader is advised to consult DSM-5 and recent Royal Australian and

cause of disability-adjusted life years among people aged 10-24 years

New Zealand College of Psychiatrists guidelines for treatment of mood

worldwide.25 The burden of this disease was further emphasized in

disorders.27

102
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episodes as well as decline in functioning and cognition.31 So far, the

2.2.2 | DSM-5 specifiers for bipolar and
related disorders

heterogeneity intrinsic to BD has prevented the clinical use of stag-

DSM-5 also includes a range of specifiers that clinicians may use to

ability of staging systems to guide prognosis and treatment is still to

further clarify the specific course, severity, and features of BDs. While

be determined. Overall, the model of staging has helped clinicians to

a more detailed description can be found in the DSM-5 manual, the

appreciate the importance of early identification and treatment as well

available specifiers and their use across the spectrum are listed in

as illness trajectories in BD.33

ing systems.32 In addition, the field of staging is in its infancy and the

Table 5. Many of these specifiers may also be used to guide treatment decisions for acute mania (Section 3) and depression (Section
4). Amongst these, the mixed features specifier, which has replaced

2.2.4 | Screening and diagnosis of bipolar disorder

mixed episodes, warrants consideration because of the multiple and

Due to frequent depressive onset, variable help seeking for hypomanic

complex presentations of mixed states it can give rise to. Furthermore,

or manic periods, temporal instability of symptoms, and high rates of

the nascency of this terminology has meant that treatment data are as

comorbidity; accurate the timely identification of BD can be difficult

yet sparse. DSM-5 has added mixed features as a specifier during an

to achieve in many cases. Indeed, many individuals are not accurately

episode of major depressive disorder (MDD) as well, which will prob-

diagnosed until up to 10 years after the onset of symptoms, with one

ably pose some pragmatic diagnostic challenges and management di-

to four alternate diagnoses typically being given prior to correct rec-

lemmas for clinicians.

ognition and treatment34,35 This delay has important consequences,
including inadequate initial treatment and worse prognosis in terms of
episode recurrence and functional outcome.36,37

2.2.3 | Staging bipolar disorder

The most frequent misdiagnosis is that of MDD, as patients

The course of BD is heterogeneous but, on average, the risk of recur-

are more likely to present for the treatment of depressive symp-

rence increases with the number of previous episodes.28 In addition,

toms and may not recall periods of hypomania or mania, or may

data examining the effect of episodes on the course of illness shows

not interpret them as being pathological. Recall and insight are

that the number of previous episodes is associated with increased du-

particularly impaired during periods of acute depression, with pro-

ration and symptomatic severity of subsequent episodes. Moreover,

nounced memory or concentration difficulties. There are several

the number of episodes is associated with a decreased threshold for

features of depression that may increase suspicion of bipolarity,

developing further episodes and with an increased risk of dementia

and prompt more careful investigation, including earlier age of ill-

in the long term.28 The progressive course of illness in patients with

ness onset, highly recurrent depressive episodes, a family history

multiple episodes is called clinical progression and the biological basis

of BD, depression with psychotic features, psychomotor agitation,

of clinical progression is defined as neuroprogression.

28,29

atypical depressive symptoms such as hypersomnia, hyperphagia,

The concepts of clinical progression and neuroprogression have

and leaden paralysis, postpartum depression and psychosis, past

provided the basis for the development of staging systems in BD.30

suicide attempts, and antidepressant-induced manic symptoms or

Overall, the staging models describe three broad clinical stages: (I)

rapid cycling (Table 6) Given the recent change in DSM-5 to allow

individuals at increased risk for developing BD due to family history

the possibility of depression symptoms with subthreshold simulta-

as well as certain subsyndromal symptoms predictive of conversion

neous hypomanic symptoms (mixed specifier), it is also important

into full-blown BD; (II) patients with fewer episodes and optimal func-

to explore if an individual is experiencing mixed symptoms.38,39

tioning in the interepisodic periods, and (III) patients with recurrent

Schizophrenia and other psychotic disorders are the second most

TABLE 5

DSM-5 specifiers for bipolar and related disorders

Specifier

Manic episode

Depressive episode

Anxious distress

X

X

Mixed features

X

X

Rapid cycling

Illness course

X

Melancholic features

X

Atypical features

X

Psychotic features

X

X

Catatonia

X

X

Peripartum onset

X

X

Seasonal pattern

X

Remission

X

X

Current episode severity

X

X

|
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common misdiagnosis, occurring as the initial diagnosis in as many
as 30% of patients.

40

103

medical or neurological conditions, substance use, and medications
must be considered in the differential diagnosis (Table 7).

In addition to this under-diagnosis, there are also concerns that
BD may be over-diagnosed in some circumstances.41 For instance, the
symptoms of borderline personality disorder, substance use disorder

2.3 | Suicide risk

(SUD) and attention deficit hyperactivity disorder (ADHD) overlap sig-

It is important for clinicians to frequently monitor suicidal ideation

nificantly those of hypomania/mania, and some reports suggest that

and risk. Suicide is one of the leading causes of death in BD, with ap-

patients with these conditions often get misdiagnosed with BD. These

proximately 6%-7% of identified patients with BD dying by suicide;

conditions also are often comorbid with BD, which makes the diagno-

thus, suicide risk is substantially higher in BD than in the general

sis of this condition often challenging.

42

population (10.7 per 100 000 per year).46,47 The fatality of suicide

Validated self-report instruments, such as the Mood Disorders

attempts is also higher in BD than in the general population.48,49

Questionnaire (MDQ), may be used as a screening tool to flag patients

Worldwide, approximately 43% of patients with BD report suicidal

for whom a more detailed assessment is needed. It is important to

ideation, 21% a plan, and 16% a suicide attempt within the past

note, that such tools have poor sensitivity and specificity, especially in

year.6 Men are at a higher risk of death by suicide, with an estimated

community or highly comorbid populations, and will thus have an ele-

rate of 0.366 per 100 person years, compared to 0.217 for women.47

vated risk of also flagging those with borderline traits.

43

As such, tools

As reviewed in the ISBD Task Force on Suicide in Bipolar

such as the MDQ should be used only as an adjunct for screening clini-

Disorder,50 a number of sociodemographic and clinical risk factors

cal populations and not for diagnostic or treatment planning purposes.

need to be considered in determining the level of suicide risk (Table 8).

To improve the accuracy of diagnosis, it is important that clinicians

Factors reported to be significantly associated with suicidal attempt

strictly adhere to diagnostic criteria rather than relying on heuristics.44

include female sex, younger age of illness onset, depressive polarity

It is important to complete a careful psychiatric history, including in

of first illness episode, depressive polarity of current or more recent

first-degree relatives, with attention paid to any suspected periods of

episode, comorbid anxiety disorder, comorbid SUD, comorbid cluster

increased activity, irritability, or other change in behaviours. Collateral

B/borderline personality disorder, first-degree family history of sui-

information from friends and family members should be included

cide, and previous suicide attempts. Only male sex and first-degree

wherever possible. Ongoing monitoring of symptoms, such as mood

family history of suicide have been significantly associated with sui-

charting, can also help to detect bipolarity that may only become ap-

cide deaths.50,51 The periods during and following hospital admission

parent over time. Confirmation of the diagnosis can then be made

further represent times of particularly high risk, with 14% of suicides

more confidently when episodes are prospectively observed.

occurring during an inpatient stay and another 26% within 6 weeks of
discharge.47,52
A comprehensive assessment for suicide risk should occur during

2.2.5 | Comorbidities and mimics

all clinical interactions. Risk stratification using assessment tools is not

As described in Section 6, patients diagnosed with BD very commonly

sufficiently accurate for prediction of suicide risk in clinical use; in-

have one or more comorbid psychiatric diagnoses, with SUDs, im-

stead, clinical assessment should focus on modifiable risk factors that

pulse control disorders, anxiety disorders, and personality disorders

could be targeted to reduce the risk.53 The ISBD has developed clinical

(especially cluster B disorders) particularly common.

45

The presence

tips and patient information sheets (translated into several languages)

of comorbidity increases the complexity of the illness and can make

that can be useful tools for clinicians, patients and families to develop

an accurate diagnosis even more difficult.

a comprehensive approach to suicide prevention (http://www.isbd.

In addition to differentiating BD from other psychiatric diagnoses,
alternative causes of mood symptoms, such as personality disorders,
TABLE 6

org/Files/Admin/Knowledge-Center-Documents/Suicide-PreventionTip-Sheet.pdf).

Features of depression that may increase suspicion of a bipolar vs unipolar illness

Feature

Suggestive of bipolarity

Suggestive of unipolarity

Symptomatology and
mental state signs

Hypersomnia and/or increased daytime napping
Hyperphagia and/or increased weight
Other “atypical” depressive symptoms such as leaden paralysis
Psychomotor retardation
Psychotic features and/or pathological guilt
Lability of mood; irritability; psychomotor agitation; racing
thoughts

Initial insomnia/reduced sleep
Appetite and/or weight loss
Normal or increased activity levels
Somatic complaints

Course of illness

Early onset of first depression (<25 years)
Multiple prior episodes (≥5 episodes)

Late onset of first depression (>25 years)
Long duration of current episode (>6 months)

Family history

Positive family history of bipolar disorder

Negative family history of bipolar disorder

Adapted from Mitchell et al.38 and Schaffer et al.39
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Differential diagnosis of bipolar disorder

Diagnosis

Distinguishing features

Major depressive disorder or persistent depressive
disorder

Manic or hypomanic episodes probed for and not present

Bipolar or related disorder due to another medical
condition

Episodes are judged to be a consequence of a medical condition such as traumatic brain
injury, brain tumours such as frontal lobe meningiomas, multiple sclerosis, stroke, Cushing’s
disease or hyperthyroidism. Onset or exacerbation of mood coincides with that of the
medical condition

Substance-or medication-induced mood disorder

Episodes are judged to be a consequence of a substance such as an illicit drug, or a medication (stimulants, steroids, l-dopa or antidepressants) or toxin exposure. Episodes may be
related to intoxication or withdrawal

Cyclothymic disorder

Hypomanic symptoms do not meet the full criteria for a hypomanic episode, and depressive
symptoms do not meet the criteria for a major depressive episode

Psychotic disorders (schizoaffective disorder,
schizophrenia and delusional disorder)

Periods of psychotic symptoms in the absence of prominent mood symptoms. Consider onset,
accompanying symptoms, pervious course and family history

Borderline personality disordera

Instability of interpersonal relationships, self-image and mood, with marked impulsivity and a
central theme of intense abandonment fears. Early onset and long-standing course. True
euphoria and prolonged well-functioning intervals are extremely rare

Narcissistic personality disordera

Grandiosity, need for admiration and lack of empathy of early onset. Grandiosity not
associated with mood changes or functional impairments

Antisocial personality disordera

Early onset of disregard for, and violation of, the rights of others, which does not occur only
in the context of a manic episode

Adapted from Yatham et al. 20052
Can occur comorbidly with bipolar disorder.

a

The association between various treatments and suicide risk

directly to the primary care provider with attention to continuity of

has been reviewed by the ISBD Task Force and others, which

care.58 Additional psychosocial treatments (described below) may also

suggest that lithium

54

and, to a lesser extent, anticonvulsants may

be selected to fit the specific needs and preferences of the patient.

contribute to preventing suicide attempts and deaths; although more

A strong therapeutic alliance is central to improve treatment adher-

data are needed to determine their relative efficacies. There were lim-

ence and outcomes.59,60 Providers should encourage individuals to ac-

ited data on both antipsychotics and antidepressant agents.47 As the

tively participate in treatment planning, using a shared decision-making

most common method of suicide in this population is self-poisoning,

approach.61,62 Whenever possible, family members or key friends should

the potential benefits of various treatments should be considered

be included as part of the care team. There is evidence that specialized,

against their risk of toxicity and lethality. One small Canadian study

team-approach-based interventions combining pharmacotherapy and

indicated higher rates of lethal doses of antipsychotics (32%), opioids

psychoeducation are more effective than standard community care.63

(29%), benzodiazepines (27%), carbamazepine (21%) and diphenhydr-

Regular, ongoing monitoring of mood symptoms and other mea-

amine (15%) compared to lithium (3%) in 34 self-poisoning deaths.55

sures related to the patient’s own individual recovery, such as sleep,
cognition, functioning, and quality of life is encouraged.18 For many

2.4 | Chronic disease management

patients, daily recording of mood symptoms such as through a
mood diary or National Institute of Mental Health (NIMH) Life Chart

Due to the chronic, relapsing and remitting nature of BD, a long-term,

Method-Self Rating Scale can help identify early warning signs of re-

multidisciplinary approach to management is needed. The Chronic

lapse, as well as outline relationships between mood and treatment or

56

Disease Management Model

outlines several important principles to

lifestyle factors such as diet, exercise, or stress.64 While many patients

enhance long-term care for these individuals and their families (Table 9).

will agree with the value of completing a mood diary, and this strategy

After basic clinical management, including attention to diagnosis, comor-

has been shown to improve treatment, regular completion can be a

bidity, and medical health has been established, patient health education

burden.65 Online solutions such as mobile apps may improve adher-

and pharmacotherapy should be the initial and foundational steps for

ence,66 such as the Self-Monitoring and Psychoeducation In Bipolar

all patients. Ideally, the patient will be connected to a health care team

Patients smartphone app (SIMPLE) which provides weekly and daily

which includes at least one other health care professional (typically a

mood tests, with reminders to take medication or see their doctor.67-69

nurse) in addition to the psychiatrist for psychoeducation, ongoing monitoring, psychosocial support, and referral to community resources.57
All patients should have access to a primary care provider to attend to

2.5 | Dealing with stigma

mental and physical health needs. If the patient is stable and discharged

Stigma is an important issue that will impact individuals with BD, as well

to primary care, the mental health care system should provide support

as their family members, potentially preventing individuals from seeking
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T A B L E 8 Summary of main factors associated with suicide
attempt and suicide deaths in bipolar disorder (BD)
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can be perceived or experienced with interactions with others, including health care providers, or internalized (self-stigma). Specific strategies to reduce stigma, particularly self-stigma, by enhancing coping

Increased likelihood of
suicide attempts

Increased likelihood
of suicide deaths

Sex

Female

Male

Age

Younger
Older—higher lethality

Older—higher ratio of
deaths/attempts

Race

Minorities—youth only

Marital status

Single, divorced, single
parents

Age of onset

Younger

may also be useful for acute depressive episodes, as well as in main-

First episode
polarity

Depression
Mixed symptoms
Mania—more violent
attempts

tenance treatment to prevent relapse and to restore quality of life

Predominant
polarity

Depressive

cognitive behavioural therapy (CBT), family-focused therapy (FFT), in-

Current
episode
polarity

Depressive
Mixed

Depressive
Mixed
Manic with psychotic
features

Other episode
characteristics

Mixed features
Greater number/
severity of episodes
Rapid cycling
Anxiety
Atypical features
Suicidal ideation

Hopelessness
Psychomotor
agitation

Substance use disorder
Cigarette smoking
Coffee intake
Anxiety disorder
Eating disorder

Anxiety disorder

Variable

Psychiatric
comorbidity

skills through improvements in self-esteem, empowerment, and help-
seeking behaviour can improve outcomes in this population.71

2.6 | Psychosocial interventions
While pharmacotherapy is essential and forms the foundation for the
successful treatment of BD, adjunctive psychosocial interventions

to the individual and family.72,73 No evidence exists, and hence there
are no recommendations, for specific psychosocial interventions in
acute mania. Positive evidence has been found for psychoeducation,
terpersonal and social-rhythm therapy (IPSRT), and peer support in
the maintenance phase of BD and these interventions are included
as recommended adjunctive treatment options. Additional studies are
needed before conclusions can be drawn regarding other strategies
such as family/caregiver interventions, dialectical behavioural therapy
(DBT), mindfulness-based cognitive therapy (MBCT), cognitive and
functional remediation, and online interventions (Table 10).
In general, provision of psychoeducation to all patients and family members is recommended for prevention of relapse, particularly at
illness onset, with selection of any additional psychosocial therapies
based on individual concerns/presentations or deficits.

2.6.1 | Psychoeducation

Personality
disorders

Present—particularly
borderline or cluster B

Psychoeducation broadly includes provision of information about

Physical
comorbidity

Obesity or high BMI

the patient and family.74 Current psychoeducational models for BD

First-degree
family history

Mood disorders
BD
Suicide

Mood disorders
BD
Suicide

Prior suicide
attempts

Present

Present

Early life
trauma

Childhood abuse
Early life stress

Psychosocial
precipitants

Interpersonal problems
Occupational problems
Bereavement
Social isolation

Sexual
dysfunction

the nature of the illness, its treatments, and key coping strategies to
teach skill development in detecting and managing prodromes of
depression and mania, ongoing stress management, problem solving, how to diminish the effects of stigma and denial of the illness,
and provide tips on enhancing medication adherence and developing healthy lifestyles (eg, minimizing the use of alcohol, tobacco,
drugs, stimulants such as caffeine; getting regular exercise; and
regulating sleep and wake times). A key goal is the creation of perPresent within 1
week of death

Present

Adapted from Schaffer et al.50
BMI, body mass index.

sonalized coping strategies to prevent mood relapse.
Psychoeducation may be delivered individually or in group settings. Empirical models of psychoeducation involve face-to-face interaction with a therapist, but new models are being tested that involve
online tools, smartphone apps, and workbooks.75 Consistent with
broader theories of learning, it is believed that psychoeducation is
enhanced when it features active learning, with attention to monitoring the development of understanding, active skill development, and
homework between sessions. Peer support and group learning are also

or engaging in treatment or causing them to conceal their illness, reduc-

postulated to add efficacy to psychoeducation. Regardless of the type

ing social support, functioning and quality of life.70 Linked to stereotypi-

of model and content included, priority should be given to maximize

cal negative attitudes that mental illness is due to personal weaknesses

the therapeutic alliance, convey empathy, and consistently monitor

or decisions, or associated with violent or criminal behaviour, stigma

symptoms.76
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TABLE 9

The chronic disease management model

Self-management support

Empower and prepare patients to manage their health and health care
Use effective self-management support strategies that include assessment,
goal setting, action planning, problem solving, and follow-up

Decision support

Promote clinical care that is consistent with scientific evidence and patient
preferences
Embed evidence-based guidelines into daily clinical practice and share this and
other information with patients to encourage their participation
Use proven provider education materials

Community

Encourage patients to participate in effective community programs
Form partnerships with community organizations

Delivery system design

Provide clinical care and self-management support that patients understand
and that fits with their cultural background
Ensure regular follow-up by the care team, with defined tasks for different
team members
Provide clinical case management services for complex patients

Clinical information systems

Provide timely reminders for providers and patients
Facilitate individual patient care planning
Share information with patients and providers to coordinate care

Health system

Measure outcomes and use information to promote effective improvement
strategies aimed at comprehensive system change
Develop agreements that facilitate care coordination within and across
organizations

Adapted from Wagner.56

Two models of psychoeducation, both delivered in group for-

additional booster sessions. Despite evidence of efficacy for CBT

mat to individuals who are well (euthymic), have published manu-

for MDD and psychosis, the results of CBT trials for BD have been

als and have substantial research support. These programmes, the

mixed. One large RCT supports it use for acute bipolar depression84

Barcelona BDs Program
Goals Program

78

77

(21 sessions over 6 months) and the Life

in a trial that compared the efficacy of up to 30 (mean 14) CBT

(phase I is six weekly sessions), also have tools

sessions against those of FFT, IPSRT, and a three-session control

to aid implementation with workbooks and handout materials,

intervention, but it was not possible to identify whether the ben-

and both are first-line psychoeducational interventions based on

efits came from changes in the medications prescribed or the psy-

level 2 evidence for the prevention of relapse. Individual psycho-

chosocial treatments. Efficacy of CBT in relapse prevention was

education based on these manuals would probably be effective,

observed in one RCT,85 but not in another larger RCT, at least in

and when individual trials utilizing several different approaches

patients who had multiple mood episodes.86 From meta-analyses,

to psychoeducation are combined in a meta-a nalysis, individual

effects on either depressive symptoms or on relapse remain uncer-

psychoeducation of at least five sessions would still be a first-

tain due to important methodological problems and study selection

line intervention for relapse prevention, based on level 2 evi-

factors.87-89 A promising new direction in CBT has been established

dence.

75,79,80

One large study demonstrated that the six-s ession

by a pilot study of “recovery-focused CBT” where 33 subjects re-

Life Goals Program psychoeducational intervention was equiva-

ceived the novel CBT intervention, with evidence of reduction of

lent in relapse prevention to 20 sessions of individual CBT, at far

relapse in the intervention group.90 Group CBT in euthymic pa-

lower cost, 81 with probable shared mechanisms. 82 Furthermore,

tients with BD is also a new direction and has shown to increase

that study demonstrated that integration of best practices in med-

time in remission.91

ication and psychotherapy simultaneously produced striking over-

In MDD, CBT, interpersonal psychotherapy (IPT) and behavioural

all improvement in course of illness. 83 Psychoeducation does not

activation have been explored in multiple RCTs and in general dis-

have any significant evidence of utility in either acute depressive

play similar efficacies.92 Based on this and the findings of the study

or manic episodes.

by Miklowitz and colleagues in acute bipolar depression,84 CBT is still
recommended as an adjunctive second-line treatment for acute bipo-

2.6.2 | Cognitive behavioural therapy

lar depression (level 2). The recommendation is also second-line for
maintenance treatment (level 2) for patients with fewer episodes and

CBT in BD is supported by several published manuals and typi-

less severe form of illness. No evidence exists, and hence no recom-

cally is given in 20 individual sessions over 6 months, often with

mendation is made, for CBT in mania.
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TABLE 10

107

Strength of evidence and recommendations for adjunctive psychological treatments for bipolar disordera
Maintenance: Recommendation
(Level of Evidence)

Depression: Recommendation
(Level of Evidence)

Psychoeducation (PE)

First-line (Level 2)

Insufficient evidence

Cognitive behavioural therapy (CBT)

Second-line (Level 2)

Second-line (Level 2)

Family-focused therapy (FFT)

Second-line (Level 2)

Second-line (Level 2)

Interpersonal and social rhythm therapy (IPSRT)

Third-line (Level 2)

Third-line (Level 2)

Peer support

Third-line (Level 2)

Insufficient evidence

Cognitive and functional remediation

Insufficient evidence

Insufficient evidence

Dialectical behavioural therapy (DBT)

Insufficient evidence

Insufficient evidence

Family/caregiver interventions

Insufficient evidence

Insufficient evidence

Mindfulness-based cognitive therapy (MBCT)

Insufficient evidence

Insufficient evidence

Online interventions

Insufficient evidence

Insufficient evidence

a

See text for specific definitions of type of therapy and number of sessions needed (“dose of psychosocial intervention”) corresponding to this recommendation and evidence.

the intensity and number of sessions, changes in medication use, or

2.6.3 | Family-focused therapy

specific attributes of IPSRT. Two small studies failed to demonstrate

FFT93 presumes that outcomes in BD may be enhanced with the sup-

specific benefits of IPSRT compared to control conditions.99,100 Other

port and cooperation of family or significant others, particularly in fam-

open studies have shown some pre-post benefits in very small sam-

ilies characterized by high levels of expressed emotion. FFT focuses on

ples.101-103 Again, since many psychosocial treatments for bipolar dis-

communication styles between patients and their families or marital

order share common core elements that may be psychoeducational,

relationships, with the goal of improving relationship functioning, and

it is possible that the relapse prevention aspects of psychoeducation

is delivered to the family and patient in 21 sessions over 9 months.

may also result from IPSRT interventions, mediated by the same ther-

For acute bipolar depression in adults, an intensive FFT (up to 30

apeutic processes.104

94

Overall, IPSRT is recommended as an adjunctive third-line treat-

although this study was limited by the caveats identified for CBT and

ment for acute depression and for maintenance, based on limited (ef-

IPSRT. Given that the original creation of FFT targeted factors related

fect size and small sample size) level 2 evidence in each phase. No

to depression, it may have specific antidepressant activity, which is

evidence exists, and hence no recommendation is made, for IPSRT for

also suggested by reduced depression relapse in maintenance stud-

mania.

sessions; mean 14) out-performed a three-session control condition,

ies. For relapse prevention, four significant RCTs of varying sizes have
been conducted, delivered to a mixed audience of young adults and
adolescents.95 In these studies, FFT demonstrated efficacy in reduc-

2.6.5 | Peer interventions

ing recurrence of new episodes of depression, but not mania. Overall,

Peer interventions, such as peer groups or one-on-one support, are

FFT is recommended as adjunctive second-line treatment for acute

an important strategy believed to reduce self-stigma and isolation in

depression (level 2) and for maintenance (level 2). No evidence exists,

BD, and to help improve engagement in treatment.105 Some caution

and hence no recommendation is made, for FFT for mania.

is needed when applying this strategy, however, as there may be risks
if the peers delivering the intervention are not adequately trained or

2.6.4 | Interpersonal and social rhythm therapy

supported, and if they promote a viewpoint that does not support
treatment compliance or promotes substance use.

IPSRT expands on the IPT focus on grief, interpersonal role tran-

Reviews of peer interventions for persons with serious mental

sition, role dispute, and interpersonal deficits by including regula-

illnesses, usually incorporating a small but significant number of in-

tion of social and sleep rhythms, specifically targeted to the bipolar

dividuals with BD, have demonstrated modest evidence from RCTs

population. It is typically delivered in 24 individual sessions over

and other controlled studies suggesting that there are important im-

9 months.

96,97

provements in self-efficacy and reduction in self-stigma.106-109 The

Few controlled trials of IPSRT have been conducted, with lim-

largest peer intervention study involving BD allocated 153 individuals

ited evidence of acute efficacy. The first, large trial98 showed no ef-

to attend 21 weekly group psychoeducation events, with another 151

fect of IPSRT compared to a control condition but did show benefit

assigned to attend 21 weekly group peer support events. The two pro-

for reduction of relapse and improved occupational functioning. An

grammes achieved similar outcomes in terms of time to relapse, and

acute bipolar depression study84 showed intensive IPSRT (up to 30

increased knowledge about BD, although psychoeducation was more

sessions; mean 14) out-performed a three-session control condition,

acceptable to the subjects and worked more effectively at preventing

but it is impossible to state whether the performance was related to

relapse in a subset of people with fewer previous episodes.110

108

|

YATHAM et al.

A significant source of peer support is emerging from online
resources, particularly through the websites of peer advocacy or-

2.6.7 | Cognitive and functional remediation

ganizations such as the Depression and Bipolar Support Alliance

Functional impairment as well as cognitive deficits are found in many

(http://www.dbsalliance.org/site/PageServer?pagename=peer_

individuals with BD, not just during an acute episode but even be-

landing), the Mood Disorders Association of Ontario (https://www.

tween episodes, prompting the evaluation of various psychosocial

mooddisorders.ca/), the research and advocacy group CREST.BD

and biological strategies to address these problems. One intervention,

(http://www.crestbd.ca/),

(www.moodswings.net.

functional remediation (FR), involves a 21-session group intervention

au/), and Revivre (http:/wwww.Revivre.org). YouTube is also emerg-

over 6 months. In a large RCT, FR was shown to have a substantial im-

ing as an important source of peer support, along with other social

pact on functioning, in comparison to treatment as usual.117 Coupled

media.111,112

with the results of other small studies involving other interventions,

MoodSwings

Overall, peer interventions receive a third-line treatment recommendation (level 2) as an adjunctive maintenance therapy.

these findings suggest that there is considerable hope in addressing
cognitive and functional deficits in BD.118 Computer-based cognitive
remediation, though, may show positive effects on cognition but not

2.6.6 | Other psychosocial interventions
Various other approaches have been tried in BD, with a variety of
aims, modalities, and outcome targets. None of the other interven-

on functioning.119

2.6.8 | Online and digital strategies

tions have been specifically targeted for bipolar depression or for

Modern trends to rely on the internet and apps, along with access

mania. Some have been designed in part to reduce episode recur-

problems in mental health, have led to the study of various online

rence, but none have been successful in providing substantial evi-

tools and mobile phone apps.120 Such strategies also build on strong

dence of efficacy. Because CANMAT recommendations are for the

traditions of self-
monitoring and self-
management developed for-

treatment of acute depression and mania, and maintenance treat-

mally in traditional psychoeducational interventions. In reviews, such

ment to prevent them, we do not make specific recommendations

internet and mobile health interventions have shown good adherence

regarding these treatments. However, some of these approaches have

to validated psychological health principles, good acceptability to pa-

been helpful in ameliorating some important symptoms in individuals

tients, ease of access, and ease of use. However, research is mostly

with BD, (such as residual mood symptoms or anxiety) and so we will

limited to pilot studies and the relatively few larger studies have not

describe them briefly.

shown unequivocal benefit.68,121

Although somewhat like FFT, family/caregiver interventions constitute a distinctly different psychosocial intervention in that the intervention is given to the family/caregiver, not the person with BD,
and evidence exists that such interventions improve clinical outcomes
in the patient.75,113 Clinical wisdom and common practice, however,
support the importance of family or caregivers being included in at

3 | ACUTE MANAGEMENT OF
BIPOLAR MANIA
3.1 | Presentations of mania

least some sessions with the patient (particularly for psychoeduca-

DSM-55 made a change to “criterion A” for mania which now requires

tion), both to reduce symptom burden on the individual with BD and

a distinct period of abnormally and persistently elevated, expansive,

to reduce burnout and emotional burden on the caregiver. Validated

or irritable mood and abnormally and persistently increased activity or

caregiver resources are available online, such as www.bipolarcaregiv-

energy present most of the day, nearly every day for at least 1 week

ers.org.
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(or less time if hospitalization is necessary). In addition, a diagnosis of

DBT, which includes distress tolerance training, has several small

a “manic episode” requires at least three (or four if the mood is only

studies showing its utility in the reduction of some depressive symp-

irritable) of the following symptoms: inflated self-esteem or grandios-

toms and suicidality.75

ity, decreased need for sleep, more talkative than usual or pressure

One RCT of MBCT involving 95 patients did not demonstrate any

of speech, flight of ideas or subjective experience that thoughts are

difference in relapse prevention compared to a treatment-as-usual

racing, distractibility, increased goal-directed activity or psychomotor

group, but did reveal fewer anxiety and depressive symptoms in the

agitation, or excessive involvement in activities with a high potential

MBCT arm.115 Coupled with the findings of other smaller studies, this

for painful consequences. The mood disturbance must lead to marked

suggests that MBCT may have a role to play in anxiety reduction in

impairment in functioning, require hospitalization, or be accompanied

BD.75,116

by psychotic features.

While not reviewed here, given that individuals with BD may have

Unlike DSM-IV, DSM-5 allows a diagnosis of BDI in patients with

histories of childhood abuse and comorbid personality disorders, and

major depression whose mania emerges during treatment (eg, during

experience various sequelae such as shame or conflict due to be-

medication or electroconvulsive therapy [ECT]) and persists at a fully

haviours experienced during acute bipolar episodes, all of these may

syndromal level beyond the physiological effect of the treatment.

rightly be a target for psychosocial intervention in a very individualized
manner.

DSM-5 has eliminated the categorical “mixed episode” specifier,
replacing it with the more dimensional “mixed features”. DSM-5 also

|

YATHAM et al.

109

includes other specifiers that can accompany a manic episode: anx-

In countries where inhaled loxapine is available, this could be consid-

ious distress, rapid cycling, mood-
congruent or mood-
incongruent

ered if there are no contraindications.

psychotic features, catatonia, peripartum onset, and seasonal pattern

If oral preparations are ineffective or if the agitation is severe

(Table 5). The utility of several of these specifiers in selecting treat-

and if the patient is refusing oral medications, or when oral ther-

ment options for mania is discussed later in this section (see “Clinical

apy cannot be safely or reliably administered, then IM formulations

features that help direct treatment choice”).

should be considered.124 Because of the strength of evidence for
efficacy in alleviating agitation in this population, aripiprazole IM
(level 2),125,126 lorazepam IM (level 2),125,127 loxapine inhaled (Level

3.2 | Management of agitation

1)128,129 and olanzapine IM (level 2)127,130-133 are recommended as

Agitation is common in mania, and is particularly frequent in patients
who have mixed features.

122

Defined in DSM-5 as “excessive motor
5

the first-line option. Sublingual asenapine (level 3),134 haloperidol IM
(level 3),131,135,136 haloperidol IM + midazolam IM (level 3),131,137 hal-

activity associated with a feeling of inner tension”, agitation can

operidol IM + promethazine IM (level 3),131,137,138 risperidone ODT

manifest as pacing or fidgeting in mild cases to uncooperative, threat-

(level 3),136 and ziprasidone IM (level 3)131,137,139 are recommended

ening, or aggressive behaviours in severe cases. Severe symptoms of

as a second-line treatment. Haloperidol per os (PO) (level 4),140,141

agitation require prompt attention in order to reduce distress, mitigate

loxapine IM (level 4) (clinical opinion), quetiapine PO (level 4),141

potentially dangerous behaviour, and allow for an assessment and

and risperidone PO (level 4)140 are included as third-line options

evaluation of underlying manic symptoms.

123

(Table 11).

A key step in treating agitation is preventing it, or at least mitigating its severity, by rapidly treating the causative manic episode. When
addressing agitation in patients with BDI, clinicians need to be aware

3.3 | Pharmacological treatment of manic episodes

that akathisia may present as agitation and, therefore, this must be

There are a range of strategies that have been investigated for use in

excluded before implementing the general principles of management

mania; including lithium, divalproex, other anticonvulsants, typical and

of acute mania described in step 1 (see “Pharmacological treatment

atypical antipsychotics, and other agents and therapies. These treat-

of manic episodes”). Since agitation in this context is a manifestation

ments have been evaluated using the criteria for strength of evidence

of mania, it is assumed that effective interventions for treating mania

for efficacy (Table 1) as well as safety and tolerability (Section 8). The

that have rapid onset of efficacy would be effective in reducing agita-

evidence for efficacy and the recommendations for treating acute

tion. Therefore, if the patient is agreeable to taking oral medications,

mania are summarized in Table 12.

antimanic agents with rapid onset of efficacy should be considered
first.

As stated previously, the firstand second-line agents are listed hierarchically taking into consideration not only their efficacy for acute

When agitation persists despite administration of antimanic

mania but also their efficacy in preventing mania or depression, treating

treatments, additional rapidly acting pharmacotherapy may often be

acute bipolar depression, safety/tolerability and the risk of treatment-

needed. The evidence for specific efficacy of various agents in short-

emergent switch. The implication of this hierarchical recommendation

term treatment of agitation is summarized in Table 11. Some of these

is that those listed higher up in the table should be considered first

agents are either not available or rarely used in North America (eg,

before moving on to the next on the list, unless other factors such

midazolam and promethazine). We further note that the dose ranges

as history of previous non-response or patient’s preferences preclude

in Table 11 are based on the doses studied in the trials, and would

such strategy in a given patient.

probably be appropriate in most situations. However, a comprehen-

Monotherapy and combination therapy are listed separately

sive evaluation of the agitated patient is necessary (ie, medical con-

as first-l ine treatments for acute mania in Table 12. This does not

ditions, treatments, drugs, intoxication, etc.) to determine a safe and

mean that all monotherapy agents should be tried first before

adequate dose.

considering combination therapy for acute mania. We suggest

As can be seen from Table 11, the highest level of evidence avail-

that the treating clinician make a decision as to whether to treat

able in short-term treatment of agitation for oral formulations of any

a given patient with monotherapy or combination therapy. That

agent is level 3, and level 2 for intramuscular (IM) or inhaled formula-

decision is typically based on the rapidity of response needed

tions. In this context, it is important to remember that the absence of

(eg, combination treatments tend to work faster), whether the

evidence does not constitute lack of efficacy. Indeed, clinical expe-

patient had a previous history of partial response to monother-

rience suggests that agitation in many patients with acute mania re-

apy, severity of mania, tolerability concerns with combination

sponds well to the oral medications. Thus, a loading dose of divalproex,

therapy, and willingness of the patient to take combination ther-

oral formulations of atypical antipsychotics, conventional antipsychot-

apy. Once a decision is made whether to treat the patient with

ics such as haloperidol or loxapine, and/or benzodiazepines such as

monotherapy or combination therapy, then hierarchy related

lorazepam may be appropriate. If a patient indicates willingness to take

to monotherapy or combination therapy could be followed. We

oral treatment but there is a suspicion that the patient might “cheek”

also suggest that clinicians evaluate the efficacy and tolerabil-

the medication, then either orally dispersing tablets (ODT), those that

ity at the end of weeks 1 and 2 and modify treatment options

rapidly melt, oral liquid, or oral inhalation forms should be considered.

accordingly.
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Level of evidence and recommendations for short-term pharmacological management of agitationa
Dose range of studiesb

Level of
recommendation

Agent

Formulation

Level of evidence

Single dose

Max/24 h

First-line

Aripiprazole

IM

2

9.75 mg

15 mg

Lorazepam

IM

2

2 mg IM

Loxapine

Inhaled

1

5 mg

10 mg

Olanzapine

IM

2

2.5 mg

10 mgc

Asenapine

Sublingual

3

10 mg

Haloperidol

IM

3

5 mg

15 mg

Haloperidol + midazolam

IM

3

2.5 mg (haloperidol) +
7.5 mg (midazolam)

5 mg (haloperidol) + 15mg
(midazolam)

Haloperidol + promethazine

IMe

3

2.5 mg (haloperidol) +
25 mg (promethazine)

5 mg (haloperidol) + 50 mg
(promethazine)

Risperidone

ODTe

3

2 mg

4 mg

Ziprasidone

IMe

3

2 mg

20 mg
15 mg

Second-line

Third-line

d

Haloperidol

PO

4

5 mg

Loxapine

IM

4

N/A

Quetiapine

POd

4

Mean (SD) = 486.7 (317.2) mg/day

Risperidone

POe

4

2 mg

a

See text for recommendations about use of oral antipsychotics and divalproex. IM, intramuscular; ODT, orally disintegrating tablet; PO, per os.
Doses are reported as per studies.
c
26.3% received two or three 10 mg injections.
d
Assessed 2 h after the dose.
e
Doses are not specifically for bipolar disorder but included schizophrenia or other diagnoses.
b

3.3.1 | Step 1: review general principles and assess
medication status

monitoring patients for a period of time after antidepressant discontinuation and obtain collateral information to confirm whether
symptoms remain and antimanic treatment is necessary. Patients

Examination of a patient presenting in a manic state should include

should also be supported to discontinue stimulant use, including caf-

an immediate assessment for risk of aggressive behaviour, violence

feine and alcohol. Current and prior therapies should be assessed,

and safety threat to others, suicide risk especially in those with mixed

including appropriateness of medications, dosing, and trough serum

features, degree of insight and the ability to adhere to treatment,

levels (where indicated), as well as past response; and this should

comorbidity (including substance use that may be aggravating or

be used to direct subsequent therapeutic choices. Attention should

contributing to clinical presentation), and availability of a psychoso-

be paid to managing withdrawal symptoms that may occur in manic

cial support network. A physical examination with laboratory inves-

patients with histories of substance abuse.

tigations (described in Section 8) should be conducted, but may be

When the symptoms of mania have remitted, behavioural and ed-

deferred for patients who are uncooperative. Results of the overall

ucational strategies should be applied to promote ongoing medication

assessment should be used to establish the most appropriate treat-

adherence, reduce residual symptoms, help identify early signs of re-

ment setting (eg, ambulatory or inpatient).

lapse, and support functional recovery (see Section 2).

Before initiating pharmacological treatment for a manic episode,
it is imperative to rule out symptoms secondary to drugs of abuse,
medications, other treatments, or a general medical or neurological
condition (although, even in these cases, symptomatic treatment

3.3.2 | Step 2: initiate or optimize therapy and
check adherence

may be applied on a short-term basis). Steps should be taken to rule

It is recommended that, for all patients (including those who are un-

out any other factors that may be perpetuating symptoms such as

treated as well as those receiving a non-first-line treatment), therapy

prescribed medication, illicit drug use/abuse or an endocrine dis-

be initiated with one of the available first-line monotherapy or com-

order. Any patients presenting with mania who have been taking

bination treatments.

antidepressants should have these medications discontinued. If
there is a previous diagnosis of BD, it is appropriate to immediately

First-line monotherapy

commence antimanic agents. If this is the first emergence of manic

Approximately 50% of patients will respond to monotherapy with

symptoms, clinicians are advised to confirm the diagnosis of BD by

significant improvement in manic symptoms within 3-
4 weeks.142

Hierarchical rankings of firstand second-line treatments recommended for management of acute mania

DVP, divalproex; ECT, electroconvulsive therapy; Li, lithium.
, level 1 evidence; , level 2 evidence; , level 3 evidence; , level 4 evidence; , level 1 negative evidence; , level 2 negative evidence; , level 3 negative evidence; , level 4 negative evidence; n.d.,
no data; Limited impact on treatment selection; , minor impact on treatment selection; , moderate impact on treatment selection;
, significant impact on treatment selection.
a
Although monotherapies are listed above combination therapies in the hierarchy, combination therapies may be indicated as the preferred choice in patients with previous history of partial response
to monotherapy and in those with psychotic mania or in situations where rapid response is desirable.
b
Did not separate from placebo in those with index mania; no studies available in index depression.
c
No controlled trials; however, clinical experience suggests that it is a useful strategy.
d
Did not separate from placebo on core symptoms of depression.
e
Divalproex and carbamazepine should be used with caution in women of childbearing age.
[Colour table can be viewed at wileyonlinelibrary.com]
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Lithium (level 1), quetiapine (level 1), divalproex (level 1), asenapine
(level 1), aripiprazole (level 1), paliperidone (level 1 for doses >6 mg),
risperidone (level 1), and cariprazine (level 1) are all recommended as

3.3.3 | Step 3: add on or switch therapy (alternate
first-line agents)

first-line treatment options. Overall, these agents show comparable

If therapy with one or a combination of the first-line agents (lithium,

efficacy (Cohen’s d 0.32-0.66; small to medium effect size).143

divalproex and/or an atypical antipsychotic) at optimal doses is inad-

Although they have comparable efficacy for treating acute mania,

equate or not tolerated, the next step is to switch to or add on an al-

we recommend that the agents listed first in the text and placed higher

ternate first-line agent. An exception is that, despite level 1 evidence

in Table 12 be tried first, in the order listed, unless there are patient-

for monotherapy with paliperidone and ziprasidone, we do not

specific reasons for choosing an agent lower down in the order (see

recommend combination therapy with these agents due to lack of

“Clinical features that help direct treatment choices”). For instance,

evidence for additional efficacy (see “No specific recommendation/

lithium should be considered first for acute mania unless there are

agents that require further study” below). Because there are multiple

specific reasons not to, such as mixed features, comorbid substance

first-line agents with substantial efficacy data and relative safety and

use or previous non-response to lithium.

tolerability, the use of second-and third-line agents is only recom-

Carbamazepine, olanzapine, ziprasidone and haloperidol also have

mended after unsuccessful trials of multiple first-line strategies.

level 1 evidence for efficacy but they are downgraded to second-line
options due to safety/tolerability risks with these agents.

3.3.4 | Step 4: add on or switch therapy (second-line
agents)

First-line combination therapy
Combination therapy with the atypical antipsychotics quetiapine

Second-line

(level 1), aripiprazole (level 2), risperidone (level 1), or asenapine (level

In patients who are inadequately responsive to first-
line agents,

2) and lithium or divalproex is also recommended as first-line treat-

second-line choices include monotherapy with olanzapine (level 1),

ment options with greater efficacy than monotherapy with lithium

carbamazepine (level 1), ziprasidone (level 1), and haloperidol (level

or divalproex alone, especially in those with higher index severity.144

1)143 or combination therapy with olanzapine plus lithium or dival-

In general, combination therapy is preferred to mood stabilizer

proex (level 1). While each of these strategies has strong support for

monotherapy because clinical trials suggest that on average about

their efficacy, as indicated above, safety and tolerability concerns

142,145,146

relegate them to second-line options. Although widely used in clini-

There is also some evidence to suggest the benefit of combination

cal practice, the combination of lithium and divalproex is also recom-

therapy compared to atypical antipsychotic monotherapy, although

mended as a second-line choice, as evidence supporting its efficacy is

there are fewer trials. Specifically, lithium plus quetiapine showed su-

limited to uncontrolled trials (level 3).148-151

20% more patients will respond to combination therapy.

periority to quetiapine alone.147 While there is also level 1 evidence

ECT is also recommended as a second-line option (level 3)152 and,

for olanzapine combination therapy over olanzapine monotherapy,

although the number of controlled trials is limited, there is evidence to

this is downgraded to second-line due to tolerability/safety concerns

suggest that up to 80% of patients will show marked clinical improve-

with olanzapine.

ments.153 Brief pulse therapy with two or three treatments per week

The decision to treat with one or a combination of available first-

has been used. Bifrontal electrode placement is preferred over bitem-

line agents should be informed by current and prior medication use,

poral as it is associated with faster treatment response and fewer cog-

with treatment previously shown to be successful in managing symp-

nitive side effects.154-156

toms preferred. Safety and tolerability factors for each medication and

When all first-line agents have failed, the hierarchy should be ap-

clinical features predictive of better response (see “Clinical features

plied to second-line agents as well. Hence, olanzapine, which is high-

that help direct treatment choices”) should also be considered. In gen-

est in the hierarchy amongst second-line agents, should be first choice

eral, combination therapy is associated with more adverse events than

before moving down the list in Table 12.

monotherapy. Whenever possible, options should be discussed with
the patient and/or their caregiver and their preferences considered
prior to treatment selection.
If symptoms are not controlled using monotherapy or combination

3.3.5 | Step 5: add on or switch therapy (third-line
agents)

therapy with first-line agents, dosing should be optimized, issues of

Third-line

non-adherence identified and addressed, and consideration given to

Agents recommended as third-line options for treatment of acute mania

possible substance use (Section 4) prior to adding or switching ther-

include monotherapy with chlorpromazine (level 2),157 monotherapy

apies (Step 3). Given that almost all antimanic agents separated from

with clonazepam (level 2),158 monotherapy or adjunctive therapy with

placebo within 1 week, some therapeutic response is expected with

clozapine (level 4),159-162 and monotherapy with tamoxifen (level 2).143

antimanic agents within 1-2 weeks. If no response is observed within

Tamoxifen is downgraded because of the risk of uterine cancer and the

2 weeks with therapeutic doses of antimanic agents, and other con-

lack of clinical experience despite evidence for efficacy. Combination

tributing factors for non-response are excluded, then switch or add-on

treatments with carbamazepine or oxcarbazepine (level 3),163 haloperi-

strategies should be considered.

dol (level 2),144,164 or tamoxifen (level 2)165 plus lithium or divalproex are
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TABLE 13

Additional agents evaluated for use in acute mania

Studies of olanzapine (level 2 negative)
174

Third-line

negative)

173

113

or risperidone (level 3

plus carbamazepine have been negative, although this is

Agent

Level of evidence

Carbamazepine/oxcarbazepine + Li/DVP

Level 3

Chlorpromazine

Level 2

tions are unpredictable and effective doses have not been established,

Clonazepam

Level 2

we are unable to provide a specific recommendation.

Clozapine

Level 4

Nutraceuticals such as branched chain amino acids (level 3),175

Haloperidol + Li/DVP

Level 2

folic acid (level 2),176 and l-tryptophan (level 3),177 as well as other

rTMS

Level 3

experimental agents such as medroxyprogesterone (level 3),178,179 me-

Tamoxifen

Level 2

mantine (level 4),180 mexiletine (level 4),181 levetiracetam (level 4)182

Tamoxifen + Li/DVP

Level 2

and phenytoin (level 3),183 have all shown indications of efficacy when

Level 1 negative

used adjunctively with other antimanic agents, as have glasses that

Not recommended Allopurinol

probably due to enzyme-inducing effects of carbamazepine. While
this may be overcome by dosing adjustments, because such interac-

Eslicarbazepine/licarbazepine

Level 2 negative

Gabapentin

Level 2 negative

Lamotrigine

Level 1 negative

Omega-3 fatty acids

Level 1 negative

Topiramate

Level 1 negative

Valnoctamide

Level 2 negative

Zonisamide

Level 2 negative

DVP, divalproex; Li, lithium; rTMS, repetitive transcranial magnetic
stimulation.

block blue light (level 3).184 Larger controlled trials are needed, however, before a recommendation for their use in mania can be made.
While an initial small RCT did not show anti-manic efficacy for verapamil,185 there is some evidence that it may work as an adjunctive
therapy (level 4)186 or as monotherapy in women (level 4).187 Larger
studies are needed before a conclusion can be made.

3.3.8 | Clinical features that help direct
treatment choices
Clinical features, including DSM-5 specifiers, may assist in making
treatment choices between firstand second-line treatment options.

also included as third-line. Repetitive transcranial magnetic stimulation

In general, lithium is preferred over divalproex for individuals who

(rTMS) in the right prefrontal cortex at 110% motor threshold (level

display classical euphoric grandiose mania (elated mood in the ab-

3)166 can also be considered in combination with pharmacotherapy.

sence of depressive symptoms), few prior episodes of illness, a mania-

The third-line agents should only be used if a patient has not re-

depression-euthymia course,188-190 and/or those with a family history

sponded to adequate trials with all firstand second-line agents alone

of BD, especially with a family history of lithium response. Divalproex

and in combination. Given that the evidence is very limited for third-

is equally effective in those with classical and dysphoric mania.

line agents, it was not possible to list them in any hierarchical order

Further, divalproex is recommended for those with multiple prior

and they are thus listed alphabetically (Table 13).

episodes, predominant irritable or dysphoric mood and/or comorbid
substance abuse or those with a history of head trauma.188,191-195
Because of its teratogenic potential, however, caution should be ex-

3.3.6 | Agents not recommended for the
treatment of acute mania

ercised when prescribing divalproex to women of childbearing age.
Patients with specific factors such as a history of head trauma, comor-

Antimanic efficacy has not been demonstrated for allopurinol (level 1
167

negative),

168

eslicarbazepine/licarbazepine (level 2 negative),

gabap-

entin (Level 2 negative), lamotrigine (level 1 negative),143 omega-3 fatty
169

acids (level 1 negative),

143

topiramate (level 1 negative),

valnoctamide

(level 2 negative),170,171 or zonisamide (level 2 negative)172 (Table 13).

bid anxiety and substance abuse, schizoaffective presentations with
mood-incongruent delusions, or negative history of bipolar illness in
first-degree relatives may respond to carbamazepine.196
Combination therapy with lithium or divalproex and an atypical
antipsychotic is recommended when a response is needed faster, in
patients judged at risk, who have had a previous history of partial acute

3.3.7 | No specific recommendation/agents that
require further study

or prophylactic response to monotherapy or in those with more severe

Trials with paliperidone (level 2 negative) and ziprasidone (level 2 neg-

Anxious distress

ative) adjunctive therapy to lithium or divalproex showed lack of ef-

Symptoms of anxiety frequently co-occur during a manic episode, and

ficacy.144 This is surprising given that all other atypical antipsychotic

are a predictor of poor outcome; including greater severity of manic

agents that showed efficacy in monotherapy have also been shown to

symptoms,197 a longer time to remission,197,198 and more reported

offer additional benefit when combined with lithium or divalproex. It is

side effects of medication.198 There have been no studies specifically

likely that methodological problems have contributed to failure in these

examining the efficacy of any agents in reducing symptoms of anxiety

studies; hence, further studies are needed before specific recommen-

during a manic episode, although these symptoms do tend to improve

dations can be made about the use of these combinations for mania.

concurrently with mood disturbance. Post hoc analyses suggest that

manic episodes.145
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divalproex, quetiapine, and olanzapine may have specific anxiolytic

double mood stabilizer therapy in a single RCT,221 although methodo-

benefits199 and carbamazepine may be useful as well.196

logical weaknesses probably limited interpretability of the findings.

Mixed features

Seasonal pattern

Depressive symptoms co-
occur alongside mania in 10%-
30% of

While some individual patients may show a seasonal pattern, Canadian

200,201

cases,

with studies suggesting mixed features are indicative of

data are mixed as to whether episodes of mania or depression in BD

a more severe and disabling course, as well as a higher rate of sui-

follow a consistent seasonal variation.222 There is no evidence for the

201,202

cide.

Evidence supports the preferential use of atypical antip-

sychotics and divalproex in these cases, with combination therapy
195,203

frequently required.

superiority of any agent in patients with an observed seasonal pattern
of manic episodes.

Atypical antipsychotics such as asenapine,

aripiprazole, olanzapine and ziprasidone have been shown to be equally
effective in treating manic symptoms in those with classical mania as
well as in mixed mania or in manic patients with mixed features.196,204,205

4 | ACUTE MANAGEMENT OF
BIPOLAR DEPRESSION

Psychotic features (mood congruent or incongruent)

4.1 | Presentations of bipolar depression

At least half of manic episodes are characterized by the presence of
psychosis,206 and theories suggest that it is a nonspecific feature which
improves alongside underlying manic symptoms.207 While the prognosis for patients experiencing mood-congruent psychotic features may
not differ from those with an absence of psychotic symptoms, limited
evidence does suggest that those with mood-incongruent features
have a more severe illness with poorer long-term prognosis.207-212
There is no evidence of superiority of any first-
line monotherapy
treatment in comparison to other monotherapy options in treating patients with psychotic features. Similarly, there is no evidence that any
first-line combination therapy of lithium or divalproex plus an atypical antipsychotic is more effective than other first-line combination
174,193,213,214

therapy.

However, clinical experience suggests that the

combination of lithium or divalproex plus an atypical antipsychotic
is more appropriate for manic patients with mood-incongruent psychotic features (ie, other than grandiose delusions). Similarly, in patients where the diagnostic possibility of schizoaffective disorder with
manic symptoms is considered, either use of an atypical antipsychotic
or combination of an atypical antipsychotic with a mood stabilizer is
more appropriate.

Rapid cycling

The DSM-
5 criteria for bipolar depression are unchanged from
DSM-IV. Depression is characterized by a minimum of 2 weeks of
depressed mood and/or anhedonia and at least four other symptoms
that include changes in sleep, appetite/weight, energy, psychomotor
activity, concentration, thought content (guilt and worthlessness),
and suicidal intent. For many patients with BD, the depressive polarity is often more pervasive and more debilitating than manic states,
with estimates that depressed mood accounts for up to two-thirds of
the time spent unwell, even with treatment.12,223,224 Subsyndromal
depressive symptoms, which persist despite treatment, are particularly common and a major source of functional impairment in these
patients.225-229 They should be treated aggressively.
DSM-5 includes several specifiers that may accompany depressive
episodes: anxious distress, mixed features, rapid cycling, melancholic
features, atypical features, mood-
congruent or mood-
incongruent
psychotic features, peripartum onset, and seasonal pattern (Table 5).
The utility of several of these specifiers in selecting treatment options
for depression is discussed later in this section (see “Clinical features
that help direct treatment choices”).

4.2 | Diagnostic and treatment challenges

Rapid cycling, or a course of illness that includes four or more mood
episodes a year, affects up to one-third of patients with BDI.215-218
Hypothyroidism, antidepressant use and substance abuse are often

4.2.1 | Misdiagnosis and delayed diagnosis

associated with rapid cycling; thus assessing thyroid function and dis-

Patients with depression occurring in the context of BD are fre-

continuation of antidepressants, stimulants, and other psychotropic

quently misdiagnosed as having MDD, since the presence of mania

agents that are contributors to cycling are imperative. Consideration

or hypomania (particularly mild or moderate episodes which do not

should be given to gradually withdrawing substances in order to pre-

require hospitalization) may be challenging to establish retrospec-

vent withdrawal, but this needs to be balanced against the severity of

tively. This is especially true in the absence of a comprehensive

mood cycling and the need for rapid mood stabilization. As there is

diagnostic interview or collateral information, as patients may often

no evidence for the superiority of any first-line treatment in address-

lack basic knowledge of what hypomania/mania is, and/or have lim-

ing acute manic symptoms in patients with a rapid cycling course,219

ited insight into these symptoms; and thus may not disclose this

appropriate pharmacotherapy should be selected primarily based on

information unless specifically asked. Alternatively, patients who

effectiveness in the maintenance phase, if known (see Section 5). It is

will ultimately present with hypomanic or manic episodes may only

likely that combinations of mood-stabilizing drugs may be more often

have experienced episodes of depression. Thus, clinicians must be

necessary than monotherapies when rapid cycling is present,220 but

vigilant for a diagnosis of BD, and routinely ask for symptoms of

triple mood stabilizer therapy has not demonstrated superiority to

a previous manic/hypomanic episode in every patient presenting
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with a major depressive episode. A diagnosis of MDD should be

further exacerbate cognitive difficulties238 (see Section 8). Although

made only after excluding the possibility of BD.

evidence for their efficacy is limited, cognitive enhancement therapies

In addition to overt manic/hypomanic symptoms, there are nu-

can be considered experimental in this population.72,239,240

merous features that increase the likelihood of a diagnosis of BD
in depressed individuals. These include earlier age of illness onset
(before 25 years), brief, highly recurrent depressive episodes, a
family history of BD, depression with psychotic features, atypical

4.3 | Psychological interventions for acute bipolar
I depression

features such as reverse vegetative symptoms of hypersomnia and

While pharmacotherapy is essential and forms the foundation for

hyperphagia, leaden paralysis, psychomotor agitation, postpartum

successful treatment of BD, adjunctive psychosocial interventions

depression or psychosis, and antidepressant-
induced irritability,

may also be useful for acute depressive episodes. As described in

manic symptoms or rapid cycling38,39 (Table 6).

Section 2, there are no first-line psychosocial treatment options for

Individuals with depression who are at high risk for BD, par-

acute bipolar depression. Selecting between second-line options

ticularly those with a strong family history of BD, should be

such as CBT (level 2) and FFT (level 2), as well as the third-line op-

closely monitored for emergence of manic or mixed symptoms.

tion IPSRT (level 3), should be based on individual strengths and

Consideration should also be given to applying the BD depression

needs.

treatment recommendations amongst those at very high risk, rather
than risk potential iatrogenic effects of antidepressant monotherapy, although this recommendation is based on clinical experience
as there is a lack of sufficient research addressing this issue. As

4.4 | Pharmacological treatment for acute
bipolar depression

discussed in Section 2, there are also several useful psychosocial

Lithium, anticonvulsants, atypical antipsychotics, and other agents

interventions, such as individual and family psychoeducation and

such as antidepressants have all been investigated for efficacy in man-

FFT, that have been shown to have some benefit in this population.

aging bipolar depression. These treatments have been evaluated using
the criteria for strength of evidence for efficacy (Table 1) as well as

4.2.2 | Suicide risk

safety and tolerability (Section 8). Recommendations are summarized
in Table 14.

Principles related to management of suicidal ideation and risk (see
Section 2 and47) are of utmost importance during depressive episodes, as >70% of suicide deaths and suicide attempts in patients
with BD occur during this phase.230,231 Depressive episodes with

4.4.1 | Step 1: review general principles and assess
medication status

mixed features are a particularly dangerous period associated

Examination of a patient presenting in a depressed state should in-

with even higher short-term risks of suicide attempts or death.232

clude an assessment of the nature and severity of depression and

Overall, it is imperative for clinicians to review risk factors (Table 9)

associated symptoms, risk of suicide/self-harm behaviour, ability

and determine an appropriate treatment setting to address any

to adhere to a treatment plan, availability of a psychosocial sup-

safety issues. All patients at risk should be encouraged to develop

port network, and functional impairment. Laboratory investigations

and share a written safety plan listing coping strategies and sources

(described in Section 8) should also be completed. Results of the

of support which may be applied during times of crisis. As described

overall assessment should be used to establish the most appropriate

in Section 2, the most common method of suicide in this population

treatment setting (eg, ambulatory or inpatient), with consideration

is self-poisoning, and so potential benefits of various treatments

given to management of safety risks. Before initiating pharmacolog-

should be considered against their risk of toxicity and lethality. One

ical treatment for a depressive episode, it is imperative to rule out

study found that there were fewer deaths due to lethal lithium lev-

symptoms secondary to alcohol/drug use, medications, other treat-

els compared to carbamazepine, and that opioids and benzodiaz-

ments, or a general medical condition. Patients should be supported

epines were the most common medication classes ingested at lethal

to discontinue stimulant use and limit nicotine, caffeine, drug, and

levels—noteworthy given the lack of efficacy of these agents in the

alcohol use. Course of illness and treatments used in current and

disorder.55

prior episodes should be assessed, including past response to and
tolerability of specific medications and doses, and used to direct

4.2.3 | Cognitive and functional impairment

subsequent therapeutic choices. Consideration should be given to

Part of the impact of acute and subsyndromal depressive symptoms

coincide with a depressive relapse.

restarting medications if their recent discontinuation appeared to

on functional impairment is thought to be mediated through cogni-

Psychoeducation and other psychosocial strategies should also

tive performance, which is both subjectively and objectively impaired

be offered alongside pharmacological treatment to promote ongoing

in bipolar depression and linked to poor psychosocial function.233-236

medication adherence, reduce residual symptoms and suicidal be-

Because of the important link between cognition and functioning,237 attention should be paid to avoiding treatments that may

haviour, help identify early signs of relapse, and support functional
recovery (see Section 2).

Hierarchical rankings of firstand second-line treatments recommended for management of acute bipolar I depression

adj, adjunctive; DVP, divalproex; ECT, electroconvulsive therapv; Li, lithium, SSRIs, selective serotonin reuptake inhibitors.
, level 1 evidence; , level 2 evidence; , level 3 evidence; , level 4 evidence; , level 1 negative evidence; , level 2 negative evidence; , level 3 negative evidence; , level 4 negative evidence; n.d.,
no data; , limited impact on treatment selection; , minor impact on treatment selection; , moderate impact on treatment selection;
, significant impact on treatment selection.
a
Trend for superiority on the primary efficacy measure, hence the lower rating.
b
Effective in those with an index episode of depression.
c
Negative data from the trial are probably due to methodological issues; rating based on expert opinion.
d
Divalproex and carbamazepine should be used with caution in women of child bearing age.
[Colour table can be viewed at wileyonlinelibrary.com]
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Why are lithium and lamotrigine recommended as first-line agents for bipolar depression?
Reconciling conflicng data
Lithium
In the only large double blind placebo controlled trial conducted to date, lithium was not more effecve than placebo for treang acute
bipolar depression(254). So, how does one jusfy recommending lithium as a first-line agent?
The mean serum lithium levels in this study was only 0.61 mEq/L and this may account for lack of efficacy as a previous study demonstrated
that lithium monotherapy was as effecve as lithium plus paroxene in those with serum lithium levels of ≥0.8 mEq/L (247).
Further, several small crossover trials demonstrated significantly higher response rates to lithium than placebo in paents with acute
bipolar depression (245). As well, the STEP-BD study suggested that mood stabilizers which include lithium are as effecve as mood
stabilizers plus andepressants in treang acute bipolar depression, although the durable recovery rate was modest, and there was no
sub analysis focusing on lithium versus other anmanic drugs (246). Thus, the findings of these studies jusfy a Level 2 rang of efficacy
for lithium.
Given that lithium also has clearly demonstrated efficacy in prevenng mood episodes and in treang acute mania, our hierarchical
ranking thus jusfies lithium as an important first-line agent for bipolar depression, and based on overall evaluaon of available studies,
it is our opinion that a trough lithium serum level of 0.8-1.2 mEq/L would be needed for clinical effecveness.
Lamotrigine
Lamotrigine monotherapy was not superior to placebo in four double blind placebo controlled trials of acute bipolar depression on the
primary outcome (254). However, a meta-analysis conducted on the response rates from these studies as well as a BDII trial showed
superiority of lamotrigine (248). Moreover, methodological issues with the trials likely led to the effect of lamotrigine being
underesmated-including the relavely low final dose (200 mg in most trials, which is lower that usually used in clinical pracce) (255)
and short trial duraon (8 weeks in most trials) which, coupled with the slow traon of lamotrigine, resulted in parcipants being on
the final dose for only a short period (around two weeks). Further, lamotrigine was superior to placebo on Montgomery–Åsberg
Depression Rang Scale (MADRS) in one of the studies (249), and changes in symptoms on this scale have since been used to demonstrate
the efficacy of other agents for acute bipolar depression. Finally, the addion of lamotrigine to lithium (253) was superior to adding placebo
to lithium and there was a trend for superiority of addion of lamotrigine to queapine vs placebo add on (252) in treang bipolar
depression. It is likely that these beneficial effects are due to the direct effect of lamotrigine and not due to pharmacokinec interacon
between lamotrigine and concomitant medicaons. Furthermore, trial design issues, especially the fact that the six-week dose traon
phase took up most of the 8 week trials, is likely to compromise efficacy signals. Lastly, the short and long-term tolerability of lamotrigine
is a major benefit. Taken together, we believe these data jusfy at least a Level 2 rang for lamotrigine for acute bipolar depression.
In addion to this Level 2 rang for bipolar depression, lamotrigine also has demonstrated efficacy in maintenance treatment and an
excellent tolerability profile-features which qualify it to be a first-line treatment for bipolar depression.
F I G U R E 2 Lithium and lamotrigine as first-line agents for bipolar I depression: Summary of evidence [Colour figure can be viewed at
wileyonlinelibrary.com]

4.4.2 | Step 2: initiate or optimize therapy and
check adherence

apply this combination in patients who experience depression when
optimized on one of either of these medications.
Recommendations as to which first-line treatment should be consid-

It is recommended for all patients that pharmacotherapy be initiated

ered first are outlined in our hierarchy. We recommend that the agents

with one or more of the available first-line agents. The choice of agent

listed first in the hierarchy be tried first, in the order listed, unless there

or agents to manage an acute bipolar depressive episode should be

are patient-specific reasons for choosing an agent lower down in the

discussed with the patient and their supporters (as appropriate) and

order, such as previous history of response/ non-response or clinical

take into account current and prior medication use and response, per-

features (see Clinical features which help direct treatment choices). For

sonal preference, and the safety and tolerability of each agent, as well

instance, if a patient presents with an acute bipolar depressive episode

as clinical features that may influence prognosis (see “Clinical features

and is not taking any treatment and has not been treated for this epi-

that help direct treatment choices”).

sode, that patient should be commenced on quetiapine monotherapy
if there is no previous history of non-response or tolerability concerns

First-line

with quetiapine. However, if a patient had been taking lithium and ei241-243

Quetiapine (level 1),

244-246

lithium (level 2),

lamotrigine (level

ther had a breakthrough acute bipolar depressive episode or did not

2)242,247,248 and lurasidone (level 2)249 are all recommended as first-

respond to monotherapy with lithium, then lurasidone or lamotrigine or

line treatment options with evidence for efficacy as monotherapy.

quetiapine add-on or switch to quetiapine monotherapy or lurasidone

Lurasidone (level 1)249,250 and lamotrigine (level 2)251,252 are also

monotherapy might be more appropriate in that order, given that lur-

recommended as first-line adjunctive treatments (Figure 2). Although

asidone and lamotrigine adjunctive therapies have demonstrated effi-

quetiapine and lithium have not been assessed for efficacy as adjunc-

cacy in lithium non-responders. Similarly, in non-responders to lithium

tive treatments for acute bipolar depression, clinicians may choose to

monotherapy, adjunctive lamotrigine could be another option.
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Clinicians are advised to appropriately dose these medications

adequately dosed antidepressant, strong consideration should be

for an adequate period of time before concluding lack of efficacy.

given to discontinuing or switching the class of antidepressant, un-

Clinical trials have shown that there is no difference in efficacy be-

less clear benefits are apparent in reducing the severity or frequency

tween quetiapine 300mg and 600mg daily doses. Lower doses of

of depressive episodes. Switch of medications should be done in an

quetiapine have not been studied in clinical trials for bipolar depres-

overlap and taper manner unless there is medical necessity for abrupt

sion. Therefore, clinicians are advised to consider a target dose of

discontinuation.257

300 mg/day for quetiapine. For lithium, we suggest that serum lith-

All first-line options should be tried in adequate doses for an ade-

ium levels should be maintained between 0.8 and 1.2 meq/L, while

quate duration of time before considering second-line options either

for lamotrigine, the target should be a minimum of 200 mg/day.

as an add-on or switch strategy.

4.4.3 | Step 3: add on or switch therapy (alternate
first-line agents)

4.4.4 | Step 4: add on or switch therapy (second-line
agents)

Across several different medications for bipolar depression, early im-

Second-line

provement (after 2 weeks) has been found to be a reasonable predic-

In patients who are inadequately responsive to first-line agents, mono-

tor of overall response, whereas lack of early improvement is a more

therapy with divalproex (level 2)242,258 is included as a second-line option.

robust predictor of non-response.

255

Lamotrigine is the exception to

Adjunctive use of antidepressant therapy (selective serotonin re-

this rule, given a necessary slow titration initiating the medication. In

uptake inhibitors [SSRIs] or bupropion) with lithium/divalproex or an

the case of non-response, dosing should be optimized and issues of

atypical antipsychotic may also be considered as a second-line add-on

non-adherence identified and addressed (see Section 2) prior to ad-

treatment. While some individual studies have failed to demonstrate

justing treatment strategies.

the efficacy of adjunctive antidepressant therapy, a recent meta-

When determining whether an agent should be switched or an-

analysis (level 1) supports efficacy, albeit with a small effect size.259

other first-line agent be added on to any current treatment, the ef-

This is a key aspect of decision-making regarding antidepressants,

fectiveness of each of the medications needs to be understood in

since historically much of the focus has been on risk of manic switch or

the context of all the goals of managing BD. It is often the case that

rapid cycling, with an underappreciation of the relatively weak efficacy

a medication may be selected to address several goals; for instance,

data. This new appreciation, exemplified by the small benefit seen in

lithium could be added for acute depression with intent to also bol-

the above meta-analysis, led to the change from the last CANMAT

ster anti-manic prophylaxis. In this scenario, if lithium is ineffective

guidelines, which previously gave add-on SSRI/bupropion antidepres-

in the individual patient for an acute bipolar depression but is also

sants a first-line recommendation. As per the ISBD Antidepressant

being used over the long term for anti-manic prophylaxis, then an

Task Force recommendations,260 antidepressants should ideally be

“add-on” intervention should be the next treatment for the acute

avoided, or used cautiously if necessary, in patients with a history of

bipolar depression. If, for instance, the anti-
manic prophylaxis is

antidepressant-induced mania or hypomania, current or predominant

already being fully provided by an atypical antipsychotic, then the

mixed features, or recent rapid cycling. Patients and caregivers (as ap-

new medication could replace lithium via a switch strategy. Decision-

propriate) should receive education regarding early warning symptoms

making must also address efficacy for comorbid conditions, as well

of mood switching or cycle acceleration, and antidepressants should

as tolerability concerns. In principle, all things being equal, a switch

be discontinued if these emerge. Antidepressant monotherapy should

is preferred over add-on to limit the degree of polypharmacy, but

NOT be used for the treatment of BDI depression.

the clinical reality is that medications may be helpful for some but

ECT (level 3) is also a second-line treatment, and should be consid-

not all components of the illness, and using rational polypharmacy

ered particularly for treatment-refractory patients and those for whom

via add-on treatments is often required. For situations in which pa-

a rapid treatment response is needed, such as those with severe de-

tients experience a depressive episode while already receiving an

pression with imminent suicidal risk, catatonia or psychotic depression,

Why are armodafinil and modafinil third-line treatments for bipolar I depression?
Armodafinil adjuncve therapy was assessed in three double blind randomized controlled trials. Of these, one was posive (270) but in the
other two studies, it failed to separate from placebo on the primary efficacy measure (286, 287) although in one of the trials several
secondary outcomes were posive (288). Furthermore, in a fourth trial, there was also suggeson of efficacy based on some secondary
measures (289). Therefore, although two trials were negave on the primary efficacy measure, based on one posive trial and some posive
secondary outcomes in two trials, this was given a Level 4 rang (expert opinion), and recommended as a third-line.
Although modafinil has been shown to be efficacious in the only trial (269), it was also recommended a third-line in light of the three negave
trials for armodafinil.
F I G U R E 3 Armodafinil and modafinil as third-line agents for bipolar I depression: Summary of evidence [Colour figure can be viewed at
wileyonlinelibrary.com]
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TABLE 15
depression

Additional agents evaluated for use in acute bipolar I

119

Agents that may be applied adjunctively include aripiprazole (level 4),266,267 armodafinil (level 4)268,269 (Figure 3), asenap-

Third-line

Not recommended

ine (level 4),270 levothyroxine (level 3),271,272 modafinil (level 2)268

Agent

Level of evidence

Aripiprazole (adj)

Level 4

Armodafinil (adj)

Level 4

Asenapine (adj)

Level 4

Carbamazepine

Level 2

oxidase inhibitors [MAOIs] could be used adjunctively but clinicians

Eicosapentaenoic
acid (EPA) (adj)

Level 2

need to ensure adequate anti-manic prophylaxis in such situations, as

Ketamine (IV) (adj)

Level 3

Light therapy
+/− total sleep
deprivation (adj)

Level 3

Levothyroxine (adj)

Level 3

Modafinil (adj)

Level 2

N-acetylcysteine (adj)

Level 3

Olanzapine

Level 1

Pramipexole (adj)

Level 3

several small studies that intravenous ketamine (level 3)284 is a highly

Repetitive transmagnetic stimulation
(rTMS) (adj)

Level 2

effective and fast-acting antidepressant, due to its invasive nature, short

SNRI/MAOI (adj)

Level 2

Antidepressant
monotherapy

Level 2 negative

Aripiprazole

Level 1 negative

Lamotrigine +
folic acid

Level 2 negative

Mifepristone (adj)

Level 2 negative

(Figure 3), and pramipexole (level 3).273,274 rTMS targeted at the left
or right dorsolateral prefrontal cortex (level 3)275 may also be used
in addition to medication. Other classes of antidepressants such as
serotonin- norepinephrine reuptake inhibitors [SNRIs] and monoamine

SNRIs and MAOIs have a higher propensity than other antidepressants
to induce manic switch and cause mood destabilization (level 2).276-278
Ancillary treatments such as adjunctive eicosapentaenoic acid (EPA)
(level 2),169,279,280 N-acetylcysteine (level 3),281 and light therapy (level
3),282 including bright light delivered midday (level 3),283 are also recommended as third-line treatment options to use adjunctively to other
medications. There may be additional benefits to using light therapy in
combination with total sleep deprivation (level 2), although there is little clinical experience with this technique. While there is evidence from

duration of effect, and lack of long-term safety data, it has been relegated

adj, adjunctive; MAOI, monoamine oxidase inhibitor; SNRI, serotonin and
norepinephrine reuptake inhibitor.

and/or when a rapid response is important for medical stabilization.
Data support efficacy for brief pulse right unilateral placement, al-

to a third-line treatment, with recommendations that it be reserved for
patients with severe symptoms or significant suicidal ideation for whom
other treatments have been unsuccessful. In clinical situations that prioritize rapidity of response to treatment, ketamine may be considered earlier
in the treatment order, although clinicians need to be aware that the data
for efficacy are limited and the effects do not appear to last longer. Further,
there are case reports of manic switch, but the clinical trial data have not
provided any confirmatory evidence.284 Also, clinicians need to be aware
of potential abuse of ketamine, especially in domiciliary use situations.285

4.4.6 | Agents not recommended for the
treatment of acute bipolar depression

though there are insufficient data to guide the decision of unilateral

Antidepressants should not be used as monotherapy in patients with

or bilateral placement for bipolar depression.261 Additional second-

BDI depression, as available trials do not support their efficacy and

line options include cariprazine, with efficacy demonstrated through

there are concerns about their safety in terms of mood switching

a large RCT
RCT

263

262

and a pooled analysis of a failed RCT and a positive

(level 2 negative).260,289-291

(level 2), although there is less clinical experience supporting

Aripiprazole monotherapy failed to separate from placebo in two

its use. Olanzapine-fluoxetine combination (level 2)264,265 is effective

bipolar depression trials.292 Although the pooled analysis reported sep-

and is also recommended as a second-line option.

aration,293 the mean difference in Montgomery–Åsberg Depression

Similar to the approach for treatment of a manic episode, multiple

Rating Scale (MADRS) change score was only 1.12 points, which is not

first-and second-line agents and combinations should be trialled be-

clinically meaningful and it is thus not recommended (level 1 negative).

fore considering initiating third-line agents in step 5.

Ziprasidone monotherapy or adjunctive therapy (level 1 negative),242,294
lamotrigine in combination with folic acid (level 2 negative),251 and mife-

4.4.5 | Step 5: add on or switch therapy (third-line
agents)
Third-line
Third-line options are listed alphabetically in Table 15. In patients
who fail to respond to multiple first-and second-line agents, third-

pristone (adjunctive) (Leve 2 negative)295 are also not recommended
due to evidence for lack of antidepressant efficacy (Table 15).

4.4.7 | No specific recommendation/agents that
require further study

line choices include monotherapy with carbamazepine (level 2)242 or

There are insufficient data to make a recommendation regarding the

olanzapine (level 1).242

use of aspirin (adjunctive) (level 3 negative),296 celecoxib (adjunctive)

120

|

YATHAM et al.

(level 3 negative),297 gabapentin (monotherapy) (level 3 negative),298
leviteracitam (adjunctive) (level 3 negative),

299

Mixed features

lisdexamfetamine (ad-

Many patients with bipolar depression will also experience at least

junctive) (level 3 negative),300 memantine (adjunctive) (level 3),301

subsyndromal hypomanic or manic features, and this presentation is

pioglitazone (adjunctive) (level 3),302,303 riluzole (level 4 negative),304

associated with more severe depressive symptoms, as well as a higher

and risperidone (adjunctive) (level 3).305 Although adjunctive therapy

rate of substance use and cardiovascular disease.317 For many of these

with pregnenolone separated from placebo at week 6, the change in

patients, combination therapy will be necessary to adequately address

depressive symptoms was not significantly different from week 8 to

symptoms.318 Pooled analysis indicates that atypical antipsychotics

week 12 between the two groups (level 2).

306

show a class effect in alleviating mixed features in bipolar depression,
with olanzapine-fluoxetine combination, asenapine, and lurasidone all
demonstrating efficacy.319 Lurasidone has further been shown to have

4.5 | Clinical features that help direct
treatment choices

efficacy in treating both depressive and hypomanic symptoms in MDD

There are limited data on predictors of treatment response in bipolar

tidepressants in patients with mixed features260 and the CANMAT/

depression. However, clinical features of a depressive episode includ-

ISBD group concurs with this recommendation.

with mixed features.320 The ISBD Task Force recommends avoiding an-

ing DSM-5 specifiers may assist clinicians in choosing among recommended treatment options.

Melancholic features
No specific studies assessed the predictive ability of melancholic fea-

Need for rapid response

tures; however, clinical experience suggests that ECT is very effective

Amongst the first-line options recommended, quetiapine and lurasi-

in this population.

done have separated from placebo in clinical trials at as early as week
1.249,307,308 Thus, these medications may be preferable when a rapid

Atypical features

response is required, for example in patients who are at increased risk

There is some evidence for efficacy of tranylcypromine in patients

of suicide or who have medical complications, including dehydration.

with anergic bipolar depression.321 However, given the risks of poten-

While ECT is recommended as a second-line option, this may also be

tial manic switch, this agent should only be used in conjunction with

used earlier when a rapid response is imperative. Second-line options

lithium or divalproex or an atypical antipsychotic. Clinicians also must

such as cariprazine and olanzapine-fluoxetine have also separated

consider adverse events of this agent related to its interactions with

from placebo at as early as week 1 and may also be considered when

food and other medications.

a rapid response is desirable, but this needs to be balanced against the
potential side effects. Lamotrigine administration requires slower ti-

Psychotic features (mood congruent or incongruent)

tration due to the risk of skin rashes, Stevens-Johnson syndrome, and

Up to 20% of inpatients experience psychosis in the context of an

toxic epidermal necrolysis, and is thus not ideal for patients requiring

acute bipolar depressive episode.322 The relative efficacy of various

a rapid response. Lamotrigine, however, is well tolerated, and there

medications to treat these features in this phase of illness has not been

is some evidence that its effectiveness may be more pronounced

examined, although clinical experience suggests that ECT and antipsy-

in patients experiencing depressive cognitions and psychomotor

chotics are highly effective for this population.

slowing.

309

Rapid cycling
Previous treatment response

As described in Section 3, hypothyroidism, antidepressants and sub-

Adjunctive antidepressant use may be appropriate in those with

stance abuse may be associated with rapid cycling, thus making as-

prior antidepressant response if there was no history of treatment-

sessment of thyroid function and discontinuation of antidepressants,

emergent switch.310

drugs of abuse, stimulants, and other psychotropic agents imperative.
As there is no evidence to support any specific agent to treat acute

Anxious distress

depression during a rapid cycling phase, appropriate pharmacotherapy

Symptoms of anxiety are often experienced during a depressive epi-

should be selected based on effectiveness in the acute and mainte-

sode, and are predictive of more persistent depressive symptoms311

nance phases. Lithium, divalproex, olanzapine, and quetiapine all ap-

and increased suicidal ideation.312 A pooled analysis of two double-

pear to have comparable maintenance efficacies in these patients.219

blind RCTs demonstrated that quetiapine is more effective than pla-

In contrast, lamotrigine did not separate from placebo in maintenance

cebo in relieving symptoms of anxiety co-occurring alongside bipolar

treatment in patients with rapid cycling BDI.323 Antidepressants are

313

depression,

and olanzapine-fluoxetine combination has also been

shown to be effective.314 In a post hoc analysis, lurasidone was ef-

not recommended, as they have been shown to destabilize patients,
even with concurrent mood stabilizer use.324

fective in improving depressive as well as anxiety symptoms in
patients with MDD who had mixed features and anxiety.315 The an-

Seasonal pattern

xiolytic effects of divalproex, risperidone, and lamotrigine appear to

While some individual patients may show a seasonal pattern, Canadian

be limited.199,316

data are mixed as to whether episodes of mania or depression in BD
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TABLE 16

121

Risk factors for partial adherence or non-adherence to medication

Sociodemographics

Male, younger age, low level of education, single

Psychological

Poor insight, lack of awareness of disease, negative attitude to treatment, fear of side effects, negative attitude to
medication, low overall life satisfaction, low cognitive functioning

Comorbidity

Alcohol or cannabis use, obsessive compulsive disorder

Social

No social activities, work impairment

Chronology

Younger age of onset, current inpatient status, hospitalization or suicide attempt in past 12 months

Disease characteristics

Mixed episode, rapid cycling, delusions and hallucinations, greater severity of illness, BDI diagnosis, higher number of
episodes

Treatment-related factors
Adapted from Leclerc et al.

Side effects of medications, inadequate efficacy of medication, use of antidepressants, low treatment doses

353

follow a consistent seasonal variation.222 There is no evidence for the

adherence behaviour and attitudes in a non-judgemental manner and

superiority of any agent in patients with an observed seasonal pattern

exploring the reasoning behind poor adherence are important parts of

of manic episodes.

treatment,341 as up to half of patients do not take their medications
as prescribed.342-344 Unrecognized treatment non-adherence can lead
physicians to believe that the patient is non-responsive, resulting in

5 | MAINTENANCE THERAPY FOR
BIPOLAR DISORDER

unnecessary dose increases (especially problematic for drugs with a
narrow therapeutic index), medication switches, or adjunctive medications.341 Treatment withdrawal may precipitate recurrence; 50%-

5.1 | Need for long-term strategies

90% of patients discontinuing lithium experience a recurrence within

Almost all individuals with BD require maintenance treatment to pre-

3-5 months,345,346 with rapid lithium discontinuation associated with

vent subsequent episodes, reduce residual symptoms, and restore

greater recurrence risk than gradual discontinuation.347 Withdrawal

functioning and quality of life. There is increasing evidence to suggest

of other mood stabilizers also predicts recurrence.348,349 Risks for

that, for a subgroup of patients, BD may be a neuroprogressive disease

hospitalization, suicide, and lost productivity are also increased

in which recurrences are associated with reductions in brain grey and

with non-adherence or discontinuation.350-352 A variety of patient,

white matter volumes, worsening cognitive impairment, a decrease in

disorder, and treatment-related risk factors for non-adherence or

inter-episodic recovery and functioning, a higher rate and severity of re-

partial adherence are outlined in Table 16.353

lapse, and a reduced rate of treatment response to both pharmacother-

Meta-analyses suggest that interventions aimed at engaging pa-

apy and psychotherapy.325 It is therefore important that comprehensive

tients in treatment may more than double adherence compared to

treatment be initiated even after a first episode.63 Effective maintenance

treatment as usual or other control groups.354 Brief psychoeducational

treatment, early in the course of illness, has been shown to reverse cog-

interventions focusing specifically on medication adherence can be in-

nitive impairment and preserve brain plasticity, particularly in those who

tegrated into clinical practice.354 Flexible and collaborative engagement

remain episode free,326,327 and may therefore lead to improved prog-

to address individual risk factors for non-adherence is recommended

328

nosis and minimization of illness progression.

There are preliminary

to optimize acceptability of pharmacological therapies.353,355-357

data suggesting that, after a first episode, lithium might be superior to
quetiapine in both volumetric and cognitive outcomes.329,330
With treatment, 19%-25% of patients will experience a recurrence
every year, compared to 23%-40% of those on placebo.331 Risk factors

5.3 | Psychosocial interventions for
maintenance therapy

for recurrence include younger age of onset,332 psychotic features,212

Although pharmacotherapy is the foundation of maintenance treatment in

rapid cycling,331 more (and more frequent) previous episodes,333 comor-

BD, it is often insufficient to prevent recurrence. Over the last two decades,

bid anxiety,334 and comorbid SUDs.335 Persistent subthreshold symp-

several controlled trials have examined the efficacy of adjunctive psychosocial

334,336,337

toms also increase risk for subsequent mood episodes,

and the

treatments in reducing recurrence. On average, adjunctive psychosocial treat-

presence of residual symptoms should therefore be an indicator of a need

ments reduce recurrence rates by about 15%. Therefore, adjunctive psycho-

for further treatment optimization. Availability of psychosocial support

social interventions are an important component of management of BD and

and lower levels of stress are also protective against recurrence.337,338

should be offered for all patients.
As described in more detail in Section 2, psychoeducation is the
only first-line psychosocial intervention for the maintenance phase

5.2 | Treatment adherence

(level 1), which should be offered to all patients. Additional second-line

Concordance between clinician and patient views of illness and treatment is a crucial determinant of adherence,

339

and reinforces the need

for a collaborative approach to the treatment alliance.340 Asking about

options such as CBT (level 2) and FFT (level 2), and third-line options
such as IPSRT (level 2) and peer support (level 2) should be offered
based on individual strengths and needs.
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not depressive episodes. However, many of these trials have been
conducted in patients with an index manic episode and, given that
the polarity of an index episode predicts the polarity of relapse, depressive relapse rates in placebo groups in such studies have been

Evidence from RCTs is at the core of the recommendations in these

low- compromising the statistical power to test the efficacy of these

guidelines. Nonetheless, RCTs are not the only source of clinically

agents in prevention of depressive relapses. Thus, the efficacy of

useful information, particularly when evaluating maintenance ther-

many of these agents in preventing depressive relapses remains

apy. RCTs offer relatively limited follow-up time-frames while, for

unknown.

some patients, maintenance therapy may extend across decades.

For patients who are currently not receiving or responding to

Furthermore, new medications are often assessed in studies with an

pharmacological treatment, a careful history including details of

enriched design (including only patients who have responded to the

clinical course, response (or lack thereof) to previously used med-

medication under study in the acute phase), limiting the generalizabil-

ications, and family history should be collected. Other variables to

ity of positive findings to patients who responded to the medication

be considered include psychiatric comorbidity (including substance

acutely.

use), the predominant illness polarity, and the polarity of the most

Useful data can be obtained from large, often whole-population

recent episode.

databases constructed from electronic medical records or electronic

Ongoing clinical monitoring, including medication blood levels

patient registries with large numbers of patients that would be diffi-

as appropriate, is also a crucial part of maintenance treatment that

cult to obtain in RCTs. In some instances, they allow comparisons of

should be used to support enhanced medication adherence, detection

multiple treatments.358-360 These large numbers make it possible to

of early symptoms of recurrence, and monitoring of side effects (see

evaluate differences in rates of rare events such as less common side

Section 8).

effects or suicide.361,362
Patient cohorts followed in a specific setting provide another
source of informative data. Their main advantage usually is the length
of observation, in some instances reaching several decades.363-365 This

5.5.2 | Step 2: initiate or optimize therapy and
check adherence

comes at the cost of generalizability, in terms of both patient selection

The choice of agent or agents used in maintenance treatment should

and non-random treatment allocation.

be discussed with the patient and their caregivers (as appropriate)
and, based on knowledge of current and prior medication use and re-

5.5 | Pharmacological treatments for
maintenance therapy

sponse, safety and tolerability of each agent, predominant episode polarity, and clinical features that may influence prognosis (see “Clinical
features that help direct treatment choices”). As with treatment for

As in earlier sections, pharmacological treatments for maintenance

mania and acute depression, we recommend that treatment choices

therapy have been evaluated using the criteria for strength of evi-

for maintenance treatment of BD should follow the hierarchy listed

dence for efficacy (Table 1) as well as safety and tolerability (Section

in Table 17 unless patient preference or other considerations such as

8). Results are summarized in Table 17.

previous response/non-response, tolerability or predominant polarity justify other choices. Similarly, as a general rule, if a patient has

5.5.1 | Step 1: review general principles and assess
medication status

been treated for an acute mood episode and responded to a first-line
maintenance treatment, we recommend continuing that treatment for
maintenance even if lower down in the hierarchy. As an example, if a

Many agents recommended for management of acute manic or de-

patient responded to asenapine in an acute manic episode, asenapine

pressive episodes have prophylactic efficacy. Generally, medications

should be continued, even if it is lower down in the hierarchy for main-

that have been found to be effective in the acute phase should be con-

tenance treatment. It may be necessary to lower the dose to some

tinued during the maintenance phase. However, there are exceptions

degree once in maintenance treatment as patients often experience

to this: the efficacy of adjunctive antidepressant therapy has not been

greater side effects once out of the acute episode.

examined systematically in large double-blind placebo-controlled tri-

There is evidence that the risk of recurrence is reduced when an

als; hence, long-term antidepressant use is not recommended, espe-

antipsychotic is combined with lithium/divalproex. When a combina-

cially in light of the concerns about potential risk of manic/hypomanic

tion therapy of an atypical antipsychotic with lithium/divalproex was

switch and mood instability. However, in the subgroups of patients

used to treat acute mania, continuing the atypical antipsychotic for

who have responded to combination treatment and are stable, pre-

the first 6 months following response offered clear benefit in reducing

liminary evidence suggests that withdrawal of antidepressants may

risk of mood episode recurrence (level 2),367 but the benefits beyond

contribute to destabilization.366

6 months remain uncertain. Therefore, clinicians are advised to re-

Clinical trials have shown that many atypical antipsychotics

evaluate risks and benefits after 6 months of sustained response to

are effective in preventing relapse of mood episodes; with many

determine whether maintenance combination therapy with an atypical

agents, this efficacy is related to prevention of manic episodes but

antipsychotic is justified.

Hierarchical rankings of first-and second-line treatments recommended for maintenance treatment in bipolar disorder

DVP, divalproex; LAI, long-acting injectable; Li, lithium, OM, once monthly.
, level 1 evidence; , level 2 evidence; , level 3 evidence; , level 4 evidence; , level 1 negative evidence; , level 2 negative evidence; , level 3 negative evidence; , level 4 negative evidence; n.d.,
no data; limited impact on treatment selection; , minor impact on treatment selection; , moderate impact on treatment selection;
, significant impact on treatment selection.
a
Did not separate from placebo in those with index mania; no studies available in index depression.
b
Did not separate on core symptoms of depression.
c
Divalproex and carbamazepine should be used with caution in women of child bearing age.
d
Trend for superiority on the primary efficacy measure, hence the lower rating.
e
Effective in those with an index episode of depression.
[Colour table can be viewed at wileyonlinelibrary.com]
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Why is divalproex recommended as a first-line maintenance treatment for bipolar I disorder?
In the only large double-blind placebo controlled RCT of divalproex monotherapy (373), it was not more effecve than placebo in
prevenng relapse of mood episodes i.e. me to any mood episode. However, in this trial, lithium which has been shown in many other
studies to be effecve in relapse prevenon, was also found to be no more effecve than placebo. Thus, these results suggest that this trial
was a failed trial and not a negave trial.
Most modern studies of maintenance therapy use enriched design, meaning that those that responded in acute phase to the medicaon
being tested are randomized to connuaon of the same drug or replacement with placebo. This pracce to a large extent mirrors clinical
pracce as clinicians are likely to connue the medicaon that worked in the acute phase for maintenance treatment. Interesngly, in the
divalproex RCT, some but not all paents that were randomized into the double-blind phase were divalproex responders. In a post-hoc
analysis of this study, in this enriched subgroup of paents that responded to divalproex during the acute phase and randomized to
connuaon of divalproex vs switch to placebo, divalproex was more effecve in prevenng relapse of mood episodes compared with
placebo.
Further, divalproex was superior to placebo on a number of other secondary efficacy measures such as lower rates of disconnuaon for
any mood episode or a depressive episode. Surprisingly, there was also a trend for superiority of divalproex relave to lithium in me to
any mood episode. Other RCTs have shown that divalproex is as effecve as lithium (221) in prevenng relapse of mood episodes.
As well, two meta-analysis have concluded that divalproex is effecve in prevenng relapse of mood episodes (370, 372), and a populaon
based cohort study in the UK showed that there were no differences in efficacy between divalproex, queapine and olanzapine in the
maintenance treatment of bipolar disorder (359).
Taken together, we believe these efficacy data support our raonale for a Level 1 rang. This along with clinical experience, real world
cohort data, and safety, jusfy our recommendaon of divalproex as a first-line maintenance treatment.
F I G U R E 4 Divalproex as a first-line maintenance therapy for bipolar I disorder: Summary of evidence
RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]

First-line

For patients who experience a recurrence or who remain symp-

Lithium (level 1),368,369 quetiapine (level 1),369,370 divalproex (level
1)

369,371,372

(Figure 4) and lamotrigine (level 1)369,373 monothera-

pies have the best combination of clinical trials, administrative data,

tomatic while on a first-line agent or a combination, dosing should be
optimized and issues of non-adherence identified and addressed prior
to moving to step 3.

and clinical experience to support their use as first-line therapies
for maintenance treatment of BD. Recent data suggest that asenapine (level 2)374 is effective in preventing both manic and depressive
episodes, and thus is recommended as a first-line treatment. Finally,

5.5.3 | Step 3: add on or switch therapy (alternate
first-line agents)

aripiprazole oral (level 2)375,376 or once monthly (level 2)377 is also rec-

If therapy with one or a combination of the first-line agents at opti-

ommended as a first-line monotherapy in view of its efficacy in pre-

mal doses is inadequate or not tolerated, the next step is to switch

venting any mood or manic episode as well as its safety/tolerability

to or add on an alternate first-line agent. Because there are multiple

profile, although it has not been shown to be effective in preventing

first-line agents with substantial efficacy data and relative safety and

depression.

tolerability, the use of second-line agents is only recommended after

Additional combination therapies included as first- line include

unsuccessful trials of multiple first-line strategies.

quetiapine adjunctive therapy with lithium/divalproex (level 1),378,379
which has demonstrated efficacy in preventing any mood, manic or
depressive episode. Aripiprazole plus lithium/divalproex (level 2)380
should also be considered as a first-line option.

5.5.4 | Step 4: add on or switch therapy (second-line
agents)
Second-line
Although olanzapine (level 1)381,382 is effective in preventing any

T A B L E 1 8 Additional agents evaluated for use in maintenance
treatment of bipolar I disorder

Third-line

Not recommended

adj, adjunctive.

Agent

Level of evidence

Aripiprazole + lamotrigine

Level 2

Clozapine (adj)

Level 4

Gabapentin (adj)

Level 4

Olanzapine + fluoxetine

Level 2

Perphenazine

Level 2 negative

Tricyclic antidepressants

Level 2 negative

mood, manic or depressive episode, it is considered second-
line
treatment because of safety issues such as metabolic syndrome.
Biweekly long-acting injectable risperidone monotherapy (level 1)383
or adjunctive therapy (level 2)384 has demonstrated efficacy in preventing any mood or manic episode, but had no clear efficacy in depressive episode prevention in these trials. Further, there was a trend
for superiority of oral risperidone adjunctive therapy at 6 months in
preventing any mood episode and in preventing mania but not depression.367 Carbamazepine (level 2) has not been assessed in any
large placebo-controlled trials, but active comparator trials support
its efficacy.385 Paliperidone (level 2) was more effective than placebo
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in preventing any mood or manic episode but less effective than
olanzapine.

386

125

adjunctive maintenance therapy is not recommended due to an increased risk of manic switch (level 2 negative)398-400 (Table 18).

Ziprasidone oral adjunctive therapy (level 2)

387

has been shown

to be effective in preventing any mood or manic episode, although
there are conflicting (positive and negative) data for acute treatment

5.5.8 | Clinical features that direct treatment choices

(see Sections 3 and 4). There was a trend for superiority of lurasidone

Clinical trials tell us how efficacious one drug is in comparison with

adjunctive therapy in preventing any mood episode (but not manic or

another (or placebo) in groups of patients. To determine the degree

depressive episodes individually) in a controlled trial with significant

of long-term response in an individual patient requires a different

separation from placebo in preventing mood episodes in those with an

evaluation and may take a considerable amount of time. Few pa-

index depressive episode.

388

Thus, lurasidone adjunctive therapy may

tients manage a lifetime of BD with monotherapy—most will re-

be appropriate for those who responded to this medication during an

quire short-or long-term combination therapies to address acute or

index depressive episode.

subsyndromal symptoms as well as to reduce rates of recurrence.
Some,359,401,402 but not all,403,404 reports suggest that long-
term

5.5.5 | Step 5: add on or switch therapy (third-line
agents)
Third-line

treatment becomes less effective with longer duration of untreated
illness, an argument for finding an effective treatment as early as
possible.
In most instances, it is difficult to differentiate nonspecific cor-

Third-line agents are listed alphabetically in Table 18. There was

relates of good prognosis of the illness from factors specific to the

a trend for superiority of adjunctive aripiprazole with lamotrigine

response to a particular mood stabilizer. Available data come mostly

(level 2)389 compared to lamotrigine monotherapy in preventing

from naturalistic/cohort studies and few randomized trials.405

mania; thus, this combination may provide additional prophylaxis for

Nevertheless, several tentative predictors are emerging from the

patients on lamotrigine monotherapy in preventing manic relapses.

available data.

Clozapine (level 4)162 and gabapentin (level 4)390 may also be useful

Factors associated with overall good prognosis of BD include

adjunctive treatments for those who incompletely respond to first-

good treatment adherence, lack of early adversity, intermediate age

or second-line therapies. The olanzapine/fluoxetine combination ap-

at onset, good social support, and the absence of spontaneous rapid

pears to maintain mood stability over a 6-month period in patients

cycling406,407 or features of a personality disorder.408

with bipolar depression who respond acutely to this combination
(level 2).391

In general, lithium is the gold standard for maintenance treatment, as it is effective in preventing both manic and depressive
episodes (magnitude of prophylactic efficacy greater against mania

5.5.6 | No specific recommendation/agents that
require further study

vs depression) and appears to have a degree of anti-suicidal effects.352,369,409-413 Patients who respond well to lithium treatment
usually have an episodic remitting pre-treatment clinical course, a

We do not provide specific recommendations for the use of caripra-

family history of BD (especially BD responsive to lithium), low rates

zine, as there is currently only evidence for efficacy in acute manic

of comorbidity (especially anxiety and substance abuse disorders),

and depressive episodes262,392 and not yet for maintenance treatment

and a pattern of mania-depression-euthymia in biphasic episodes,

(level 4). While a small RCT suggests a lack of efficacy for flupenthixol

as well as a typical clinical presentation.414-416 Responsiveness may

as maintenance treatment, larger studies are needed before definite

also be a familial trait, with a study showing that patients who have

393

Likewise, oxcarbaz-

a lithium-responsive relative have a 67% likelihood of also being lith-

epine adjunctive therapy requires further evaluation (level 4).394-396

ium responsive, versus 35% of those without a responsive relative.417

No recommendation is made for topiramate as there is an absence of

Among biological measures, lack of electroencephalogram (EEG) ab-

controlled data supporting its efficacy in maintenance (level 4 nega-

normalities, higher brain lithium concentration, increased N-acetyl

conclusions can be drawn (level 3 negative).

tive), and a lack of efficacy in acute mania

381

; however, its use may be

aspartate and lower myo-
inositol peaks on magnetic resonance

indicated as it has efficacy for many syndromes that are often comor-

spectroscopy, as well as several variants in candidate gene studies,

bid with BD (Section 7).

may predict response,418 but these studies require confirmation.
Response to lithium in particular seems to be quite specific, as shown

5.5.7 | Agents not recommended for
maintenance treatment
Perphenazine is not recommended for maintenance based on evidence

in a study of neurons derived from induced pluripotent stem cells.
The neurons from people with BD were hyperexcitable and their activity was selectively modified by in vitro lithium in accordance with
clinical response.419

that patients treated with perphenazine and a mood stabilizer follow-

Responders to lamotrigine have a predominantly depressive polar-

ing an episode are more likely to have emergent depressive symptoms

ity as well as comorbid anxiety.420,421 Lamotrigine monotherapy is not

or intolerable side effects, compared to those maintained on the mood

appropriate for patients with frequent manic episodes, as it has limited

stabilizer alone (level 2 negative).397 Tricyclic antidepressant mono or

efficacy in preventing mania.
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Quetiapine has been shown to be effective in preventing manic,
depressive and mixed episodes in patients with index manic, depressive and mixed episodes, and thus may be particularly valuable
in those with mixed features.422 Asenapine appears to be effective
in preventing both mania and depression, although the magnitude of
prophylactic efficacy is greater for mania relative to depression. In a

T A B L E 1 9 Strength of evidence and treatment recommendations
for acute management of bipolar II depression
Recommendation

Agent

Level of evidence

First-line

Quetiapine

Level 1

Second-line

Lithium

Level 2

Lamotrigine

Level 2

Bupropion (adj)

Level 2

ECT

(Level 3)

randomized open trial of carbamazepine versus lithium, responders to
carbamazepine were more likely to have an atypical illness, BDII or
schizoaffective disorder.

405

Sertralinea

Data to differentiate anti-psychotic medication responders from
non-responders are lacking.
Overall, some of these possible predictors can have clinical utility,

Venlafaxine
Third-line

Level 2
a

Level 2

Agomelatine (adj)

Level 4

but not all are practical. For instance, it is difficult to evaluate a pre-

Bupropion (adj)

Level 4

treatment course in patients who started their treatment after one or

Divalproex

Level 4

EPA (adj)

Level 4

Fluoxetinea

Level 3

Ketamine (IV or
sublingual) (adj)c

Level 3

dressed. These include discontinuation of stimulants and antidepres-

N-acetylcysteine
(adj)

Level 4

sants and treating hypothyroidism if present. With regard to treatment

Pramipexole (adj)

Level 3

stabilizer is often ineffective and patients may require a combination

T3/T4 thyroid
hormones (adj)

Level 4

of mood stabilizers to achieve mood stability.

Tranylcypromine

Level 3

Ziprasidoneb

Level 3

Paroxetine

2 negative

two episodes (practice recommended by most treatment guidelines),
and biomarkers are intriguing but lack sufficient replication and are
not readily available.
In patients with a history of a rapid cycling course, as indicated in
previous sections, factors associated with rapid cycling must be ad-

options, the evidence suggests that monotherapy with a single mood

Treatment-refractory bipolar disorder
Treatment refractoriness may be related to non-adherence to oral
medications, failure to optimize evidence-based oral medication therapy/therapies, comorbidities complicating therapeutic response or
true resistance to pharmacotherapy. Clinicians are advised to make a

Not recommended

adj, adjunctive; ECT, electroconvulsive therapy; EPA, eicosapentaenoic
acid.
a
For patients with pure depression (non-mixed).
b
For patients with depression and mixed hypomania.

comprehensive assessment to determine factors responsible for treatment refractoriness. Adequate doses of firstand second-line agents
should be employed for an adequate period of time (eg, this is typically individualized based on the previous course of mood episodes in

therapy has been shown to be effective in reducing symptoms and
total medication use in treatment-resistant patients.162

each patient) to assess prophylactic response. Comorbidities should
be addressed with pharmacological or psychological strategies as appropriate. While genotyping for cytochrome P450 enzymes such as
2D6 and 3A4 which metabolize most psychotropic drugs is not routinely recommended, clinicians are advised to consider this in patients

6 | BIPOLAR II DISORDER
6.1 | Presentation of bipolar II disorder

with refractory BD who have not responded to high doses of various

BDII is a distinct disorder from BDI, with a similar Canadian preva-

first, second, and third-line treatments or their combinations in order

lence (0.67% compared to 0.87% for BDI).7 The diagnosis of BDII

to exclude the possibility of ultra rapid metabolic status contributing

requires one or more episodes of hypomania, one or more episodes

to poor response.

of depression, and an absence of manic episodes. The DSM-5 cri-

In patients who are non-adherent, psychosocial strategies such

teria for hypomania are similar to those for mania, with symptoms

as psychoeducation should be used to improve treatment adher-

being uncharacteristic of the individual, observable by others, and

ence. If ineffective, long-acting injectable medications should be

lasting at least 4 consecutive days. In contrast to mania, they can-

offered. Risperidone long-
acting injectable monotherapy383 or

not be severe enough to cause marked impairment or require hos-

adjunctive therapy (level 2)384 once every 2 weeks or aripiprazole

pitalization, and there must be an absence of psychosis. Further,

once-monthly injectable monotherapy (level 2)377 has been shown

DSM-5 has added a mixed feature specifier to hypomania as well.

to be effective in preventing relapse of mood episodes in patients

The diagnosis of BDII is generally stable over time, although there

with BD.

may be a higher risk of conversion to BDI early in the illness, sug-

There is a dearth of clinical trial data to inform treatment options
for management of patients with refractory BD. Clozapine adjunctive

gesting that BDII may be a risk factor or prodrome of BDI in some
patients.423
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Why is lithium recommended as a second-line agent for bipolar II depression?
Reconciling conflicng data
In a 16-week double blind RCT, lithium was as effecve as sertraline and lithium + sertraline combinaon (427) which qualifies lithium for
Level 2 evidence. Addional supporng data come from a single-blinded trial which showed that lithium was as effecve as lamotrigine in
treang BDII depression over 6 weeks (445). However, neither of these studies had a placebo arm. Posive placebo-controlled data come
from 4 small placebo-controlled crossover studies conducted in the 1960s and 1970s, in which lithium was effecve in a mixed sample of
BDI and BDII depressed paents (446-449). Results were reported separately for BDII in 2 of the studies and were idencal to BDI
(pooled response rate = 65% for both) (446).
In contrast, in the only modern a placebo-controlled parallel group study, lithium was not superior to placebo in BDII depression (254).
Further, lithium was less effecve than venlafaxine in a 12-week RCT (450).
A potenal explanaon might have to do with trough serum lithium levels. Lithium levels ranged from 0.8-1.3 mEq/L, and were oen at the
high end of that range in the older placebo-controlled RCTs while in the negave placebo-controlled RCT, the mean serum lithium level was
lower (<0.61 mEq/L in the combined BDI + BDII sample, not reported separately for BDII). Thus, the opmal serum level for treang bipolar
II depression is unclear. However, based on the placebo-controlled BDII trials, as well as placebo-controlled studies in BDI (247), a serum
level of 0.8-1.2 mEq/L appears most likely to be beneficial.
In addion to the evidence for efficacy in acute depression, lithium also has efficacy in prevenng mood episodes in BDII (400, 452-454).
Therefore, in balance, we believe the evidence, though mixed, jusfies recommending lithium as a second-line agent for BDII depression.
F I G U R E 5 Lithium as a second-line agent for bipolar II depression: Summary of evidence.
BDI, bipolar disorder type I; BDII, bipolar disorder type II; BDNOS, bipolar disorder not otherwise specified; RCT, randomized controlled trial
[Colour figure can be viewed at wileyonlinelibrary.com]

Should andepressants be used in bipolar II depression?
Addressing the controversy
The queson of whether, and if so when and how, to use andepressants in BDII remains controversial due to concerns regarding both
safety (parcularly the possibility of hypomanic switch, mixed symptoms, and increased cycling) and efficacy.
With respect to safety, a meta-analysis that compared rates of andepressant-associated mood elevaons in BDII, BDI, and MDD
reported that they were significantly less frequent in BDII than BDI, and occurred almost exclusively into hypomania rather than mania
(454). Switch rates were low even during andepressant monotherapy and with andepressants associated with high switch rates in BDI
(tricyclics, venlafaxine). An ISBD task force report on andepressants also concluded that their risk-benefit rao was more favorable in
BDII (261, 449).
The issue of efficacy is less clear due to limited evidence. RCTs have shown that sertraline monotherapy was as effecve as lithium and
lithium+ sertraline combinaon, and that venlafaxine monotherapy was more effecve than lithium, sufficient for level 2 evidence for
these agents. In a RCT of BDI and BDII paents, bupropion was shown to be as effecve as sertraline and venlafaxine (277). Open-label
data also suggest efficacy for fluoxene, and there are maintenance data for venlafaxine and fluoxene in prevenng relapses. These
posive findings should be balanced against the fact that paroxene and bupropion were not beer than placebo for acute depression in
paents taking concomitant mood stabilizing medicaons. Moreover, it is important to bear in mind that 1) there are no placebo-controlled
acute-phase trials of andepressant monotherapy in BDII, 2) many andepressants have not been studied at all (and we do not believe it is
warranted to extend posive findings from sertraline/venlafaxine -or for that maer negave findings from paroxene/bupropion -to
“andepressants” generally), 3) the exisng trials enrolled people with pure (non-mixed) depression, and their efficacy/safety in the
broader spectrum of BDII paents is unclear, and 4) many of the exisng trials have significant weaknesses, including one or more of:
low dosing of the andepressant; sub-therapeuc dosing of comparator medicaons; and lack of replicaon.
All of this makes it parcularly difficult to make evidence based recommendaons regarding andepressants in BDII. We have restricted
our recommendaons to the specific agents that have been studied, and we recommend bupropion, sertraline,and venlafaxine
monotherapy as second-line treatments; and fluoxene as third-line. We further recommend that any andepressant, especially in
monotherapy, be reserved for paents with pure depression and avoided in those with mixed symptoms or a history of andepressantinduced hypomania (261). Whether andepressants should also be avoided in paents with rapid cycling is unclear, since some studies
report poorer outcomes in rapid-cycling paents (455) while others do not (450, 456-458). Paents prescribed andepressants must be
educated regarding early-warning signs of hypomania and carefully monitored for them. Finally, there is a pressing need for further studies
of other andepressants in BDII, in both monotherapy and combinaon therapy.
F I G U R E 6 Antidepressants for bipolar II depression: What is their role?
BDI, bipolar disorder type I; BDII, bipolar disorder type II; ISBD, International Society for Bipolar Disorders; MDD, major depressive disorder;
RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]
Although hypomania is, by definition, less severe than mania,

greater.425,426 This is because patients with BDII spend as much time

the disability associated with BDII is comparable to that associated

symptomatic as those with BDI, with mood symptoms predominantly

with BDI,14,424 and the economic burden of BDII is up to four times

in the depressive phase.427,428 Rates of attempted and completed
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Why is lamotrigine a second-line recommenda on for bipolar II depression?
Reconciling conflicng data
Lamotrigine monotherapy was studied in two trials in BDII depression: one in which 221 BDII paents received 200 mg/day or placebo for
8 weeks, and a second in which 206 BDI or BDII paents (N = 84 with BDII) received 100–400 mg/day for 10 weeks (254). Both produced
negave results. A meta-analysis confirmed that lamotrigine was not superior to placebo in BDII depression, although it did separate from
placebo in BDI (248). Several methodological shortcomings likely resulted in the studies underesmang the drug’s effect, including 1) a
slow traon which resulted in subjects being on the target dose for a short me, 2) a target dose lower than that oen used in clinical
pracce and in successful maintenance studies (255, 324), and 3) higher placebo response rates. In contrast, a single-blind RCT with a
relavely high dose (final peak dose=300mg) and a longer duraon (16 weeks) found that lamotrigine monotherapy was as effecve as
adequately-dosed lithium (mean final serum level=1.1 mEq/L) in N=98 BDII paents (445). Two large RCTs in BDI+BDII and a 12-week
open-label trial in paents with BDI+BDII+BDNOS also reported that adjuncve lamotrigine was effecve, but did not report results
separately for BDII (252, 253). Finally, lamotrigine has robust efficacy in prevenng depressive relapse in BDI and BDII (324, 459).
Taking all of these factors into consideraon we recommend lamotrigine as a second-line treatment, parcularly for paents who can
tolerate a slow traon and delayed effect.
F I G U R E 7 Lamotrigine as a second-line agent for bipolar II depression: Summary of evidence
BDI, bipolar disorder type I; BDII, bipolar disorder type II; RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]
suicide are similar in BDI and BDII, with approximately one-third of patients with BDII attempting suicide over the course of their illnesses429

T A B L E 2 0 Strength of evidence and treatment recommendations
for maintenance treatment of bipolar II disorder

and one in twenty-five completing suicide.430

6.2 | Pharmacological treatment of bipolar II disorder
6.2.1 | General considerations for interpreting
recommendations

Recommendation

Agent

Evidence level

First-line

Quetiapine

Level 1

Lithium

Level 2

Lamotrigine

Level 2

Second-line

Venlafaxine

Level 2

Third-line

Carbamazepine

Level 3

The treatment of BDII has been understudied relative to BDI. This

Divalproex

Level 3

is probably due to the long-standing but discredited impression of

Escitalopram

Level 3

BDII as a less severe form of BD. The number of RCTs in BDII is sub-

Fluoxetine

Level 3

stantially smaller than that in BDI, and those studies that do exist are

Other antidepressants

Level 3

frequently under-powered. It also remains common for trials to enrol

Risperidonea

Level 4

patients with both BDII and BDI without reporting results separately,
making it difficult to determine if there are clinically meaningful differ-

a

Primarily for prevention of hypomania.

ences in treatment response between the two illnesses. This is important because, while clinical experience and the results of many studies
suggest that response to mood stabilizers and antipsychotics is similar

6.2.2 | Acute management of hypomania

in BDII and BDI, there are enough exceptions to suggest this should

The general principles for assessing mania apply to hypomania.

not be taken for granted.248,405,431 This is also the case for antidepres-

For some patients, hypomania causes no to minimal functional im-

sants, which may have a more favourable risk-benefit ratio in BDII

pairment and may even be associated with brief periods of above-

(reviewed below). Therefore, in formulating our recommendations,

normal functioning. However, prolonged, relatively severe, or mixed

studies that enrolled patients with both BDII and BDI but did not

or irritable hypomania may be impairing.423 Treatment should in-

report results for BDII separately are assigned level 4 status (expert

clude discontinuing agents that can worsen or prolong symptoms,

opinion) if the proportion of patients with BDII was less than 50%.

including antidepressants and stimulants, and initiating appropriate

The relative paucity of large, methodologically sound clinical trials

pharmacotherapy.

in BDII creates challenges in formulating evidence-based guidelines.

Unfortunately, many standard medications for mania, including

As will be seen, there are fewer treatments with high-quality evidence

lithium and most atypical antipsychotics, have not been studied in

in BDII compared to BDI and fewer first-line treatment recommenda-

hypomania. There are four placebo-controlled trials that investigated

tions. The limitations of the evidence base necessitate an awareness

divalproex (level 4),432 N-acetylcysteine (level 4),433 and quetiapine

of the nuances of the available studies, and a greater reliance on clin-

(level 4)434,435; and one open-label study of risperidone (level 4)436 in

ical experience. We thus have endeavoured to be clear in outlining

acute hypomania. The studies generally suggested efficacy but all had

the rationale for selecting first, second, and third-line treatments for

significant weaknesses, including one or more of: (i) small sample sizes,

hypomania, depression, and maintenance treatment of this important

(ii) mixed samples with BDI, BDII, and BD NOS; (iii) mixed samples

illness. There is clearly a pressing need for adequately powered trials

with hypomania and mania, and (iv) positive findings on some but not

in BDII across all illness phases.

all outcomes. The small numbers of patients and mixed samples mean
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that even the placebo-controlled trials only met criteria for level 4 evidence (Table 1).

129

Intravenous ketamine (level 3)477,478 has rapid onset of efficacy
and may be considered for patients who are refractory to first and

These methodological limitations, coupled with the lack of clin-

second-line treatments, as well as for those in need of rapid response.

ical trial evidence for many medications, make it difficult to make
specific suggestions for the treatment of hypomania. Clinical experi-

No specific recommendation/agents that require further study

ence suggests that all anti-manic medications are also efficacious in

A number of agents do not have sufficient data to warrant specific recom-

hypomania. Thus, when hypomania is frequent, severe, or impairing

mendations for BDII depression, including cranial electrotherapy stimu-

enough to require treatment, clinicians should consider mood stabi-

lation (CES),479 dextromethorphan + quinidine,480 light therapy,481-485

lizers such as lithium or divalproex and/or atypical antipsychotics. N-

lisdexamfetamine (adjunctive),300 olanzapine,486 pioglitazone,302 ad-

acetylcysteine may also be of benefit, but further studies are needed.

junctive pregnenolone,306 celecoxib,297 levetiracetam,487 adjunctive
lisdexamfetamine,300 s-adenosylmethionine,488-490 acetyl-
l-carnitine +

6.2.3 | Acute management of bipolar II depression

alpha-lipoic acid,491 adjunctive modafinil,268 rTMS,275,492,493 and
memantine.494

The general principles for assessing depression in patients with BDI
apply to those with BDII. First, second, and third-line treatment

Not recommended

options are listed below and shown in Table 19. Specific consid-

Based on negative placebo-controlled data, we do not recommend

erations regarding each treatment are highlighted in the relevant

paroxetine (level 2 negative).245

sections.

6.2.4 | Maintenance treatment

First-line
Quetiapine is the only recommended first-line treatment for BDII de-

Maintenance treatment is important to prevent relapse, reduce sub-

pression (level 1). Pooled analyses of five identically designed trials

syndromal symptoms, and improve quality of life. As with BDI, se-

demonstrated that quetiapine was superior to placebo, and moreo-

lection of an agent should be informed by acute phase treatment.

ver was equally effective for acute depression in BDI and BDII.243,437

Recommended agents and their evidence ratings are listed in Table 20.

The latter finding must be reconciled with the fact that quetiapine
beat placebo in only three of the five individual trials in patients

First-line

with BDII, compared to all five in patients with BDI.253,290,438-440

Monotherapy with quetiapine (level 1),495 lithium (level 2),399,450,452

This is probably because the smaller sample of BDII patients—only

and lamotrigine (level 2)323 are first-line options.

about half as many patients with BDII as BDI were enrolled in each

Quetiapine. In two 52-week maintenance studies, patients with

of the trials—provided less statistical power for BDII. Finally, open-

BDII who achieved remission from depression with quetiapine mono-

label studies also suggest efficacy for adjunctive quetiapine (level

therapy continued it or switched to placebo.495 A pooled analysis

4).

441,442

reported that patients treated with quetiapine had a significantly
longer time to relapse into any mood episode (hazard ratio [HR]

Second-line

0.33, or a 67% reduction in the risk of relapse) and into depression

Second-line treatments include lithium, ideally at a serum level of

(HR 0.28 or a 72% risk reduction). Time to relapse into hypomania

0.8-1.2 mEq/L (level 2) (Figure 5), and the antidepressants sertra-

was not significantly greater (HR 0.65 or a 35% risk reduction). The

and venlafaxine (level 2),443,444 mainly for patients

latter finding may be related to the low base rate of hypomania,

with pure (non-
mixed) depression (Figure 6). Lamotrigine (level

which occurred in only 10% of all study participants. Quetiapine was

2) is also recommended as a second-line agent despite conflict-

at least as effective in BDII as in BDI, for which the risk reductions

ing evidence, with the rationale for this provided in Figure 7. ECT

were 42% for any relapse, 48% for depression, and 30% for mania.

(level 3)261 can also be considered second-line and is a good option,

Adjunctive quetiapine was also studied in a 6-month single-blind trial

particularly for treatment refractory patients and those in need of

which randomly assigned patients with either BDI or BDII to lithium

rapid response.

or quetiapine added to treatment as usual. They were equally effec-

line (level 2)

426

tive in preventing relapse.453 Results were not presented separately

Third-line

for BDII, but BDII patients responded better to both treatments than

The third-
line options include monotherapy with divalproex (level

did BDI patients.

4)258,459,461,462-466 fluoxetine (mainly for patients with pure depres-

Lithium. In three placebo-controlled RCTs conducted in the 1970s

sion) (level 3)467-469 tranylcypromine (level 3),278 or ziprasidone (solely

and 1980s (duration = 11-25 months), lithium decreased the frequency

for patients with depression and mixed hypomania) (level 3).470,471

and/or severity of hypomanic and depressive episodes.399,450,452 Serum

Adjunctive agomelatine (level 4),472 bupropion (level 4)276 eicosa-

lithium levels were 0.8-
1.2 mEq/L. A number of active comparator

pentaenoic acid (EPA) (level 4),473-475 N-
acetylcysteine (level 4),476

studies also support lithium. As noted above, lithium was as effective

pramipexole (level 3),274 or thyroid hormones (level 4)272 may also be

as quetiapine in preventing relapse in a 6-month single-blind trial.453 A

considered.

20-month study comparing lithium and divalproex in rapid cycling BDI
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+ BDII found the two drugs to be equally effective in preventing re496

lapses.

The authors noted that findings were similar for BDII and BDI,

but results were otherwise not reported separately for BDII. In a 2.5-

No specific recommendation/agents that require further study
There are insufficient data to make a recommendation regarding
olanzapine.506

year study in BDII + BD NOS, lithium and carbamazepine were equally
effective on most outcomes, although a numerical advantage favoured
carbamazepine for reducing clinical plus subclinical recurrence.405 In
contrast, head-to-head comparisons with antidepressants (reviewed
below) found that lithium was not as effective in preventing depressive
469,497

relapse as fluoxetine or venlafaxine.

This may be explained by the

mean lithium levels, which were 0.7 mEq/L in both studies, while the
fluoxetine trial was also enriched for fluoxetine responders.
Long-term naturalistic data also provide strong support for lithium.

7 | SPECIFIC POPULATIONS
7.1 | Management of bipolar disorder in women at
various stages of the reproductive cycle
7.1.1 | Pre-conception, psychoeducation and
contraceptive counselling

In a 6-year study of patients with either BDI or BDII (39% with BDII),

The importance of pre-conception counselling should be raised with

lithium reduced time in hypomania/mania by 61% and time in depres-

all women of child bearing age. It should be provided for all patients at

sion by 53% in the entire sample, compared with the period before lith-

least 3 months prior to considering pregnancy or immediately for those

ium treatment was initiated.498 The authors noted that the proportion of

already pregnant. The issues most frequently raised are fear of adverse

time with mood symptoms was significantly lower for BDII than for BDI.
Lamotrigine. In a 6-month placebo-controlled RCT of lamotrigine
monotherapy in rapid cycling BDI + BDII, post hoc analysis showed that

T A B L E 2 1 US Food and Drug Administration (FDA) classification
of teratogenicity for medications commonly used in bipolar disordera

significantly more lamotrigine-treated than placebo-treated patients
with BDII were stable without recurrence into any mood episode,323
although lamotrigine was not superior to placebo in BDI. In a large 52-

Lithium

week RCT in BDI + BDII, adjunctive lamotrigine was superior to pla-

Anticonvulsants

cebo for improving depression severity and remission rates. However,
results were not presented separately for BDII.251 Open-label trials
and retrospective chart reviews also support lamotrigine.248,499-502

Pregnancy risk
categoryb

Lactation risk
categoryc

D

L4

Carbamazepine

Dm

L2

Divalproex

Dm

L4

Lamotrigine

Cm

L2

Atypical antipsychotics

Second-line

Aripiprazole

Cm

L3

Monotherapy with venlafaxine (level 2) or fluoxetine (level 3) are

Clozapine

L3

second-line options.

Bm

Olanzapine

Cm

L2

Quetiapine

Cm

L2

Risperidone

Cm

L2

Ziprasidone

Cm

L2

Citalopram

Cm

L2

Escitalopram

Cm

L2

Venlafaxine. In a small 6-month RCT in patients with BDII who responded acutely to venlafaxine or lithium without hypomanic switch,
there was a trend for lower rates of relapse into depression for patients
treated with venlafaxine. Further, the rate of sustained response was

SSRI antidepressants

significantly greater in those who continued venlafaxine compared to
those who continued lithium.497 No hypomanic episodes occurred in
either group.

Fluoxetine

Cm

L2

sion was significantly longer for fluoxetine than for lithium or placebo.

Fluvoxamine

Cm

L2

Patients had responded acutely to open-label fluoxetine, making the

Paroxetine

Dm

L2

sample enriched for fluoxetine response. Hypomanic episodes occurred

Sertraline

Cm

L2

Bm

L3

Fluoxetine. In a 50-week RCT, the mean time to relapse into depres-

in a similarly low frequency in the three groups.469 In a separate small

Other antidepressants

6-month placebo-controlled trial, there was a statistical trend for lower
relapse rates with fluoxetine compared to placebo.503 Finally, a post
hoc analysis of a large 12-month placebo-controlled trial found that response rates to fluoxetine were similar in BDII and MDD.468 However,
it did not report whether fluoxetine was superior to placebo in BDII.

Third-line
Divalproex (level 4),504 carbamazepine (level 3),405 escitalopram (level
3),505 other antidepressants (level 3),454 and risperidone (mainly for prevention of hypomania) (level 4)436 may be considered as third-line options.

Bupropion
a

FDA has replaced these risk categories in 2015 with Pregnancy and
Lactation Labeling Final Rule (PLLR). SEE TEXT FOR DETAILS.
b
Adapted from ACOG Committee on Practice Bulletins–Obstetrics878: US
Food and Drug Administration Rating. A = controlled studies show no risk;
B = no evidence of risk in humans; C = risk cannot be ruled out (human
data lacking, animal studies positive or not done); D = positive evidence of
risk (benefit may outweigh risk). The “m” subscript is for data taken from
the manufacturer’s package insert.
c
Hale TW and Rowe HE.879 Lactation risk categories are listed as follows:
L1, safest; L2, safer; L3, moderately safe; L4, possibly hazardous; L5,
contraindicated.
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effects of medications on the fetus, fear of illness recurrence, and genetic transmission to offspring.

507

131

Regardless of treatment decisions made prior to or following

Other important topics to review

conception, it is also important to work with the patient to develop

include the effect of BD on risk for gestational hypertension, antepar-

and agree upon a monitoring schedule and treatment plan to be im-

tum haemorrhage, induction of labour, caesarean section, instrumen-

plemented should clinically significant symptoms emerge. Education

tal delivery, preterm delivery, and neonatal size.508,509 Discussion of

about the risks of psychotropic medications is critical, and careful dis-

modifiable risk factors is critical in pre-conception management of BD.

cussion is needed regarding the magnitude of risks and benefits and

For instance, pregnant women with BD are more often overweight,

limitations with the data. It is important to acknowledge the patient’s

more often smoke tobacco during pregnancy, have poorer diet quality,

desire to do what is right for the child and support the decision made.

and present more often with a history of drug and alcohol misuse in

Whenever appropriate, involve partners in the discussion and review

509

pregnancy.

Modification of these risk factors may have a significant

positive impact on outcomes for both the mother and child.

the decision and supporting evidence for it directly or through educational materials.520

Decisions should be made collaboratively on whether medications
should be continued, discontinued, or switched; and whether any dosage changes are needed. Conventional antipsychotics and risperidone
may need to be discontinued to increase the likelihood of conception,

7.1.2 | Screening for bipolar disorder during
pregnancy and postpartum

as these medications often increase serum prolactin levels and thus

All women with depressive symptoms should be screened for BD

interfere with ovulation and decrease fertility.510 For women who wish

during pregnancy and the postpartum period.521,522 Standardized

to have a medication-free pregnancy, it might be appropriate to have

screening tools such as the Mood Disorder Questionnaire alone or in

one or more psychotropic medications gradually tapered off prior to

conjunction with the Edinburgh Postnatal Depression Scale are use-

conception provided they have been clinically stable for a minimum

ful.521-524 Importantly, screening should be followed by a clinical in-

of 4-6 months and are considered at low risk of relapse. Information

terview to confirm or exclude a diagnosis of BD. Women should also

regarding potential teratogenic effects of different psychotropic med-

be assessed for other psychiatric disorders that commonly co-occur

ications, as well as limitations of the scientific evidence, should be

with BD, such as anxiety disorders or obsessive compulsive disorder

discussed and carefully considered. The decision to stop medications

(OCD).525

pre-conceptually should ideally occur only after careful individualized
risk-benefit analysis for a given patient.511-513 If pharmacotherapy is
required, monotherapy at minimum effective dose is recommended
whenever possible.514,515

7.1.3 | Pharmacological management of bipolar
disorder during pregnancy

Contraceptive counselling, including emphasis on its effectiveness

Given the complexity of the risks faced by women with BD in preg-

in reducing the likelihood of unintended pregnancies, should be in-

nancy and puerperium, it is good clinical practice to encourage liai-

cluded as part of a comprehensive treatment plan for women with BD.

son between the mental health and obstetrics/gynecology teams. A

Several anticonvulsants, including carbamazepine, topiramate,

longitudinal study conducted in a tertiary care centre found a high

and lamotrigine, can affect the pharmacokinetics of oral contracep-

risk of recurrence during pregnancy: 85% of pregnant women with

tives and some might significantly reduce the effectiveness of oral

BD who discontinued a mood stabilizer and 37% of those who were

contraceptives, and this should be considered when making treatment

maintained on one or more mood stabilizers experienced a mood

decisions.516,517 Oral contraceptives might also have effects on the ef-

episode—predominately depressive or mixed—during pregnancy. For

ficacy of lamotrigine via reduction in lamotrigine levels.516

nearly half of the patients, recurrence occurred in the first trimester,

While folic acid supplementation is protective against sponta-

with the median time for recurrence for those abruptly discontinuing

neous spina bifida, there is not enough evidence to indicate that

treatment being 2 weeks, compared to 22 weeks for those who were

folic acid, even in high doses, protects against spina bifida following

gradually tapered off.511 However, studies from primary care, as well

the use of anticonvulsants.

518

In addition, Health Canada recom-

mends that “Valproate products (valproic acid, divalproex sodium)

as obstetric centres, found low rates of relapse or hospitalizations in
pregnancy.526

should not be used in female children, in female adolescents, in

The hierarchies presented throughout these guidelines should be

women of childbearing potential and pregnant women unless al-

followed for management of the various phases of BD, with consid-

ternative treatments are ineffective or not tolerated because of

eration given to specific risks associated with the use of each med-

its high teratogenic potential and risk of developmental disorders

ication using the most up-
to-
date information available from the

in infants exposed in utero to valproate.” Health Canada also rec-

US Food and Drug Administration (FDA) website (http://www.fda.

ommends that women of childbearing potential must use effec-

gov/ForConsumers/ByAudience/ForWomen/WomensHealthTopics/

tive contraception during treatment and be informed of the risks

ucm117976.htm).

associated with the use of valproate products during pregnancy,

Table 21 includes a brief overview of medications commonly

and in women planning to become pregnant every effort should

used in BD and the risk categories. This list should not be viewed

be made to switch to appropriate alternative treatment prior to

as complete or comprehensive. Further, the FDA has replaced these

conception.519

risk categories in 2015 with Pregnancy and Lactation Labeling Final
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Rule (PLLR) with narrative sections and subsections. For instance, for

Patients should be encouraged to initiate or optimize maintenance

pregnancy, the information for each medication is provided using the

treatment as soon after giving birth as possible, with preference given

following subheadings: Pregnancy exposure registry, Risk summary,

to medications that have previously been shown to be successful.

Clinical considerations, and Data. The last three subsections apply

Near delivery, close monitoring is essential for early detection and

to medication risks during lactation. The FDA has not finalized and

management of symptoms that might signal onset of a mood or psy-

published the data for all medications as of completion date of these

chotic episode.538 If an acute mood episode emerges in the postpar-

guidelines (February 2018), and new data appear to suggest that

tum period, the hierarchies for non-postpartum episodes should be

risks may have been overestimated for some medications such as

followed, but, because most psychotropic medications are excreted in

lithium.527 Thus clinicians are strongly advised to use all the current

breast milk, treatment choice should take into consideration safety in

data, including the FDA PLLR information if available, in collaboration

breastfeeding when applicable.

with patient and family members to make final treatment decisions.

The FDA website mentioned in the previous section as well as

Wherever possible, psychosocial strategies should be preferred

Table 21 also include information on lactation. The FDA PLLR should

over medications in the first trimester as this period holds the high-

be consulted for further information about medication risks, as many

est risk for teratogenicity. When medications are deemed necessary,

are secreted in milk, if breastfeeding is being considered.

preference should be given to monotherapy using the lowest effective
dose.

The potential risks and benefits of taking medications while breastfeeding should be discussed with the patient. Education about early

Each pregnancy should be closely monitored and appropriate

recognition of drug toxicity and requirement for ongoing monitoring of

screening tests (eg, foetal ultrasound if lithium is used in the first

infants is also critical.539 A recent systematic review suggested queti-

528

Divalproex should be avoided

apine and olanzapine as preferred choices for breastfeeding, consider-

during pregnancy due to elevated risk of neural tube defects (up to

ing their relatively lower infant dosages.540 The impact of medication on

5%), even higher incidences of other congenital abnormalities, and

the infant can be reduced by scheduling medication administration after

evidence of striking degrees of neurodevelopmental delay in chil-

breastfeeding.541

trimester) should be performed.

529-531

Replacing or supplementing breast milk with formula can also be

Because of changes in physiology in the second and early third tri-

considered. Although there are many benefits to breastfeeding, associ-

mesters, such as increased plasma volume, hepatic activity, and renal

ated sleep disruption may increase the risk of mood episodes in women

clearance, patients may require higher doses of medications towards

with BD. If possible, bottle feeding at night by the woman’s partner or

the later part of the pregnancy. Prenatal vitamins, including high-

a support can be beneficial to allow the woman to maintain a better

dose (5 mg/day) folic acid, are also recommended, preferably even

sleeping schedule. In women with postpartum psychosis or mania,

before conception and continuously through pregnancy; and prepa-

breastfeeding may be more risky, and therefore may not be indicated,

rations containing choline have recently been recommended as pos-

as the mother may be too disorganized to safely breastfeed.542

dren at 3 years of age and loss of an average of nine IQ points.

sibly preventive of the later development of schizophrenia.

532

While

As childbirth can be a trigger for first onset of hypomania/mania in

it is important to note that folic acid may reduce the effectiveness of

women with MDD, antidepressants should be used cautiously, espe-

lamotrigine,251 the anti-teratogenic effects of folate may outweigh

cially in women with a family history of BD.543 Women with first onset

the potential for this loss of effectiveness. However, recent concerns

of depression in the postpartum period or those who have recurrence

have been raised regarding a potential association between very

of depression during the early postpartum period, may also be at a high

high plasma levels of maternal folate and risk of autism spectrum

risk of switching to BD following treatment with antidepressants.537

disorders.

533

7.1.5 | Impact of the menstrual cycle on symptoms

7.1.4 | Pharmacological management of bipolar
disorder during the postpartum period

Despite the paucity of large, well-designed research studies examining the impact of the menstrual cycle on mood symptoms in BD,

The postpartum period is a time of elevated risk for recurrence, with

accumulating evidence suggests that hormonal changes can impact

66% of women who were medication free during pregnancy and 23%

the course of illness. Several case reports and prospective studies

of those on treatment experiencing a mood episode following the de-

suggest that women who experience premenstrual symptom exac-

livery.534 The risk of postpartum relapse is highest in women who also

erbation are more likely to have a highly symptomatic and relapse

experienced a mood episode during pregnancy and those who are not

prone illness.544,545 One of the largest studies (n = 1099) found that

on prophylactic treatment.

535

Despite the high prevalence of postpar-

women who met DSM-5 provisional criteria for premenstrual dys-

tum episodes, there is a dearth of studies investigating the efficacy of

phoric disorder (PMDD) had an earlier illness onset, more comorbid

medications during this period. There is evidence of efficacy of benzo-

Axis I disorders, a higher number of hypomanic/manic and depres-

diazepines, antipsychotics, and lithium for postpartum mania,
quetiapine for postpartum bipolar depression (level 4).

536

535

and

sive episodes, and higher rates of rapid cycling.546 In this study,

There are

there was a closer gap between BD onset and age of menarche in

no studies of psychotherapy in the acute or preventative treatment of

women with comorbid PMDD, which suggests that sensitivity to

bipolar postpartum depression.537

endogenous hormones may influence the onset and the clinical
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TABLE 22

133

Differential diagnosis of manic symptoms in children and adolescents

Symptom

Bipolar mania hypomania

Attention deficit hyperactivity disorder

Oppositional defiant disorder

Elation

Episodic, prolonged, pathological (inappropriate to context or uncharacteristic),
associated with change in functioning,
“travels” with ≥3 other manic symptoms

If present, not clearly episodic or
pathological

If present, not clearly episodic or
pathological

Irritability

Episodic, prolonged, pathological, associated
with change in functioning, “travels” with ≥4
other manic symptoms

Can be an associated feature, related to
stimulant rebound, or due to a
comorbid illness (eg, ODD)

Diagnostic criterion, lacks distinct
prolonged episodes, does not “travel”
with other manic symptoms

Sleep

Reduced need for sleep (ie, significantly less
sleep than usual without increased daytime
fatigue or somnolence); change must be
mood-related

Insomnia (ie, difficulty falling asleep); can
be an associated feature or associated
with stimulants, but need for sleep is
unchanged

Not a symptom or common characteristic; may defy bedtime rules or
routine

Grandiosity

Distinct uncharacteristic increase in
confidence or self-importance; change must
be mood-related

Not a symptom or common
characteristic

Defiance toward authority figures is
common but not necessarily
mood-related

Hyperactivity
and
distractibility

Episodic; if comorbid ADHD is diagnosed,
then distinctly “worse than usual” change
must be mood-related

Diagnostic criteria, nonepisodic

Not prominent or episodic

ADHD, attention-deficit hyperactivity disorder; ODD, oppositional defiant disorder (Adapted from Goldstein and Birmaher 2012555).

course of BD. Premenstrual syndrome (PMS) and PMDD also occur

which symptoms manifest themselves, the actual diagnosis of BD

more frequently in women with BD.547,548 Importantly, an accurate

in children and adolescents should be made based on the same set

diagnosis of comorbid PMDD in women with BD is made during

of symptoms as applied to adults.563 When defined rigorously ac-

euthymia, with a minimum of 2 months of prospective symptom

cording to DSM-5 criteria, the course of illness in childhood and

charting.549

adolescence is characterized by eventual high rates of symptomatic
recovery, but also high rates of recurrence, even in the context of

7.1.6 | Menopause

naturalistic treatment.564 While the concepts of “over-diagnosis”
and “over-treatment” in pediatric BD have received substantial at-

For many women, stress and hormonal changes associated with

tention,565 representative population studies demonstrate that ad-

the transition to menopause may increase or trigger mood symp-

olescent BD is characterized by low rates of treatment, alongside

550-552

A post hoc analysis of the prospective Systematic

high rates of suicidality and comorbidity.566,567 Risks of incorrectly

Treatment Enhancement Program for Bipolar disorder (STEP-
BD)

diagnosing and treating BD in a child or adolescent should thus be

study showed increased rates of depressive, but not manic episodes

carefully weighed against the risk of incorrectly or not diagnosing or

during menopause transition.553 However, due to the paucity of clini-

treating,568 keeping in mind that the duration of treatment delay has

cal trials in this area, more data are needed before treatment recom-

been shown to be an independent risk factor for a poor outcome in

mendations can be made.554

adulthood.569

toms.

Distinguishing early-onset mania or hypomania from other psy-

7.2 | Management of bipolar disorder in children and
adolescents
7.2.1 | Presentation and diagnosis

chiatric disorders is important as there is a high level of symptomatic
overlap for multiple conditions including but not limited to ADHD,
oppositional defiant disorder (ODD), disruptive mood dysregulation
disorder (DMDD), substance abuse, personality disorders and generalized anxiety disorder555,570 (Table 22). The discrete episodes of mania/

As the following section comprises only a brief overview of the epide-

hypomania and the non-overlapping symptoms can facilitate accurate

miology, phenomenology, and differential diagnosis of BD in children

diagnosis. When a comorbidity is present, such as ADHD, overlapping

and adolescents, the reader is referred to more detailed reviews for

symptoms (eg, distractibility and hyperactivity) should only count to-

further information.555-560

wards a diagnosis of mania or hypomania if they intensify during in-

Between one-third (community samples) and two-thirds (clinical

tervals of elation or irritability. Notably, ADHD is an ongoing condition

samples) of patients with BD experience their first mood episode

whereas BD is episodic, and decreased sleep, hypersexuality, hallucina-

during childhood or adolescence, with an earlier onset related to a

tions or delusions, and homicidal or suicidal thoughts and actions occur

more severe illness characterized by increased symptom burden and

with childhood mania, but are rare or absent in uncomplicated ADHD.

comorbidity.

561,562

In contrast to the controversies of as recently as

It is important to note that, while chronic irritability with episodic be-

a decade ago, there is now far greater consensus in the field that,

havioural outbursts or rages can be seen in multiple paediatric psychiat-

although there are developmental differences in the manner in

ric disorders (including emerging personality disorders, substance abuse,
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Reconciling the paucity of RCT data with abundant clinical experience in determining level of
recommendaon for treatment of pediatric bipolar depression
Aside from lurasidone, which has posi ve RCT data (597) alongside good tolerability, op ons include either treatments with substan al
tolerability concerns (olanzapine-fluoxe ne combina on) or treatments with no RCT data (eg. lithium, lamotrigine) or without posi ve
RCT data (eg.que apine). In this instance, clinical experience combined with tolerability considera ons and adult data informed the
ranking of recommenda ons. Lithium and lamotrigine have not been tested in RCTs in pediatric bipolar depression. However, there is
abundant clinical experience with these agents in trea ng depression in the pediatric group alongside posi ve open trials. Further, these
agents are recommended for trea ng acute bipolar in adult popula ons, and they have good tolerability. Thus, despite lack of RCT data,
they are recommended as second-line agents for trea ng acute bipolar depression in pediatric popula on.
In terms of que apine, of the two nega ve RCTs (601, 602), one had a dose range of 300-600 mg/day but was limited to 32 par cipants
and had a 67% placebo response rate. The other study was dosed at only 150-300 mg/day and had a 55% placebo response rate. One can
argue that the que apine studies have been failed, rather than truly nega ve, studies. Therefore, given its demonstrated efficacy in adult
bipolar depression and methodological problems in studies of pediatric bipolar depression and based on clinical experience, it is
recommended as a third-line op on.
Ul mately, treatment decisions in general, but par cularly in the context of empirical uncertainty, should be informed by a thorough
discussion of compara ve risks and benefits of compe ng op ons. Risk-benefit ra os may differ across pa ents depending on factors
such as BD subtype, comorbid anxiety, and sleep disturbance.
FIGURE 8

Treatments for pediatric bipolar depression: Summary of evidence [Colour figure can be viewed at wileyonlinelibrary.com]

ODD, pervasive developmental disorders, and major depressive episodes),

treatment response. An online program for weekly parental ratings (of

such irritability and explosiveness are not sufficient to make a diagnosis,

depression, anxiety, ADHD, oppositional behaviour, and mania) of chil-

even when severe. The recent DSM-5 diagnosis DMDD—which includes

dren aged 2-12 years is available at www.bipolarnews.org, click on Child

chronic irritability as a defining feature—lists BD as an exclusion criterion.

Network.581

However, the DMDD phenotype is evident in about 25% of adolescents
with episodic BD, and is associated with factors such as greater family
conflict and ADHD comorbidity.571 Classical BD and chronic irritability

7.2.2 | Pharmacological management

are therefore not mutually exclusive, the nonspecific nature of the latter

General principles

notwithstanding.

The general principles for managing adults with BD also apply to

A significant minority of children or youth with MDD will even-

children and youth. In youth, themes of comorbidity and tolerabil-

tually go on to develop BD, with an average rate of 28% being re-

ity are accentuated. Comorbid ADHD is more common in children

ported.572,573 Risk factors for switch to mania following a depressive

and adolescents as compared to adults with BD. Moreover, ADHD

episode include a family history of mood disorders, emotional and

symptoms often do not improve following mood stabilization, and

behavioural dysregulation, subthreshold manic symptoms, cyclothy-

may require concurrent ADHD treatment. In addition, due to ele-

mia, atypical depression and psychosis.572 A recent meta-analysis sug-

vated risk for accelerated atherosclerosis and early cardiovascular

gested that the most potent predictors were family history, an earlier

disease in this population, cardiovascular risk factors should also be

age of onset and the presence of psychotic symptoms.

574

There is an

assessed regularly and intervention implemented. Lifestyle manage-

increased prevalence of BD among offspring of parents with BD.575-

ment including attention to diet, substance use, smoking and physi-

577

Although there is no uniform strategy for managing depression (or

cal activity should be implemented alongside any psychological or

ADHD, anxiety, etc.) in the child of a parent with BD, increased caution

pharmacological interventions.582 Relatedly, children and adoles-

is warranted when prescribing antidepressant or stimulant medica-

cents are more susceptible than adults to the metabolic side effects

tions as these have the potential to precipitate mania/hypomania.578

of psychiatric medications, particularly the atypical antipsychotics

Patients and their parents should be informed of the potential switch

that are considered first-line treatments.583 Taken together, these

risk and close monitoring for treatment-emergent manic/hypomanic

distinguishing features underscore the importance of ensuring that

switch should be instituted.

polypharmacy, as often required, is judicious and informed by a bal-

Self-report and/or parent-reported questionnaires can be informative and can raise the index of suspicion for BD.579 However, scores on

ance of factors including mood symptom burden, global functioning,
and physical health.

such questionnaires as the Child Behaviour Checklist (CBCL) “dysregulation phenotype”, previously described as “BD phenotype”, have poor

Acute management of mania

capacity for differentiating BD from other complex and severe symp-

First-line. Lithium (level 1),583-585 risperidone (level 1),584,586 aripipra-

580

Questionnaires can be used as screeners, but

zole (level 2),587 asenapine (level 2),588 and quetiapine (level 2)583,589

do not substitute for a thorough diagnostic evaluation. Longitudinal

are recommended as first-line options. Risperidone may be preferable

rating by parents may be most helpful in diagnosis and assessment of

to lithium for non-obese youth, and youth with ADHD.584

tomatic presentations.
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Second-line. Due to safety and tolerability concerns, olanzapine
590

(level 2)

591

and ziprasidone (level 2)

should be considered second-

line options. Quetiapine adjunctive therapy (level 3)592 is also recom-
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studies in adults to a greater extent than the above acute mania
recommendations.
First-line. Preferred maintenance treatment options for this population are aripiprazole (level 2),602,603 lithium (level 2)604 and divalproex

mended as a second-line treatment.
Third-line. Despite low response rates in two RCTs, a long history

(level 2).604,605 However, it should be noted that follow-up duration for

of use among adults with BD, combined with positive findings in open-

the aripiprazole study was only 30 weeks, and the sample size in the

label studies are grounds for considering divalproex as a third-line op-

18-month maintenance study of lithium vs divalproex was only 30 par-

tion for youth who do not respond to or tolerate firstor second-line

ticipants. It is important to note that few patients continued to do well

agents (level 4).593

upon the switch to either lithium or divalproex monotherapy and the

Not recommended. Oxcarbazepine was not superior to placebo in a
large RCT (level 2 negative).594

majority re-responded when the combination was reinstated. Further,
other studies have also suggested the efficacy of combination therapy
(eg, risperidone plus lithium or divalproex584 and lithium plus divalproex

Acute management of bipolar depression

or carbamazepine606) to achieve and maintain remission. Adjunctive la-

The data in paediatric samples are very limited, and complicated by ex-

motrigine may also be considered for those aged ≥ 13 years (level 2).607

tremely high placebo-response rates in RCTs. These recommendations
are therefore to a greater extent informed by clinical experience and stud-

Second-line. No treatments with level 3 or higher evidence are
available to recommend as second-line options for maintenance.

ies in adults than the above acute mania recommendations (see Figure 8).

Third-line. Although there has been far less experience with

First-line. A recently published RCT found that lurasidone was

asenapine than with other medications discussed in this section, a re-

superior to placebo (level 2)595 in improving depressive symptoms

cent open-label extension study suggests continual reduction in manic

in children and adolescents with acute bipolar depression; however

symptoms over 50 weeks (level 4).608 Further, a recent RCT in adults

there is comparatively little clinical experience in this population.

confirmed its efficacy in preventing relapse of mood episodes.374

Nevertheless, given its efficacy and clinical experience in adult bipolar

Although there have not been maintenance studies for quetiapine,

depression, lurasidone is recommended as a first-line treatment.

risperidone, or ziprasidone in this population, clinical experience

Second-line. Although lithium and lamotrigine were recom-

and open-label studies indicate that continuation and maintenance

mended as first-line agents for bipolar depression in adults, there

treatment with these medications is another option, particularly for

are only open-label data for lithium (level 4)

596

and lamotrigine (level

those patients who have responded well to acute treatment (level

4)597 in children and youth. Despite limited RCT data, there is, how-

4).591,609,610 Further, there is evidence that oral quetiapine and long-

ever, substantial clinical experience with these agents as they are

acting injectable risperidone monotherapy and adjunctive therapy and

widely used in clinical practice. For this reason, together with the

oral ziprasidone adjunctive therapy are effective in preventing mood

strength of evidence in adults, lithium and lamotrigine are recom-

episodes in adults with BD.369,370,383,384,387

mended as second-line, rather than third-line agents (see Figure 8).
Third-line. There is a positive RCT of olanzapine-fluoxetine com-

Treatment of comorbid conditions

bination among youth with bipolar depression (level 1)598; however,

ADHD. Stimulants may also be used for comorbid ADHD in stable/

metabolic concerns regarding olanzapine, and limited clinical expe-

euthymic youth taking optimal doses of anti-
manic medications.

rience with olanzapine-fluoxetine combination in youth lead to the

Adjunctive mixed amphetamine salts (level 3)611 and methylpheni-

positioning of this option as third-line. Despite negative findings in

date (level 3)612 have both been shown to be effective in address-

599,600

is also recom-

ing attention symptoms and have been well tolerated overall within

mended as third-line for this population due to the abundance of

the RCTs completed to date, theoretical and epidemiological data

evidence from adult studies combined with substantial clinical experi-

regarding risks of induction of mood elevation notwithstanding.613

ence. There are also several methodological concerns with the studies

Although open trials suggest potential benefits of atomoxetine (level

done in pediatric samples (see Figure 8).

4),614,615 the possibility of inducing mania or hypomania remains,616

paediatric samples, quetiapine (level 2 negative)

Despite limited knowledge regarding the precise risks of
antidepressant-
induced mania in youth with BD, observational

suggesting the need for RCTs before clinical recommendations can
be made.

pharmaco-epidemiology studies support the conclusion that antide-

Substance use. Comorbid substance use should be treated con-

pressants should be used with caution in BDI and BDII, and in com-

currently to mood symptoms, with inpatient hospital or community

bination with mood-stabilizing medication (level 4).578,601

residential treatment employed as clinically indicated. A small study

Not recommended. A large RCT found that oxcarbazepine was not

suggests that lithium may be effective for reducing substance use in

superior to placebo (level 2 negative)594 although it was effective in

this population (level 3),617 and FFT should also be considered (Section

the youngest group of patients but not the older adolescents.

2). Positive trials of N-acetylcysteine for cannabis use disorders among
adolescents,618 smoking,619 and bipolar depression among adults

281

Maintenance treatment

suggest that N-acetylcysteine may benefit adolescents with comorbid

The data in paediatric samples are very limited. These recom-

bipolar and SUDs; however, studies examining this hypothesis have

mendations are therefore informed by clinical experience and

not yet been completed (level 4).
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populations.642 Because of these high rates of comorbidities, assess-

7.3 | Management of bipolar disorder in older age

ment of an older adult with BD should include a thorough physical
and neurological examination, including clinical laboratory tests.

7.3.1 | Presentation and course

Neuroimaging should also be applied as indicated, particularly in the

Because of the aging population in Canada and many countries around

presence of focal neurological signs and symptoms or abrupt late onset,

the world, knowledge of pertinent issues related to the management

or if the presentation is different from prior episodes. Coordination

of older adults is becoming increasingly important. Approximately 6%

with other health care providers is also imperative, as this can optimize

of geriatric psychiatry outpatients and 10% of inpatients have BD,620

physical health,643 as can smoking cessation.

and proportionally this population is one of the highest users of psychiatric and physical health services.621 Approximately 25% of the patients with BD in the USA in 2005 were over the age of 60 years,622

7.3.3 | Pharmacological treatment

and by 2030 >50% of patients with BD are expected to be aged >60

The data supporting efficacy of medications in various mood states

years.623

in this population are limited, with only a single RCT exclusively in

The lifetime prevalence of late-life BD is about 1%-2% with a 1-

geriatric patients completed to date, comparing lithium vs divalproex

year prevalence of 0.1%-0.7% in the general population. About 90%-

for the treatment of mania/hypomania.644 Despite this, open-label

95% of older adults with bipolar disorder have their initial episode

trials, naturalistic studies, and post hoc analyses of mixed aged RCTs

prior to age 50 years, although there is a minority who will have a

suggest that medications efficacious in adults overall will also be ef-

624,625

Late onset is often related to neurological or physical

fective in older adults, although additional considerations regarding

comorbidity,626 and may carry a negative prognosis,627 although this is

medication tolerability and age-related changes in pharmacokinetics

not a consistent finding.628

and pharmacodynamics must be taken into account. Because of the

later onset.

While symptoms of mania or hypomania are generally less prom-

high number of medical comorbidities as well as physical changes

inent in older adults, depressive and cognitive symptoms are more

related to the aging process, strict attention must be paid in these

often observed, and hyperactivity, aggression, insomnia, impulsiv-

patients to potential pharmacokinetic issues, drug-drug interactions,

ity, and self-neglect may pose a significant risk to the patient and

side effects, and the need for ongoing monitoring (see Section 8).

others.629,630 Psychiatric comorbidity is also generally lower than in

Amongst other effects, lithium has been associated with adverse

younger patients, with anxiety and substance use being the most com-

neurological effects645 and renal disease.646 Divalproex has been as-

631

Compared to younger patients, older adults are less likely to

sociated with motor side effects645 and metabolic effects (weight gain

utilize inpatient, outpatient, and emergency room services and more

and diabetes mellitus).647 Carbamazepine induces cytochrome P450

mon.

likely to use case-management and conservator services.

632

enzymes and can reduce the levels of divalproex and other medica-

Cognitive dysfunction is a significant concern for this population,

tions.648 Regarding antipsychotics, which are now very commonly used

with >30% showing significant deficits across all mood states, includ-

for BD in older adults, dose reduction may be beneficial in some aging

ing euthymia.633 This cognitive dysfunction is relatively stable, related

patients to lower the risk of motor, sedation, metabolic syndrome, and

to the number of mood episodes earlier in life, and does not appear

cognitive effects.649 There is an association between mortality and

to exceed normal aging in 2-5-year follow-up.634-636 Lithium use has

antipsychotics in patients with dementia650 but it is unclear how this

been associated with lower rates of cognitive disorders in BD,

637

and

higher lithium levels in drinking water may be associated with lower
dementia risks,

638,639

should be managed for patients with BD. Recently there have also been
data linking antipsychotics with acute kidney injury.651

although prospective trials are required to de-

In particular, when lithium is used in this population, lithium level

finitively assess this. Standardized instruments, such as the Montreal

and renal monitoring should occur at least every 3-6 months, as well

Cognitive Assessment (MoCA), should be used to quantify cognitive

as 5-7 days following a lithium dose adjustment or adjustment of non-

dysfunction. Because of the link between cognition and functioning

steroidal anti-inflammatory drugs (NSAIDs), antiontensin II receptor

in BD,634,640 the impact of medications (particularly those with a high

blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), or

anticholinergic burden) on cognition should be considered when mak-

thiazide diuretic dosing.652 Special consideration also needs to be given

ing treatment decisions. Furthermore, improvement of modifiable risk

to dose selection. A post hoc analysis of the STEP-BD study found that

factors such as diet, exercise, and mental stimulation should also be

while, on average, older patients required a similar number of med-

promoted in order to further diminish the risk of cognitive decline.

ications to younger patients to achieve recovery, lower doses were
used. In that sample, over twice as many older patients as younger

7.3.2 | Medical comorbidity

ones recovered using lithium alone (42% vs 21%, respectively).653 In
general, starting at a lower dose (eg, 150 mg nightly for lithium) is rec-

Older adults with BD have an average of three to four medical co-

ommended, with gradual adjustments to reach the lowest end of the

morbidities, with metabolic syndrome, hypertension, diabetes, car-

therapeutic range for adults, with subsequent titration based on toler-

diovascular disease, arthritis, and endocrine abnormalities being the

ability and effectiveness; keeping in mind that some older patients will

most common.631,641 Together, these contribute to a reduction in

require similar blood levels as the general adult population in order to

life expectancy of 10-15 years in BD compared to non-psychiatric

achieve remission. Further discussion, including clinical guidance and
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more detailed treatment recommendations, can be found in the ISBD
Task Force report.654 In light of very limited international guidelines for
maintenance treatment of older adults with BD, an ISBD Task Force
is currently undertaking a Delphi survey of international experts, and
clinicians are advised to consult this as results become available in the
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7.4 | Management of comorbid conditions in
bipolar disorder
7.4.1 | Comorbid psychiatric disorders
Epidemiology

future (Shulman K, personal communication).
Pharmacological treatments have been evaluated using the cri-

Most patients diagnosed with BD will also have at least one comor-

teria for strength of evidence for efficacy (Table 1) in older adults

bid psychiatric diagnosis. The most common comorbid conditions are

as well as safety and tolerability (Section 8). Unfortunately, there

substance use disorder, anxiety disorder, personality disorder, and im-

is a dearth of literature for efficacy of treatments in older adults.

pulse control disorder (such as ADHD, ODD, and CD).45 Comorbidity

However, clinical experience supports the notion that treatments

impacts the course of BDs by increasing the likelihood of treatment

known to work in general adult populations are also effective in older

resistance and suicide risk, and also by increasing the time spent with

adults. Tolerability may be different and this is an important consid-

impairing symptoms.34,50,669,670

eration in treatment selection in older adults. General principles for

When treating comorbid conditions, determining which disorder

management of acute episodes described in Sections 3 and 4 also

to address first requires careful consideration. Some comorbid disor-

apply to this population.

ders may be managed with the same treatment employed to manage
bipolar symptoms (eg, quetiapine for comorbid anxiety and BD), while

Acute mania

other comorbid disorders (eg, ADHD) may require distinct treatments.

Monotherapy with lithium (level 2)644 or divalproex (level 2)644 is

Importantly, some treatments for comorbid disorders may lead to

recommended as a first-line treatment. Quetiapine (level 2)655 can

bipolar symptom destabilization; for instance, an antidepressant em-

be considered as second-line. Asenapine (level 4),656,657 aripiprazole

ployed to treat an anxiety disorder may provoke mood elevation.

658

659

654

may

Safely and effectively managing comorbid conditions often ne-

be applied as third-line treatments. For treatment-resistant episodes,

cessitates the implementation of a hierarchical approach, depend-

clozapine (level 4)660 and ECT (level 4)654 should also be considered.

ing on each patient’s individual needs and preferences. In general,

(level 4),

risperidone (level 4),

or carbamazepine (level 4)

the disorder or symptom associated with the greatest morbidity

Bipolar depression

and mortality—such as acute mania, psychosis, or suicidal ideation—

There are no RCTs of any agents in older adults with acute bipolar

should be managed first. Substance use disorders may be addressed

depression. Post hoc analyses of RCTs suggest efficacy of quetiapine

concurrently or sequentially, depending on severity and contribution

(level 2)661 and lurasidone (level 2)662 monotherapy and hence these

to mood instability. Once mood stability is established, the treat-

are recommended as first-line options. However, in older adults, given

ment of additional comorbid conditions, such as ADHD or metabolic

the concerns about side effects of atypical antipsychotics, clinicians

disorders, should follow based on their impact and the patient’s

may wish to try lithium or lamotrigine first based on their efficacy in

preference.

adult populations, although the evidence of efficacy is limited in older
663,664

adults (lithium, level 4; lamotrigine, level 4).

Divalproex (level 4),

There is a dearth of research to guide the best management of
BD in the context of comorbid conditions. There have been few trials

aripiprazole (level 4),658 and carbamazepine (level 4)665 are third-line

designed with comorbid symptoms as the primary target for mood-

options. ECT (level 4)654 is an important option that should be consid-

stabilizing treatments—evidence is mainly derived from secondary

ered in treatment-resistant cases, for suicidal patients, or for patients

analysis of published data. Thus, the limited research informing the

with inadequate food or fluid intake.

treatment of comorbidities constrains our ability to make definitive

While the use of antidepressants in BD remains controver-

recommendations. However, because comorbidity is so common and

sial260,426 and there have been no studies in older age BD; antide-

burdensome for patients, appropriate management is a challenging

pressants are frequently used in this population (>40% of patients).666

daily reality in clinical practice. Therefore, CANMAT decided to pro-

Antidepressants with lower manic switch potential (eg, SSRIs and bu-

vide a brief overview of relevant clinical issues and the evidence base

propion)260 used in combination with mood stabilizers may be benefi-

for pharmacological treatments for treating comorbid populations. The

cial in selected patients who cannot tolerate/do not respond to other

reader is advised to consult the following references for the role of

agents with a stronger geriatric evidence base. Possible medication

psychological treatments in managing comorbidity.671-673

interactions with ongoing medications for non-psychiatric conditions

Substance use disorders

must always be considered.

Two recent reviews indicated that the prevalence rate of comorbid

Maintenance

SUD in BD is about 33% in general population surveys674 and ap-

Choice of agents should be based on what has been effective in the

proximately 45% in clinical settings.675 SUD can negatively impact the

acute phase, with recommended options with geriatric efficacy data

course of BD, resulting in lower rates of remission,407 a higher number

667,668

being lithium (level 2),
667

(level 3).

668

lamotrigine (level 2),

and divalproex

of hospitalizations,676,677 and an increased risk of suicide attempts429
and perhaps suicide deaths.678
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Substance use should be addressed as early as possible, as it is

No specific recommendations are given regarding acamprosate

likely to interfere with treatment for BD. However, the presence of a

at this time. In a smaller RCT, acamprosate add-on was ineffective in

SUD should not preclude an attempt to treat BD, which might result in

improving drinking-related outcomes in BDI/BDII patients with alco-

an individual being more amenable to treatment. As the directionality

hol dependence (level 3 negative)702 but a post hoc analysis showed a

of the interaction between SUD and BD is rarely clear in the reality of

small decrease of the Clinical Global Impression scores for substance

clinical practice, it is recommended that the two conditions be treated

use severity towards the end of the trial. Further studies are needed.

simultaneously.
A more detailed discussion on the impact of and the general principles of the treatment of substance use comorbidity can be found in
a CANMAT Task Force publication,
a meta-analysis

680

679

and other reviews

673,681

Cannabis use disorder
About 20% of patients with BD have cannabis use disorder at some

and

point in their life.675 Cannabis use disorder is associated with younger

published on the topic since 2012. Here we pro-

age, manic/mixed episode polarity, presence of psychotic features,

vide a brief update on the pharmacological treatments identified in

and comorbid nicotine dependence, alcohol use disorder, and other

the CANMAT Task Force publication. It is important to note that the

SUDs.703 Cannabis use is also associated with more time in affective

criteria for level of evidence used here are more stringent than those

episodes and rapid cycling.704

applied to the Task Force report.

There is limited research into treatment options for this frequent

The levels of evidence for treatment of comorbid SUD are low.

SUD. Lithium and/or divalproex have level 3 evidence.617,682,685-687

This is because of (i) the paucity of data, (ii) complexity of study de-

Quetiapine failed to provide any benefit in terms of mood and anxiety

signs (given the fact that many patients will be using more than one

symptoms in a small subsample of highly comorbid patients with BD.

substance), and, most importantly (iii) inconsistency of the outcome

generalized anxiety disorder (GAD) and cannabis use disorder701 (level

variables used in these studies; hindering direct comparison of results.

3 negative). The effect of quetiapine on specific cannabis use-related

Nevertheless, some evidence-based recommendations are available

outcomes was not reported.

for clinicians, starting with general principles of treatment: if at all
possible, avoid medications that could increase the risk of destabiliz-

Stimulants: cocaine, amphetamine, and methamphetamine use

ing the BD, and choose treatments that could help both conditions.

disorders
Citicoline adjunctive therapy had a positive outcome in two RCTs in

Alcohol use disorder

patients with BD with comorbid cocaine use disorder, although the

A combination of divalproex and lithium is the only treatment for al-

benefits of citicoline decreased over time in the more recent study

cohol use disorder comorbid with BD that meets criteria for level 2

(level 2).705,706

evidence.

682,683

In a small RCT, there was a significant reduction in

Lithium or divalproex, either alone or in combination, were proven

the number of drinks per drinking day, as well as per heavy drinking

useful in small studies addressing cocaine use disorder682,685-687,707,708

day, in the combination group compared to the group with lithium

(level 4). Quetiapine in monotherapy or in combination with the ongo-

alone when adherence to treatment was added as a covariate. There

ing treatment shows evidence of efficacy for cocaine, amphetamine

is only level 3 evidence for lamotrigine,684 and divalproex mono-

and methamphetamine use disorder709-711 (level 3). Risperidone has

therapy or add-on.685-687 While lithium may also show some benefits

been studied alone and as an add-on agent for cocaine and for meth-

(level 3),617 it has to be used with caution in heavy drinkers because

amphetamine use disorders with level 3 evidence for efficacy.711,712

of potential electrolyte imbalance; and anticonvulsants warrant liver

Bupropion has anecdotal reports favouring efficacy in cocaine

function tests and lipase levels before initiating treatment. Agents for

use disorders (level 4).713 Citicoline improved depressive symp-

primary alcohol use disorder may also show benefits in BD, such as

toms in patients with methamphetamine use disorder and bipolar

disulfiram (level 3),688-691 naltrexone (level 3)692-695 and gabapentin

depression.714

696,697

Furthermore, guidelines for pharmacotherapy in al-

Lamotrigine has been studied in a 10-week RCT of lamotrigine

cohol dependence alone can offer some guidance in the absence of

(level 4).

vs placebo added to ongoing medication. While results were nega-

comorbidity-specific trials.698

tive for the a priori outcome variable (positive urine drug screens),

Quetiapine is not recommended for the treatment of alcohol

they were positive on the secondary outcome of the amount of

use disorder comorbid to BD because of lack of efficacy. Quetiapine

dollars spent per week on cocaine purchases (level 2 negative). 715

add-on therapy was not more effective than placebo add-on in reducing the number of drinks per day or other alcohol-related measures in

Opioid use disorder

patients with BDI699 or BDI and BDII with alcohol dependence (level

While methadone has the most evidence of efficacy in comorbid BD

1 negative).700 In another RCT, quetiapine monotherapy or add-on

and opioid use disorder (level 3),716,717 because of the lack of research

therapy to mood stabilizers was compared with placebo monotherapy

in this area and increasing concern related to risk of overdose, cli-

or add-on therapy in patients with bipolar depression with comorbid

nicians should consult the Canadian Research Initiative in Substance

anxiety and substance use disorders.701 No significant improvement

Misuse (CRISM) national treatment guidelines on primary opioid use

was found in depressive or anxiety symptoms but alcohol or substance

disorder when available (anticipated 2018) for further advice on man-

use-related outcomes were not reported separately.

aging opioid use disorders in their patients.
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Primary treatments for anxiety disorders: Should they be used to treat co-morbid anxiety in
bipolar disorder?
There are no large RCTs that examined the efficacy of SSRIs, SNRIs, pregabalin or lorazepam in treang anxiety symptoms in BD paents
with co-morbid GAD. However, several RCTs assessed the efficacy of these agents in paents with primary GAD and have been found to
be effecve (723). So,should clinicians employ these treatments in treang co-morbid anxiety symptoms in GAD? As with any clinical
decision, CANMAT recommends assessing risk-benefit rao.
Pregabalin is effecve and is not associated with risk of mood destabilizaon and is well tolerated. Hence, pregabalin would be considered
an appropriate opon although this has not been tested in BD populaon with co-morbid anxiety. Lorazepam also does not cause mood
instability but given the potenal dependence with longer-term use, only short-term use of lorazepam may be appropriate. In the case of
andepressants, especially with SNRIs, the risk of manic/hypomanic switch is likely higher. Therefore, if andepressants are being
considered for treang anxiety symptoms, it is recommended to primarily use SSRIs. Further, if SSRIs are used, it is important to ensure
adequate mood stabilizaon with one or more prophylacc anmanic agents (eg. lithium or divalproex or an atypical anpsychoc).
Lorazepam and clonazepam do not provoke mood instability, they are rapidly effecve for the acute management of anxiety and they may
address early warning signs of mania by inducing sleep. While inappropriate prescribing may result in misuse and dependence and cauon
must be exercised when prescribing benzodiazepines to elderly paents in parcular, the use of benzodiazepines may be appropriate for
treang anxiety associated with bipolar disorder. Short-term use is desirable but some paents are unable to tolerate other anxiety
treatments and experience significant symptomac relief and funconal improvement due to the judicious use of benzodiazepines.
F I G U R E 9 What is the role of primary treatments for anxiety disorders in treating co-morbid anxiety in bipolar disorder?
RCT, randomized controlled trial [Colour figure can be viewed at wileyonlinelibrary.com]

Others

benzodiazepines are an important clinical tool because they can rap-

Olanzapine add-on therapy was effective in decreasing manic symp-

idly alleviate anxiety, clinicians should strive to prescribe them at the

toms and measures of substance use such as reduction in cravings in

lowest possible dose for the shortest period possible, given the con-

hospitalized inpatients (level 2).718 Aripiprazole has level 4 evidence to

cerns about suicide risk, abuse and dependence. CBT continues to be

decrease craving of alcohol, but not consumption, and level 4 evidence

an appropriate first-line treatment for anxiety.

to decrease cocaine use in polysubstance users.719

Generalized anxiety disorder and panic disorder
Anxiety disorders

Quetiapine was superior to placebo and divalproex in improving anxi-

Patients with BD frequently experience symptoms of anxiety and co-

ety symptoms in patients with comorbid GAD and/or panic disorder

morbid anxiety disorders (GAD, panic disorder, post-traumatic stress

(level 2).724 Further, secondary analyses from several RCTs indicate

disorder and others). Clinical samples indicate that 24%-56% of pa-

that quetiapine monotherapy significantly reduces symptoms of

tients with BD meet criteria for one or more anxiety disorders, with

GAD and panic disorder in patients with bipolar depression.290,313,725

the highest rates in women.

720

Comorbid anxiety symptoms and anxi-

Negative trials include risperidone versus placebo in patients with BD

ety disorders are associated with a higher number of mood episodes

and comorbid GAD and/or panic disorder726 and ziprasidone versus

and depressive symptoms, including suicidality and sleep disturbance,

placebo in a similar trial.727

and greater impairment of psychosocial functioning and quality of

For patients who are euthymic and treated with lithium, the addi-

life.721 The presence of a comorbid anxiety disorder is also associ-

tion of lamotrigine or olanzapine has demonstrated similar anxiolytic

ated with high rates of use of antidepressants,722 which should be

effects (level 3).728 In a secondary post hoc analysis, combinations of

employed with caution due to their potential for mood destabilization

olanzapine and fluoxetine (level 3), and to a lesser extent olanzapine

(Section 4).

monotherapy, were effective in reducing anxiety in patients with bipo-

While the CANMAT Task Force report720 described key studies

lar depression.314

and treatment recommendations in length, those recommendations

Gabapentin employed as an adjunctive therapy in open-
label

have been updated below. However, it remains the case that there

studies reduced anxiety symptoms in patients with BD (level 4).696,729

are few studies that have focused exclusively on anxiety symptoms or

Given its relatively benign side effect profile and efficacy in other pri-

disorders comorbid with BD, whether for treatment efficacy or safety.

mary anxiety disorders, gabapentin is an appropriate strategy.

While there are treatment options, the limitations resulting from a
paucity of data prevent the development of clear guidelines or treat-

Obsessive compulsive disorder

ment algorithms.

Obsessive compulsive disorder was re-categorized in DSM-5 and is

A “step-wise” approach was recommended in the 2012 CANMAT

no longer characterized as an anxiety disorder; however, anxiety is a

recommendations for managing comorbid anxiety. In general, mood

cardinal feature. OCD is a comorbid condition in 10%-20% of patients

stabilization is the priority before specific anxiety treatments are

with BD730-733 compared with 2%-3% in the general population.734

considered (Figure 9). Despite clinical experience, antidepressants,

However, the prevalence appears to vary widely, depending on the

particularly serotoninergic agents, should be employed with cau-

clinical setting and bipolar subtype.731 Comorbid OCD may be more

tion due to their potential to provoke mood destabilization. While

common in children and adolescents with BD than in adults731 and has
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been reported to co-occur more commonly with BD than other anxiety
735

small trial that combined psychoeducation and skills training for pa-

736

tients with a mood disorder plus a personality disorder and suicidal

When diagnosed comorbidly with BD, OCD has been associated

ideation (level 3),761 showed a modest long-term benefit. Larger, more

with an earlier onset of BD, a higher number of previous mood episodes,

specific studies are needed. There are also data to support the utility

rapid cycling, seasonality, substance misuse, and lower overall function-

of DBT for the treatment of BD, which has robust data for efficacy in

disorders,

732,737-742

ing.

although other studies have not found that association.

Jeon et al recently conducted a comprehensive review of

the treatment of borderline personality disorder.75,762,763

patients diagnosed with BD and comorbid OCD and found twice the

Since those CANMAT recommendations were published in 2012,

rate of pharmacological switch to mania or hypomania, but suggested

few new studies have significantly contributed to our understand-

this could be due to the more frequent use of antidepressants in that

ing of the appropriate treatment of these highly comorbid disorders.

732

population.

743

Other authors have raised similar concerns.

Alesiani and colleagues assessed the value of the Systems Training for

Symptoms of OCD may precede or follow mood symptoms and the

Emotional Predictability and Problem Solving (STEPPS) program for 32

severity of OCD symptoms tends to fluctuate with mood changes.744

subjects with personality disorder and mood disorder (half MDD and

The high rate of co-occurrence and the many shared clinical features

half BD, mostly BDII), and a history of suicide attempts or self-harm

of OCD and BD suggest a shared neurobiology. Some researchers

and emotional and behavioural dysregulation. Although results are

have posited that the high rate of co-occurrence might reflect a dis-

preliminary due to small sample size and high drop-out rate, findings

tinct bipolar phenotype rather than separate disorders.736,745

suggest that such group treatment may improve symptoms, as well as

OCD symptoms may remit during effective treatment of BD; mood

reduce suicide attempts and hospitalizations.761

stabilizers alone or with atypical antipsychotics may be adequate to
resolve comorbid symptoms of OCD and antidepressants might not

ADHD

be necessary for the majority of patients.730,736 If antidepressants

ADHD and BD co-occur far more commonly than would be expected

are used, clinical experience suggests that SSRIs are preferred, but

based on their individual prevalences in the general population.

because of the potential risk of manic switch clinicians need to op-

Approximately 10%-20% of patients with BD meet the criteria for

timize prophylactic antimanic agents before initiation. The CANMAT

adult ADHD and up to 20% of adults with ADHD also meet the cri-

Task Force 2012 report included several small case reports indicating

teria for BD.764 BD and ADHD have a high degree of symptom over-

743

lap, making the comorbid diagnosis difficult and requiring careful

the potential benefit of lithium,
747,748

ine,

risperidone,

749,750

anticonvulsants,
751

quetiapine

743,746

and aripiprazole

olanzap-

752

for the

treatment of comorbid OCD (all level 4 evidence).

attention to childhood history and lifetime course of illness. Patients
with comorbid ADHD often experience a more treatment-refractory

Since the 2012 CANMAT publication, there has been very limited
new evidence regarding the treatment of comorbid BD and OCD. Two

course, more mood episodes, greater functional impairment and a
heightened risk of suicide.765

published case reports described successfully employing aripiprazole

The treatment of ADHD presenting comorbidity with BD is dis-

once monthly753 and orally754 for patients with intractable bipolar and

cussed in detail in a previous CANMAT Task Force Recommendation

OCD symptoms. Another case report described benefits of ECT,755 and

paper.765 Recommendations were to treat bipolar symptoms first with

756

mood stabilizers and/or atypical antipsychotics to stabilize mood be-

a small trial also found benefits with adjunctive topiramate (level 3).

fore considering treatment for ADHD symptoms. Mixed amphetamine

Personality disorders

salts (level 3),611 methylphenidate (level 3),612 atomoxetine (level 4),615

A meta-analysis indicates that 42% of patients with BD also have

bupropion (level 4),766 or lisdexamfetamine (level 4)767 add-ons to

a comorbid personality disorder, and this feature can be both a di-

mood-stabilizing treatments have been reported to be efficacious in

agnostic confound and predictor of poorer treatment response.

improving ADHD symptoms.

The most prevalent was obsessive compulsive personality disorder

In a s Swedish national patient registry study of patients with BD

(18%), followed by borderline (16%), avoidant (12%) paranoid (11%),

and ADHD, methylphenidate monotherapy significantly increased the

and histrionic (10%) personality disorders.757 Despite the high preva-

risk of mania, while those patients treated concurrently with a mood

lence of these comorbidities, research assessing the effectiveness

stabilizer experienced a significantly reduced risk of mania when

of treatments is sparse. The CANMAT Task Force recommendations

methylphenidate was employed.289

describe key issues in the management of personality disorders, including the relationship between personality and mood disorders,
accurate diagnosis, and the effect on treatment response and clinical
course.758

7.4.2 | Comorbid metabolic disorders
Epidemiology

The 2012 CANMAT Task Force recommendations for comorbid

While there is consistent evidence showing the high prevalence of comor-

personality disorder concluded that divalproex (level 3)466 and lamo-

bid medical conditions in BD768-774 and the negative impact these diagno-

trigine (level 4)759 may provide some symptomatic relief for comorbid

ses have on longevity,775,776 these conditions frequently go undiagnosed

borderline personality disorder. Psychoeducation might be of value,

or undertreated. In a large UK cross-sectional analysis of electronic data

as one small RCT that included patients with any comorbid personal-

sets involving 1.7 million patients in primary care, those diagnosed with

ity disorder (level 3)760 demonstrated. That study, along with another

BD, when compared with healthy controls, had lower rates of diagnoses
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(odds ratio [OR] 0.59, 95% confidence interval [CI] 0.54-0.63) and treat-

hypertension, diabetes, cardiovascular disease, arthritis, and endo-

ment of medical conditions, despite higher rates of one (OR 1.2, 95% CI

crine disorders.631,641 This highlights the necessity for vigilance when

769

1.16-1.39) or multiple illnesses (OR 1.44, 95% CI 1.3-1.64).

treating all patients with BD, including regular assessments of their

Metabolic syndrome in particular is a highly prevalent comorbidity,

metabolic parameters.

present in 20-65% of patients with BD.777 Defined as a cluster of clin-

Working collaboratively with other members of a patient’s health

ical and biochemical features, including abdominal adiposity, hyper-

care team is as essential aspect of good clinical care. Comprehensive

tension, impaired fasting glucose, diabetes mellitus, and atherogenic

management of comorbid medical conditions should include a mul-

dyslipidaemia,778 metabolic syndrome not only greatly increases an

tidisciplinary team-based approach, including primary care, medical

individual’s risk for cardiovascular disease, diabetes mellitus, and pre-

specialists, nurses, psychologists, and social workers as appropriate,

780,781

with patients taking an active role in their care. Treatment strategies

Increased body mass index (BMI) is an important contributor to met-

should focus both on the psychiatric symptoms and medical issues and

abolic syndrome, although metabolic dysfunction is not always ac-

risk factors.

mature mortality

779

but also worsens bipolar clinical outcomes.

companied by overweight/obesity, and so patients with normal BMI
should also receive regular monitoring (Section 8).

A promising strategy for improving the medical care of people with
BD is through “primary care-based medical homes” where those with

It has been hypothesized that BD and metabolic syndrome share

a serious mental illness and at least one other chronic condition re-

a set of common risk factors and overlapping pathophysiology.782-784

ceive integrated care. While most studies do not separate BD from

While medications used to treat BD, particularly atypical antipsy-

other major mental illnesses in analyses, matched samples in the North

chotics, can also lead to metabolic dysfunction and weight problems

Carolina Medical Homes programme indicate that patients with BD

(Section 8), insufficient access to primary and preventative health care,

(n = 13 406) in primary care medical homes had greater use of primary

low socioeconomic status, habitual inactivity, insulin dysfunction, pe-

care and specialty mental health care compared with propensity-

ripheral inflammation and neuroinflammation, oxidative stress, and

matched controls, and marginally lower use of emergency services.

childhood adversity are also important contributors.

785

However, of three diagnostic groups studied (depression, schizophrenia and BD), use of preventative services such as lipid screening

Principles of management

and cancer screening was only greater in the subgroup with depres-

As noted in previously in these guidelines, older adults commonly have

sion.786 At the same time, a cross-sectional Canadian study examin-

three or more medical comorbidities that contribute to the 10-15 year

ing patient-centred medical homes in naturalistic practice found that,

lower life expectancy compared to non-psychiatric populations.642

where rostering was elective, individuals with BD and psychosis were

The most common medical comorbidities are metabolic syndrome,

differentially excluded (relative risk [RR] 0.92, 95% CI 0.90-0.93),787
suggesting that concentrated efforts should be made to ensure appro-

T A B L E 2 3 Baseline laboratory investigations in patients with
bipolar disorder

priate access to these services.

CBC

Treatment recommendations

Fasting glucose

Treatment strategies that target metabolic disorders should include

Fasting lipid profile (TC, vLDL, LDL, HDL, TG)
Platelets
Electrolytes and calcium
Liver enzymes
Serum bilirubin
Prothrombin time and partial thromboplastin time

non-pharmacological lifestyle interventions. Replacing “high metabolic
risk” psychiatric medications with medications that have a more favourable profile is highly recommended if the therapeutic advantage
of the high-risk agent over the alternative is minimal and metabolic/
weight issues persist. Bariatric surgery should be considered following
unsuccessful attempts at the aforementioned strategies if the individual has a BMI ≥27 with weight-related morbidity or a BMI ≥30 without

Urinalysis

significant metabolic morbidity. Readers are referred to the CANMAT

Urine toxicology for substance use

Task Force report785 for further detailed discussion on foundational

Serum creatinine

principles for managing metabolic conditions in patients with BD.

eGFR

While there is no evidence specifically regarding treatment of

24h creatinine clearance (if history of renal disease)

comorbid dyslipidaemia or hypertension in BD, it is noteworthy that

Thyroid-stimulating hormone

many of the medications used to manage these comorbid medical dis-

Electrocardiogram (>40 years or if indicated)

orders have epidemiological or even clinical trial evidence that they

Pregnancy test (if relevant)
Prolactin
CBC, complete blood count; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglyceride; vLDL, very low density lipoprotein (Adapted from
Yatham et al. 20062).

may benefit mood. Examples include statins, aspirin and angiotensin antagonists.788-793 The implications are that clinicians should be
actively engaged in the management of these disorders, and should
select therapies from those agents that may have benefit in mood
symptoms. This again is concordant with the notion of shared risk
pathways for these non-communicable disorders.
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7.4.3 | Other comorbid medical conditions

and instituting other therapeutic strategies to treat serious rashes
and prevent destabilization of BD. Further, prior to commencing

Two studies from a random sample of 1 million people, taken from a

carbamazepine, patients with ancestry in genetically at-risk popu-

large population-based retrospective cohort in Taiwan, demonstrated

lations such as Han Chinese and other Asian patients should have

a reduced risk of both stroke and cancer associated with lithium

genotyping performed to ensure that they do not have the human

treatment for BD. The lithium group was compared with propensity-

leucocyte antigen (HLA)-B*1502 allele, which confers a high risk for

matched controls.

SJS/TEN with carbamazepine.800 In addition, those on carbamaze-

The first study reported hazard ratio for stroke over 11 years of

pine therapy should have serum sodium levels measured at least an-

0.39 (95% CI 0.22-0.68) for those prescribed lithium, even when ad-

nually and as clinically indicated given the risk of hyponatraemia with

justing for the risks associated with typical and atypical antipsychot-

this compound. Patients on atypical antipsychotics should have their

ics. The reduced risk was also correlated with a higher dose, longer

weight monitored monthly in the first 3 months and every 3 months

treatment duration and a higher rate of exposure to lithium.794 In the

thereafter. Blood pressure, fasting glucose and lipid profile should

second study, in a sample of 4729 patients diagnosed with BD, lith-

be assessed at 3 and 6 months, and yearly thereafter. Children under

ium exposure was associated with a reduced risk of cancer, compared

10 years of age, seniors, medically ill patients, and patients on com-

to a group prescribed anticonvulsant medications. (Lithium with or

bination treatments should receive more frequent monitoring. Re-

without anticonvulsant HR = 0.735, 95% CI 0.55-0.97). The study

emergence of clinical symptoms, as well as signs of haematological,

also demonstrated a dose-response relationship.795 In a subsequent

hepatic, cardiovascular, and neurological dysfunction, should also

large BD cohort study (n = 9651) focusing on genitourinary cancer,

signal the need for additional investigations.

however, lithium was not associated with any change in risk.796
A recent meta-
analysis suggests increased risk of dementia in
BD.797 There is some evidence that lithium in drinking water reduces
the risk of dementia in the general population

638

Patients receiving treatment should be regularly monitored for
side effects, including weight changes and other adverse events such
as extrapyramidal symptoms (EPS).

as does the use of

lithium in patients with BD.798

8 | SAFETY AND MONITORING
8.1 | Medical evaluation and laboratory
investigations

8.2 | Monitoring medication serum levels
Patients on lithium, divalproex, or carbamazepine need to have
their serum medication levels monitored regularly. This is particularly important for those who may be non-adherent to treatment.
Measurement of serum levels should be repeated at the trough point,
which is approximately 12 h after the last dose. It is recommended

A complete medical history including assessment of BMI and base-

that two consecutive serum levels be established in the therapeutic

line laboratory investigations (Table 23) should be performed prior

range during the acute phase for lithium and divalproex, and then

to initiating pharmacological treatment for BD or, in the case of an

measurement be repeated every 3-6 months or more frequently if

acute clinical situation, as soon as the patient is cooperative. For

clinically indicated. For carbamazepine, serum level monitoring is

more detail, readers are referred to comprehensive guidelines for

mainly done to ensure that the levels are not in the toxic range and

safety monitoring in BD.652 In women of childbearing age, preg-

to check for treatment adherence as there is no established relation-

nancy should be ruled out, and they should be counselled about

ship between efficacy and serum level; thus, monitoring for serum

the possibility of lamotrigine and carbamazepine affecting the ef-

carbamazepine levels may be done at 6-12 monthly intervals and as

ficacy of oral contraceptives before initiating pharmacotherapy.

clinically indicated.

For those on maintenance therapy with lithium, thyroid and

The target serum level for lithium in acute treatment is 0.8-

renal function as well as plasma calcium799 should be assessed at

1.2 mEq/L (0.4-0.8 mEq/L in older adults) while in maintenance treat-

6 months and at least annually thereafter or as clinically indicated.

ment, serum levels of 0.6-1 mEq/L may be sufficient801,802; serum

Menstrual history (to assess for polycystic ovary syndrome), hae-

levels should be obtained about 5 days after the most recent dose

matology profile, and liver function tests should be obtained at

titration. Clinicians may wish to consult the “lithiumeter” schematic

3-
6 month intervals during the first year, and yearly thereafter

for further guidance.803 It is important to avoid toxic levels as these

and as clinically indicated, in patients on maintenance treatment

are associated with an increased risk of kidney damage in the long

with divalproex. Patients initiated on lamotrigine or carbamazepine

term.804 The target serum level for divalproex is 350-700 mM/L (50-

should be routinely educated about the risks of skin rashes and the

100 ug/mL) in the acute phase and should be obtained 3-5 days after

potential for Stevens-Johnson syndrome (SJS) and toxic epidermal

the most recent dose titration. There is some evidence for a linear re-

necrolysis (TEN). They should be advised to contact the treating

lationship between serum divalproex level and therapeutic efficacy in

physician if they observe any type of skin rashes or mucosal ulcers

acute mania, with higher levels associated with greater efficacy.805 It is

as they require urgent medical evaluation to determine the nature

currently unknown what levels of divalproex offer optimum efficacy in

of rashes/ulcers and implementation of most appropriate treatment

maintenance treatment as no study to date has systematically assessed

options which might include discontinuation of these medications

the relationship between serum divalproex level and the maintenance
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Safety/tolerability concerns and risks of treatment-emergent switch with pharmacological agents indicated for use in bipolar
Safety concerns

Lithium

Tolerability concerns

Risk of treatment emergent switch

Acute

Maintenance

Acute

Maintenance

Mania/hypomania

Depression

+

++

+

++

−

−

++

++a

+

++

−

−

a

Anticonvulsants
Carbamazepine
Divalproex

−

++

+

+

−

−

Gabapentin

−

−

+

+

−

−

Oxcarbazepine

+

+

+

+

−

−

Lamotrigine

++

−

−

−

−

−

Aripiprazole

−

−

+

+

−

−

Asenapine

−

−

+

+

−

−

Cariprazine

−

−

+

−

−

−

Clozapine

++

+++

++

+++

−

−

Lurasidone

−

−

+

+

−

−

Olanzapine

+

+++

++

++

−

−

Paliperidone

−

+

+

++

−

−

Quetiapine

+

++

++

++

−

−

Risperidone

−

+

+

++

−

−

Ziprasidone

++

++

++

+

−

−

Haloperidol

+

+++

++

++

−

++

Loxapine

+

+

+

+

−

nk

Agomelatine

+

−

−

−

+

−

Bupropion

+

−

+

−

+

−

Ketamine IV

++

nk

++

nk

nk

nk

MAOIs

++

++

+

++

++

−

SNRIs

−

+

+

−

++

−

SSRIs

−

−

+

+

+

−

TCAs

++

++

++

++

+++

−

Amphetamines

−

++

+

−

+++

−

Modafinil

−

−

−

−

++

nk

−

+

−

−

++

nk

Atypical antipsychotics

Conventional antipsychotics

Antidepressants (adjunctiveb)

Stimulants

Dopamine agonists
Pramipexole

MAOIs, monoamine oxidase inhibitors; SNRIs, serotonin norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic
antidepressants.
−, limited impact on treatment selection; +, minor impact on treatment selection; ++, moderate impact on treatment selection; +++, significant impact on
treatment selection; nk, not known.
a
divalproex and carbamazepine should be used cautiously in women of child bearing age (Section 7).
b
Antidepressant monotherapy is not recommended in bipolar I disorder; for more information on bipolar II disorder, see Section 6.

efficacy. Therefore, clinician are advised to maintain serum divalproex

Patients who are treated with concurrent carbamazepine or other

levels within the accepted laboratory range values during maintenance

hepatic enzyme-inducing agents should have serum levels of all psy-

treatment and carefully monitor patients for emerging mood symp-

chotropic medications monitored, particularly in cases of inadequate

toms and tolerability and adjust the dose of divalproex as needed in

response or non-response, to determine whether efficacy has been

order to achieve optimum efficacy and tolerability.

compromised because of reduced serum levels.
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8.3 | Safety and tolerability of pharmacotherapy

levels, multiple daily lithium doses (vs once daily), concurrent
medications (eg NSAIDs, ARBs, ACEIs and diuretics), somatic ill-

Safety and tolerability issues, in addition to efficacy data, have been

nesses (eg, hypertension, diabetes mellitus and coronary artery

considered when determining recommendations for each phase of

disease) and older age.819,820 Instances of lithium toxicity will

illness. The most notable concerns are described below and a sum-

also greatly increase risk of renal dysfunction.821 Lithium use is

mary of their potential impact on treatment selection is included in

associated with a two-fold higher risk of chronic kidney disease

Table 24, as well as in treatment hierarchy tables in Sections 2-4. As

in older adults (>66 years).822 While the overall risk for progres-

medication side effects are an important contributor to medication

sive renal failure is low, plasma creatinine concentrations and ide-

non-adherence, these potential concerns should be discussed with

ally estimated glomerular filtration rate (eGFR) for these patients

patients receiving or considering treatment with various agents to

should be measured at least every 3-6 months.652 Since 37% of

help inform decision making.

patients aged >70 years have an eGFR <60 mL/min per 1.73 m2,823
a strict eGFR cut-off for lithium discontinuation is difficult. The UK
National Institute for Healthcare and Excellence (NICE) guidelines

8.3.1 | Weight gain

for chronic kidney disease (CKD) recommend nephrologist consul-

As described in Section 6, despite normal weight at illness onset,806

tation if there is rapidly declining eGFR (>5 mL/min per 1.73 m2

it is common for patients with BD to become overweight or obese,

in 1 year, or >10 mL/min per 1.73 m2 within 5 years), if the eGFR

and several medications used to treat the illness may also exacer-

falls below 45 in two consecutive readings, or if the clinician is

bate this effect. The likelihood of medications to cause weight gain

concerned.646,824

should be carefully considered, as this is one of the most frequent

Because of its narrow therapeutic window, acute lithium intoxica-

treatment-related factors of non-adherence; contributing to upwards

tion is also a complication, which, though reversible, can lead to reduc-

of 60% of cases.807 The medications most commonly associated with

tions in glomerular filtration rate.825,826 Drugs that alter renal function

weight gain are olanzapine, clozapine, risperidone, quetiapine, gabap-

and general medical conditions characterized by decreased circulating

entin, divalproex and lithium; with carbamazepine, lamotrigine, and

volume all contribute to increased risk.827

ziprasidone being the safer or options associated with less weight
gain.808 Recent reviews further suggest that asenapine and aripiprazole (longer term use) 809 also may lead to weight gain, but the impact

8.3.4 | Haematological effects

of lurasidone on weight is minimal.810 All patients should be regularly

Carbamazepine may be a risk factor for leucopenia,828-830 although

monitored for weight changes.

this finding is not robust.831 This side effect is generally reversible
with dose reduction or discontinuation. There is also some concern
about rapidly developing bone marrow suppression resulting from hy-

8.3.2 | Gastrointestinal symptoms

persensitivity, particularly in older patients.831,832

Both lithium and divalproex are commonly associated with nausea,

Clozapine carries the greatest risk for drug-induced changes in

vomiting, and diarrhoea, with 35%-45% of patient experiencing these

white blood cell counts, with approximately 0.18% of patients expe-

side effects.372,811 For lithium, this is particularly pronounced during

riencing changes rated as probably or definitely drug induced.828 All

treatment initiation, or rapid dose increases.

812

Gradual dose titra-

patients started on clozapine should have a baseline haematological

tion, taking the medication at bedtime, taking medications with food,

profile established and be enrolled in the clozapine monitoring pro-

and slow release preparations may reduce nausea and other side

gramme which requires regular monitoring of haematological param-

effects.

813

eters: weekly at first and then every 2-4 weeks later in the course of
treatment.833

8.3.3 | Renal toxicity
Lithium has a well-recognized potential for renal toxicity, includ-

8.3.5 | Cardiovascular effects

ing nephrogenic diabetes insipidus (NDI), chronic tubulointersti-

Lithium can increase the risk of abnormal QT prolongation or T-wave

tial nephropathy, and acute tubular necrosis, with NDI reported

abnormalities,834 an impact more pronounced with age, as almost

in 20%-40% of patients.

814-816

Upwards of 70% of patients on

60% of older patients on lithium maintenance therapy have ECG

chronic lithium treatment will experience polyuria, which can

abnormalities.835 Several antipsychotics, including risperidone, olan-

cause impairment in work and daily functioning. This side effect

zapine, ziprasidone and asenapine, are also associated with arrhyth-

is commonly underreported, unless it is directly inquired about. 817

mias, QTc prolongation, and other cardiovascular adverse events.

Long-term administration (ie, 10-20+ years) is further associated

Clozapine may increase the risk of several rare but serious events

with decreased glomerular filtration rate and chronic kidney dis-

such as dilated cardiomyopathy, myocarditis, and pericarditis. Of the

ease.818 While long-
term lithium administration is probably an

antipsychotics, lurasidone and aripiprazole are considered safe from

important risk factor for developing chronic kidney disease, fac-

a cardiac perspective, although aripiprazole may increase the risk for

tors that may increase susceptibility include higher plasma lithium

hypotension.810
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however; quetiapine, clozapine, and olanzapine will generally have

8.3.6 | Endocrine effects

higher rates of sedation compared to ziprasidone, risperidone, and ari-

There is also a strong link between lithium maintenance treatment

piprazole.810 Lamotrigine and lithium have both been found to be less

and hypothyroidism, which is also associated with increased risk of

likely to cause sedation than divalproex.854,855

affective episodes, rapid cycling, and more severe depression.

836,837

Routine screening of thyroid function is therefore recommended for
all patients on lithium treatment. Since lithium can also cause hy-

8.3.9 | Neurological effects, including EPS

perparathyroidism, routine monitoring for serum calcium is recom-

Tremor can be a significant cause of frustration for many patients,

mended, and, if elevated, further investigations should be performed

and is experienced by up to 10% of those treated with lithium or di-

838

Hypothyroidism is ordinarily

valproex.668,856,857 New onset neurological symptoms in patients on

not an indication for lithium cessation in a patient with a good re-

divalproex should raise suspicion of hyperammonaemic encephalopa-

sponse; rather, thyroid supplementation is recommended.

thy, which, while rare, can be potentially fatal, and hence early detec-

to evaluate for hyperparathyroidisim.

New onset oligomenorrhoea or hyperandronism is more common in
839

tion and discontinuation of divalproex is critical to prevent morbidity

While there are reports of an increased incidence

and mortality858 Sustained release formulations and dose reductions

of polycystic ovary syndrome (PCOS) in divalproex treatment, a recent

may limit symptoms.802,859,860 While conventional antipsychotics such

divalproex users.

840

meta-analysis did not support this.

In those who develop PCOS on

as haloperidol are often associated with EPS (including pseudoparkin-

divalproex, there is evidence from a small sample that discontinuing

sonism, akathisia, acute dystonia, and tardive dyskinesia),861 this risk is

divalproex results in remission of some of the aspects of PCOS.841

either absent or low with atypical antipsychotic agents.862,863 Among

Hyperprolactinaemia is common with some antipsychotics, and

the atypical agents, risperidone, aripiprazole, cariprazine, ziprasidone

can have short-term and long-term adverse effects. Risperidone, ami-

and lurasidone are more likely to cause EPS, particularly at higher

sulpride and paliperidone are more likely than other compounds to

doses.810 In older patients, impaired swallowing function and dys-

cause it.842 Hyperprolactinaemia can induce amenorrhoea, sexual dys-

phagia have also been linked to atypical agents, particularly at higher

function, and galactorrhoea, amongst other effects. In the long term,

doses.864,865

it can cause gynaecomastia and osteoporosis.

843

When such effects

Although rare, neuroleptic malignant syndrome (NMS) is a po-

are seen, it may advisable to reduce the dose or switch to a different

tentially life-threatening adverse event associated with antipsychotic

medication.844

agents. The risk with atypical agents was considered negligible initially; however, while the risk is very low, several atypical agents have
nevertheless been associated with NMS.866 While generally unpre-

8.3.7 | Cognition

dictable, the risk is greatest during the initial phase of treatment or

While many patients experience cognitive impairment, these deficits

change of dosage, with intravenous or intramuscular administration,

may be attributable to the disease itself, with more pronounced effects

with high dosages or polypharmacy, when the patient is physically

in those with more severe or chronic illness.845 While a small study has

restrained or dehydrated, in high ambient temperatures, in older

led to suggestions that medicated patients who are euthymic do per-

patients and in patients with medical or psychiatric comorbidities.

846

form similarly to those not receiving treatment,

other naturalistic tri-

Patients with a previous history of NMS and/or a personal or family

als point towards the potential negative impact of several medications,

history of catatonia are also at higher risk.867 Antipsychotics may also

845

Lithium

impact thermoregulation, with case studies indicating the potential

can also lead to impairment in processing speed and memory, which

with the effects of antipsychotics being the most significant.

for both heat-related illnesses868 and hypothermia869; thus, patients

patients may find distressing,847 although recent randomized con-

should be made aware and monitored for these risks during periods

trolled data suggest lithium is superior to quetiapine in this regard.329

of extreme temperatures.

Indeed, the effects of lithium on neurocognition are complex and further research is needed to fully elucidate its neurocognitive impact.848
Anticonvulsants, except for lamotrigine, are also linked to subjective

8.3.10 | Dermatological reactions

cognitive impairment.847 Given the importance of cognition on a pa-

Approximately 10% of patients being treated with lamotrigine will expe-

tient’s function and quality of life, further studies are needed in this area.

rience a non-serious rash, with 0.3%-1% developing a serious rash such
as toxic epidermal necrolysis and SJS,870 although for those initiated on
a dose of 25 mg with a gradual titration increasing the dose by 25 mg

8.3.8 | Sedation

biweekly, the risk of developing serious rash may be as low as 0.02%

Sedation is a concern for many, and is reported by over half of patients
as a reason for treatment non-adherence.

807

or 1 in 5000.871 In some cases, an even lower rate of titration may be

Divalproex and atypical

used (ie 12.5 mg/day and then gradually increase as per instructions.

antipsychotics are most likely to lead to these effects, with 30%-50%

Carbamazepine is also associated with increased risk of rash and SJS,

of patients on atypical antipsychotics experiencing sedation, com-

especially in the first 8 weeks of therapy,872 although the baseline risk

pared to 8%-13% with placebo

164,214,849-851

and 21%-29% of patients

is extremely low. Similarly, while these can also occur with divalproex,

on divalproex.852,853 This is not a concern with all antipsychotics,

the risk is extremely low. Nevertheless, it is important that patients be
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informed of these risks and told to report any rash immediately, and
these treatments should be discontinued if a serious rash is suspected.
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